<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/"
     xmlns:pp="http://www.presspage.com/rss/"
     version="2.0"
     xmlns:atom="http://www.w3.org/2005/Atom">
                <channel>
                    <title><![CDATA[Cedars-Sinai Newsroom | Health Breakthroughs & Expert News]]></title>
                    <link>https://www.cedars-sinai.org/newsroom/</link>
                    <description></description>
                    <language>en-us</language>
                    <lastBuildDate>Sun, 15 Nov 2026 22:37:17 +0100</lastBuildDate>
                    <pubDate>Sat, 14 Nov 2026 05:19:18 +0000</pubDate>
                    <image>
                        <title><![CDATA[Cedars-Sinai Newsroom | Health Breakthroughs & Expert News]]></title>
                        <url>https://content.presspage.com/clients/150_2110.png</url>
                        <link>https://www.cedars-sinai.org/newsroom/</link>
                        <width>144</width>
                    </image><item>
                        <title>NIH Awards Cedars-Sinai More Than $12 Million for Pulmonary Fibrosis Research</title>
                        <link>https://www.cedars-sinai.org/newsroom/nih-awards-cedars-sinai-more-than-12-million-for-pulmonary-fibrosis-research/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/nih-awards-cedars-sinai-more-than-12-million-for-pulmonary-fibrosis-research/</guid><pp:caseid>824323</pp:caseid><pp:subtitle>Investigators Aim to Uncover the Biological Processes Leading to Lung Damage After Viral Infections</pp:subtitle><description><![CDATA[<p><span>The National Institutes of Health have awarded Cedars-Sinai more than $12 million to find out how viral infections cause lung scarring that does not heal.</span></p><p><span>Over the course of five years, investigators will work to identify the molecular interactions that trigger lung scarring, which is known as </span><a href="https://www.pulmonaryfibrosis.org/understanding-pff/about-pulmonary-fibrosis/what-is-pulmonary-fibrosis" target="_blank" rel="noreferrer noopener"><span>pulmonary fibrosis</span></a><span>. Drugs can slow the progression of lung damage in people with pulmonary fibrosis, but they cannot repair damage that has already occurred.</span></p><p><span><img class="image_resized image-style-align-right" style="width:289px;" src="https://content.presspage.com/uploads/2110/1aef1618-6209-4079-88a9-1fc2178a8128/800_chen-peter.jpeg" alt="Peter Chen, MD" width="289" />“By studying the processes that cause the initial lung damage after viral infection, we can identify diagnostic markers for early disease or find new therapeutic pathways to halt serious lung disease,” said<strong> </strong></span><a href="https://researchers.cedars-sinai.edu/Peter.Chen?adobe_mc=MCMID%3D91216484600684362372808378783723549900%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1746810142&prevPageName=cs-org%3Acedars-sinai%3Anewsroom%3Apulmonary-expert-to-be-honored-for-scientific-accomplishments"><span>Peter Chen, MD</span></a><span>, director of Pulmonary and Critical Care Medicine at Cedars-Sinai and principal investigator of the research initiative. “We trust this major grant will advance scientific knowledge and help improve outcomes for patients with pulmonary fibrosis.”</span></p><p><span>Chen said respiratory infections such as the flu, pneumonia and COVID-19 can cause long-lasting lung damage. They primarily do this by attacking the alveoli, the tiny sacs at the end of breathing tubes that help blood exchange oxygen and carbon dioxide. Viral infections can make it difficult for the alveoli to repair themselves.</span></p><p><span>“We want to know how cumulative viral infections over our lifetime may make certain people more vulnerable than others to pulmonary fibrosis,” Chen said. “It could be that a combination of viral infections and other factors such as genetics, behavior and environmental exposures increase individual risk.”</span></p><p><span>The grant, awarded by the </span><a href="https://www.nhlbi.nih.gov/" target="_blank" rel="noreferrer noopener"><span>National Heart, Lung, and Blood Institute</span></a><span>, will fund 12 investigators working on three research projects and four shared resource units known as research cores.</span></p><p><span>The projects will be carried out by:</span></p><ul><li><span>A team at Cedars-Sinai, led by Chen, that will focus on how viruses reprogram lung stem cells in ways that alter their regenerative ability and make lungs more vulnerable to scarring</span></li><li><span>A team at the University of Virginia, led by </span><a href="https://www.immunology.virginia.edu/Sun/team.php" target="_blank" rel="noreferrer noopener"><span>Jie Sun, PhD</span></a><span>, that will work to uncover how the body’s immune response creates a lung microenvironment that promotes the development of lung fibrosis</span></li><li><span>A team at Cedars-Sinai, led by Research Assistant Professor </span><a href="https://researchers.cedars-sinai.edu/Xue.Liu"><span>Xue Liu, PhD</span></a><span>, that will study how cell signaling in viral-damaged lungs causes healthy lung cells to become scar-forming cells</span></li></ul><p><span>The work builds on </span><a href="https://www.cedars-sinai.org/newsroom/immune-cells-prevent-lung-healing-after-viral-infection/"><span>previous research</span></a><span> in laboratory mice led by Chen and Sun. That research described a pathway by which immune cells prevent the lungs from healing after viral infections.</span></p><p><span>“With these new studies, we hope to identify a measurable process in the body that can help doctors detect early signs of lung scarring in their patients,” said Sun, the Harrison Distinguished Teaching Professor of Medicine at the University of Virginia.</span></p><p style="margin-left:0in;"><span style="color:hsl(353,76%,49%);"><i><span><strong>Read more from Cedars-Sinai Stories and Insights: </strong></span></i></span><a href="https://www.cedars-sinai.org/newsroom/pulmonary-expert-to-be-honored-for-scientific-accomplishments/"><span style="color:hsl(353,76%,49%);"><i><span><strong>Pulmonary Expert to Be Honored for Scientific Accomplishments</strong></span></i></span></a></p>]]></description><category><![CDATA[Faculty News,Stephanie Cajigal,peter-chen-1272861,Pulmonology]]></category>
            <pubDate>Thu, 12 Nov 2026 08:00:00 -0800</pubDate>
            <pp:lastModified>Thu, 12 Nov 2026 01:49:23 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/2ad6f8f0-386b-4815-88e6-456fd462501b/500_lung-image-cedars-sinai.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/2ad6f8f0-386b-4815-88e6-456fd462501b/500_lung-image-cedars-sinai.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/2ad6f8f0-386b-4815-88e6-456fd462501b/lung-image-cedars-sinai.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Cedars-Sinai experts in pulmonology and lung transplantation will be in attendance at the American Thoracic Society&amp;rsquo;s 2024 International Conference in May. Image by Getty.]]></pp:imageTitle><pp:imageDescription><![CDATA[Computer illustration of human lungs.]]></pp:imageDescription></item><item>
                        <title>New Treatments Are Changing Lives for People With This Heart Disease</title>
                        <link>https://www.cedars-sinai.org/newsroom/new-treatments-are-changing-lives-for-people-with-this-heart-disease/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/new-treatments-are-changing-lives-for-people-with-this-heart-disease/</guid><pp:caseid>824325</pp:caseid><pp:subtitle>Cedars-Sinai Research Helps Bring New Therapies to Patients With Transthyretin Amyloid Cardiomyopathy</pp:subtitle><description><![CDATA[<p><span>A few years ago, corporate real estate executive Larry Teel was looking forward to swapping weekly business travel for leisurely trips with his wife. But as Teel approached retirement in 2024, he could barely walk from a ticket counter to a plane without stopping to catch his breath.</span></p><p><span>A doctor diagnosed Teel, 74, of <img class="image_resized image-style-align-right" style="width:221px;" src="https://content.presspage.com/uploads/2110/9b69e43f-0846-4f00-beca-b063392240dd/800_lily-stern-md-cedars-sinai.jpg" alt="Lily Stern, MD" width="221" />Newport Beach, California, with a heart condition called </span><a href="https://www.heart.org/en/health-topics/cardiomyopathy/what-is-cardiomyopathy-in-adults/transthyretin-amyloid-cardiomyopathy-attr-cm" target="_blank" rel="noreferrer noopener"><span>transthyretin amyloid cardiomyopathy</span></a>. <span>He was told he had just two years to live.</span></p><p><span>“Before I got sick, I would be up at 5 a.m. and down at 11 p.m.,” Teel said. “I was always active. But at that point I had no energy, no concentration, and just felt terrible.”</span></p><p><span>His symptoms were the result of a protein, transthyretin, misfolding and forming threadlike structures called amyloid fibrils. In people with transthyretin amyloid cardiomyopathy, a form of a condition called amyloidosis, the fibrils accumulate in the heart and cause it to become stiff and lose its ability to pump. Blood backs up into the lungs and causes shortness of breath, swelling in the legs, and congestion of the liver and kidneys.</span></p><p><span>As the disease progresses, it can lead to heart failure.</span></p><p><span>Teel’s cardiologist referred him to </span><a href="https://www.cedars-sinai.org/provider/lily-stern-3784448.html"><span>Lily Stern, MD</span></a><span>, an advanced heart disease cardiologist in the </span><a href="https://www.cedars-sinai.org/programs/heart.html"><span>Smidt Heart Institute at Cedars-Sinai</span></a><span>. Stern confirmed Teel’s diagnosis with noninvasive tests and started him on a recently approved therapy.</span></p><p><span>Stern offered a more optimistic outlook: Teel’s condition was treatable.</span></p><h2><strong>Why Earlier Diagnosis Matters More Now</strong></h2><p><span>“Within the last 10 years, there’s been an explosion of novel therapeutics for this condition, and that means fewer people progressing to heart failure,” said Stern, associate director of the </span><a href="https://www.cedars-sinai.org/programs/heart/specialties/advanced-heart/cardiac-amyloidosis.html"><span>Cardiac Amyloid Program</span></a><span> in the Smidt Heart Institute. “These treatments work best when patients are diagnosed early, before showing significant signs of heart failure. Larry came to Cedars-Sinai at just the right moment.”</span></p><p><span>Transthyretin amyloid cardiomyopathy is considered rare, but experts believe it is severely underdiagnosed.</span></p><p><span>Symptoms of </span>the disease<span> may</span> <span>develop slowly, and doctors may attribute them to other conditions rather than the underlying disease. Teel, for example, had been diagnosed with atrial fibrillation, an irregular heart rhythm, which his doctors now understand was related to the accumulation of amyloid fibrils in his heart.</span></p><p><span>There are two main types of transthyretin amyloid cardiomyopathy, also called</span><i><span><strong> </strong></span></i><span>ATTR-CM. One, a hereditary type, is caused by a mutation in a gene called </span><i><span>TTR</span></i><span>. The other—the type that Teel has—is wild-type transthyretin amyloid cardiomyopathy, where the gene is normal, but the transthyretin protein still misfolds.</span></p><h2><strong>New Treatments Are Changing Amyloid Cardiomyopathy Care</strong></h2><p><span>It used to be that people with transthyretin amyloid cardiomyopathy had no treatment options and lived with their condition getting worse every year. For those with advanced disease, only a few were eligible for a heart transplant. A pivotal moment came in 2019 when the U.S. Food and Drug Administration (FDA) approved the first medication specifically indicated for transthyretin cardiac cardiomyopathy. The drug, </span><a href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=363312" target="_blank" rel="noreferrer noopener"><span>tafamidis</span></a><span>, works by preventing transthyretin from breaking apart and misfolding into amyloid.</span></p><p><span>Stern and research colleagues from the U.S. and abroad were part of clinical trials that led to approval in 2024 of another transthyretin stabilizer, </span><a href="https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-heart-disorder-caused-transthyretin-mediated-amyloidosis" target="_blank" rel="noreferrer noopener"><span>acoramidis</span></a><span>. Stern’s team enrolled patients from Cedars-Sinai in the Phase III clinical trial of that drug, which found that people who took acoramidis had fewer hospitalizations and other complications over 30 months than patients given placebo.</span></p><p><span>Most recently, in 2025, the FDA approved </span><a href="https://cardiovascularbusiness.com/topics/clinical/pharmaceutics/fda-approves-vutrisiran-treat-attr-cm" target="_blank" rel="noreferrer noopener"><span>vutrisiran</span></a><span>, a drug that limits the production of transthyretin. More drugs are being studied and developed, including ones that permanently edit out the </span><i><span>TTR</span></i><span> gene. Scientists are also studying treatments that clear amyloid from the heart.</span></p><h2><strong>Answering the Next Questions About Amyloid Cardiomyopathy</strong></h2><p><span>Stern helped<img class="image_resized image-style-align-right" style="width:281px;" src="https://content.presspage.com/uploads/2110/a9ac92ea-6914-4960-895a-be0336ad22ce/800_susan-cheng-md-mph-cedars-sinai.jpg" alt="Susan Cheng, MD, MPH" width="281" /> create a registry that includes more than 2,800 patients from 28 medical centers across North America who have been diagnosed with different types of amyloid cardiomyopathy. Researchers plan to use the data to improve knowledge of how amyloid cardiomyopathy</span> p<span>rogresses and is affected by treatments.</span></p><p><span>The ongoing investigations have the potential to not only help people like Teel, but also those who develop other heart conditions, Cedars-Sinai experts say.</span></p><p><span>“Knowing we can now offer patients like Larry meaningful treatment outcomes for a complex heart condition is further motivation to accelerate scientific findings that can be applied to multiple diseases,” said </span><a href="https://www.cedars-sinai.org/provider/susan-cheng-763325.html"><span>Susan Cheng, MD, MPH</span></a><span>, chair of the Department of Cardiology in the Smidt Heart Institute.</span></p><p><span><img class="image-style-align-right image_resized" style="width:284px;" src="https://content.presspage.com/uploads/2110/ef600a7e-19b5-4651-8c1e-b987fbe98179/800_michelle-kittleson-md-phd-cedars-sinai.jpg" width="284" alt="Michelle Kittleson, MD, PhD" />Although scientists have made major advances in diagnosing and treating this disease, more research is needed, according to </span><a href="https://researchers.cedars-sinai.edu/Michelle.Kittleson?adobe_mc=MCMID%3D15143042538955239740718824350024281938%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1793660254&previousPageName=cs-org%253Acedars-sinai%253Aother"><span>Michelle Kittleson, MD, PhD</span></a><span>, professor of Cardiology in the Smidt Heart Institute. “There remain many unanswered questions regarding response to therapy and adjustment of therapy in response to disease progression,” she said.</span></p><p><span>Teel is grateful for the medical research and care that has given him more time with his wife, six children and five grandchildren.</span></p><p><span><strong>“</strong>About two months after treatment, suddenly I could think,” he said. “About three months later, I could walk. More than a year later, I feel like I'm alive again.”</span></p><p><span style="color:hsl(353,76%,49%);"><i><span><strong>Read more from the Cedars-Sinai Newsroom: </strong></span></i></span><a href="https://www.cedars-sinai.org/newsroom/webmd-navigating-hattr-cmwhy-self-advocacy-matters/"><span style="color:hsl(353,76%,49%);"><i><span><strong>WebMD | Navigating hATTR-CM—Why Self-Advocacy Matters</strong></span></i></span></a></p>]]></description><category><![CDATA[Stephanie Cajigal,Heart,Advanced Heart,lily-stern-3784448,News]]></category>
            <pubDate>Thu, 12 Nov 2026 07:00:00 -0800</pubDate>
            <pp:lastModified>Thu, 12 Nov 2026 15:32:58 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/a30874de-8d9f-4232-b6ed-7b21e23d78ce/500_stiff-heart-cedars-sinai.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/a30874de-8d9f-4232-b6ed-7b21e23d78ce/500_stiff-heart-cedars-sinai.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/a30874de-8d9f-4232-b6ed-7b21e23d78ce/stiff-heart-cedars-sinai.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Lisa and Larry Teel can continue their travels thanks to treatment Larry received at Cedars-Sinai for stiff heart syndrome. Photo courtesy of Larry Teel.]]></pp:imageTitle><pp:imageDescription><![CDATA[A husband and wife standing outside in front of a large fountain.]]></pp:imageDescription></item><item>
                        <title>Earlier Valve Replacement Benefits Some Patients With Moderate Aortic Stenosis</title>
                        <link>https://www.cedars-sinai.org/newsroom/earlier-valve-replacement-benefits-some-patients-with-moderate-aortic-stenosis/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/earlier-valve-replacement-benefits-some-patients-with-moderate-aortic-stenosis/</guid><pp:caseid>823081</pp:caseid><pp:subtitle>Clinical Trial Co-Led by Cedars-Sinai Finds Earlier Treatment May Reduce Heart-Failure Events in Certain Patients</pp:subtitle><description><![CDATA[<p><span>Patients with moderate aortic stenosis, a narrowing of the heart’s aortic valve, may benefit from undergoing transcatheter aortic valve replacement (TAVR) before the disease becomes severe, according to findings from a clinical trial co-led by Cedars-Sinai investigators.</span></p><p><span><img class="image_resized image-style-align-right" style="width:350px;" src="https://content.presspage.com/uploads/2110/2c6077ce-ce82-498d-90ad-6bd2becb8a66/800_1920-raj-makkar-md-cedars-sinai-smidt-heart.jpg?x=1793396688561" alt="Raj Makkar, MD" width="350" />The study found that earlier TAVR treatment lowered the combined risk of death or a heart-failure event over two years in certain patients with moderate aortic stenosis.</span></p><p><span>Findings from the </span><a href="https://clinicaltrials.gov/study/NCT04889872" target="_blank" rel="noreferrer noopener"><span>PROGRESS</span></a><span> clinical trial were published in </span><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2607326" target="_blank" rel="noreferrer noopener"><i><span>The New England Journal of Medicine</span></i></a><span> and presented Nov. 2 at the </span><a href="https://www.tctconference.com/" target="_blank" rel="noreferrer noopener"><span>Transcatheter Cardiovascular Therapeutics (TCT) 2026</span></a><span> symposium in San Diego.</span></p><p><a href="https://researchers.cedars-sinai.edu/Raj.Makkar"><span>Raj Makkar, MD</span></a><span>, vice president of Cardiovascular Innovation and Intervention in the </span><a href="https://www.cedars-sinai.org/programs/heart.html"><span>Smidt Heart Institute</span></a><span> at Cedars-Sinai, is the national principal investigator for the trial.</span></p><p><span>The benefit of earlier treatment was shown by patients experiencing fewer heart-failure events, including hospitalizations, Makkar said.</span></p><p><span>“Patients with moderate aortic stenosis can already have symptoms and signs that their heart is under strain. These results show that for selected patients with at-risk features, treating the valve earlier can reduce the risk of heart-failure events before the narrowing becomes severe.”</span></p><p><span>The Smidt Heart Institute at Cedars-Sinai enrolled more patients than any other participating center, giving patients a key role in advancing research into the disease.</span></p><p><span>“Our extensive experience with treating valvular heart disease, along with our ability to integrate research into routine patient care, powered our ability to enroll a significant number of patients,” said Makkar, the Karsh Distinguished Chair in Interventional Cardiology.</span></p><p><span><img class="image_resized image-style-align-right" style="width:350px;" src="https://content.presspage.com/uploads/2110/800_aakriti-gupta-md-cedars-sinai.jpeg?x=1793396705961" alt="Aakriti Gupta, MD" width="350" />Aortic stenosis, which reduces blood flow from the heart to the body, affects more than 3% of adults 65 and older. Current guidelines recommend an echocardiogram every one to two years in patients with moderate disease, and valve replacement only when the stenosis becomes severe or another indication for surgery develops.</span></p><p><span>The PROGRESS trial enrolled 744 patients 65 or older at 74 centers in six countries. All had moderate aortic stenosis and at least one feature indicating increased risk, such as symptoms or abnormalities in heart structure or function. Investigators randomly assigned 373 patients to TAVR and 371 to clinical surveillance, with valve replacement available when indicated.</span></p><p><span>After two years, 23.9% of those assigned to surveillance had experienced heart failure or died, compared with 16.7% of patients assigned to TAVR. Patients who underwent TAVR were hospitalized for heart failure at half the rate of surveillance patients: 7.4% compared with 14.9% of those in the surveillance group.</span></p><p><span>“More than half of the patients initially assigned to surveillance underwent valve replacement within two years, suggesting that the disease can progress quickly from moderate to severe in some patients,” said </span><a href="https://researchers.cedars-sinai.edu/Aakriti.Gupta"><span>Aakriti Gupta, MD</span></a><span>, study co-author and an assistant professor in the Smidt Heart Institute.</span></p><p><span>The findings do not mean that every patient with moderate aortic stenosis should undergo TAVR. Researchers plan to follow participants for 10 years to determine whether the early reduction in heart-failure events translates into longer survival. They also will assess valve durability, the potential need for future procedures and which patients are most likely to benefit.</span></p><p><span><img class="image-style-align-right image_resized" style="width:350px;" src="https://content.presspage.com/uploads/2110/f089de87-a276-4b7c-9a18-2a283fac475f/800_eduardo-marban-cedars-sinai.jpg?x=1793396816925" width="350" alt="Eduardo Marbán, MD, PhD" />Because participants were an average of 78 years old, researchers also will examine whether the findings apply to younger patients or those without the at-risk features studied in PROGRESS.</span></p><p><span>“Helping patients avoid heart-failure episodes and the hospital stays that come with them is an important goal,” said </span><a href="https://researchers.cedars-sinai.edu/Eduardo.Marban"><span>Eduardo Marbán, MD, PhD</span></a><span>, executive director of the Smidt Heart Institute and the Mark Siegel Family Foundation Distinguished Chair. “As an institution that is well-positioned to treat the most complex heart valve cases, we are grateful to our patients, who were willing to participate in a clinical trial to help answer a question that could improve care for others.”</span></p><p><i><span>Additional authors include Philippe Généreux, MD, Raj Makkar, MD, Philippe Pibarot, DVM, PhD, Jeroen J. Bax, MD, Brian R. Lindman, MD, Kamran Muhammad, MD, J. Bradley Oldemeyer, MD, Mark Pirwitz, MD, Colin M. Barker, MD, Vinod H. Thourani, MD, Pradeep K. Yadav, MD, Roberto Rodriguez, MD, MSc, Justin Strote, MD, Rahul Sakhuja, MD, MPP, MSc, Ramzi Khalil, MD, Rahul Sharma, MD, Adnan Chhatriwalla, MD, Jacob M. Mishell, MD, Biswajit Kar, MD, Sameer Gafoor, MD, Joseph Walsh, MD, Daniel Spoon, MD, Andrew Frutkin, MD, Andrei Pop, MD, Nicolas M. Van Mieghem, MD, Ruby Satpathy, MD, Kenji Ando, MD, Joseph Montarello, MD, John Webb, MD, Sreekanth Vemulapalli, MD, David J. Cohen, MD, MSc, Brandon Park, PhD, Heather Prince, PhD, Philipp Blanke, MD, Michael Mack, MD, Martin B. Leon, MD on behalf of the PROGRESS Trial Investigators.</span></i></p><p><i><span>Disclosures:<strong> </strong>Raj Makkar – Consultant for and research grants from Edwards Lifesciences, Medtronic, Abbott, Jena Valve, Boston Scientific. Scientific Advisory board and equity for iCardio.ai, AllHeart, and PiCardia.</span></i></p><p><i><span>Funding: The PROGRESS trial was funded by Edwards Lifesciences (PROGRESS ClinicalTrials.gov number, NCT04889872).</span></i></p><p><span style="color:hsl(353,76%,49%);"><i><span><strong>Cedars-Sinai Health Sciences University is advancing groundbreaking research and educating future leaders in medicine, biomedical sciences and allied health sciences. </strong></span></i></span><a href="https://www.cedars-sinai.edu/health-sciences-university.html"><span style="color:hsl(353,76%,49%);"><i><span><strong>Learn more</strong></span></i></span></a><span style="color:hsl(353,76%,49%);"><i><span><strong> about the university.</strong></span></i></span></p>]]></description><category><![CDATA[News,Kristin Reynolds,Heart,Heart Research,Heart Failure Research,rajendra-makkar-885543,aakriti-gupta-3174704]]></category>
            <pubDate>Mon, 02 Nov 2026 10:00:00 -0800</pubDate>
            <pp:lastModified>Fri, 30 Oct 2026 22:24:35 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/1c942c36-8396-45f0-98e5-c3a97f65e048/500_aorta-illustration-cedars-sinai.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/1c942c36-8396-45f0-98e5-c3a97f65e048/500_aorta-illustration-cedars-sinai.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/1c942c36-8396-45f0-98e5-c3a97f65e048/aorta-illustration-cedars-sinai.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[The PROGRESS trial, in which Cedars-Sinai was a top enrolling site, found that transcatheter aortic valve replacement reduced the risk of death or heart-failure events in selected patients with moderate aortic stenosis. Image by Getty.]]></pp:imageTitle><pp:imageDescription><![CDATA[An illustration of the aortic valve on a black background]]></pp:imageDescription></item><item>
                        <title>Cedars-Sinai Appoints Chair of Imaging</title>
                        <link>https://www.cedars-sinai.org/newsroom/cedars-sinai-appoints-chair-of-imaging/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/cedars-sinai-appoints-chair-of-imaging/</guid><pp:caseid>822897</pp:caseid><pp:subtitle>Marcel M. Maya, MD, FACR, Will Advance Clinical, Research and Education Programs in His New Leadership Role</pp:subtitle><description><![CDATA[<p><a href="https://researchers.cedars-sinai.edu/Marcel.Maya"><span>Marcel M. Maya, MD, FACR</span></a><span>, a Cedars-Sinai neuroradiologist who has led transformational initiatives to improve patient imaging over the last two decades, has been named chair of the Department of Imaging.</span></p><p><span>Maya, a professor of Imaging, has served as co-chair of the department since 2011 and will now lead its clinical, research and education programs. He was director of the Radiology Residency Program from 2003-11.</span></p><p><span>“Dr. Maya will drive innovation and continuous improvement of our imaging services across Cedars-Sinai,” said </span><a href="https://www.cedars-sinai.org/about/leadership/executive-management/ravi-thadhani-md-mph.html"><span>Ravi Thadhani, MD, MPH</span></a><span>, executive vice president, chief physician executive and dean of the Medical Faculty.</span></p><p><span>Among Maya’s primary goals as chair will be to deliver safe and timely access to high-quality imaging while supporting growing clinical needs as the demand for Cedars-Sinai services increases. He also will aim to strengthen organizational partnerships, including joint ventures, to deliver leading-edge services.</span></p><p><span>Maya currently practices as a neuroradiologist and neuro-interventionalist, integrated into Cedars-Sinai’s stroke, cerebrospinal fluid (CSF) leak, spine and multiple sclerosis programs. While he will devote most of his time to his new responsibilities as chair, he will continue to provide clinical support for these programs.</span></p><p><span>In clinical practice, Maya uses advanced imaging to diagnose conditions affecting the brain and spine, and minimally invasive and image-guided techniques to diagnose and treat strokes, CSF leaks and other conditions.</span></p><p><span>Maya has authored more than 120 peer-reviewed publications. His scholarly and clinical contributions are most notable in CSF leak and spontaneous intracranial hypotension, a neurological disorder caused by loss of cerebrospinal fluid volume and reduced cushioning of the brain.</span></p><p><span>“Dr. Maya’s clinical leadership and commitment to quality care, physician education and interdisciplinary research will strengthen the care we provide to our patients,” said</span> <a href="https://www.cedars-sinai.org/about/leadership/executive-management/bryan-croft.html"><span>Bryan Croft</span></a><span>, executive vice president and chief operating officer at Cedars-Sinai Medical Center.</span></p><p><span>Maya earned his medical degree from Istanbul University in Istanbul, Turkey. After completing pathology residency training at Istanbul University Cerrahpaşa Medical Faculty Hospital, he completed a radiology residency and served as chief resident at Lenox Hill Hospital in New York. He completed a neuroradiology fellowship at New York University Medical Center, followed by a visiting fellowship in pediatric neuroradiology at Children’s Hospital of Philadelphia.</span></p><p><span>“I am honored to lead the Department of Imaging and to continue working alongside our outstanding physicians, technologists, nurses, staff and trainees,” Maya said. “Together, we will build on the department’s strengths in patient care, education and research, while advancing innovation and improving access to imaging for the patients and communities we serve.”</span></p><p><span style="color:hsl(353,76%,49%);"><i><span><strong>Cedars-Sinai Health Sciences University is advancing groundbreaking research and educating future leaders in medicine, biomedical sciences and allied health sciences. </strong></span></i></span><a href="https://www.cedars-sinai.edu/health-sciences-university.html?adobe_mc=MCMID%3D79521921680015491943235909713257507329%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1733161540&prevPageName=cs-org%3Acedars-sinai%3Anewsroom%3Adrug-combo-cuts-risk-of-death-in-advanced-prostate-cancer-by-40"><span style="color:hsl(353,76%,49%);"><i><span><strong>Learn more</strong></span></i></span></a><span style="color:hsl(353,76%,49%);"><i><span><strong> about the university.</strong></span></i></span></p>]]></description><category><![CDATA[Exclude,Faculty News,Imaging,marcel-maya-2789006]]></category>
            <pubDate>Fri, 30 Oct 2026 08:30:00 -0700</pubDate>
            <pp:lastModified>Fri, 30 Oct 2026 15:10:50 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/d3f06fbe-baa5-4feb-9171-d3448a91bb56/500_marcel-maya-md-cedars-sinai-preferred.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/d3f06fbe-baa5-4feb-9171-d3448a91bb56/500_marcel-maya-md-cedars-sinai-preferred.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/d3f06fbe-baa5-4feb-9171-d3448a91bb56/marcel-maya-md-cedars-sinai-preferred.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Marcel M. Maya, MD, FACR, will drive innovation and efficiencies for all imaging within the Cedars-Sinai Health System.  Photo by Cedars-Sinai.]]></pp:imageTitle><pp:imageDescription><![CDATA[Marcel M. Maya, MD, FACR, chair of the Department of Imaging at Cedars-Sinai, stands wearing navy suit jacket and light blue button down dress shirt.]]></pp:imageDescription></item><item>
                        <title>Nearly Half of On-Duty Firefighter Deaths Are Heart Related</title>
                        <link>https://www.cedars-sinai.org/newsroom/nearly-half-of-on-duty-firefighter-deaths-are-heart-related/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/nearly-half-of-on-duty-firefighter-deaths-are-heart-related/</guid><pp:caseid>821468</pp:caseid><pp:subtitle>Study Suggests Firefighters May Benefit From More Comprehensive Heart Screening</pp:subtitle><description><![CDATA[<p><span>Cardiac events account for nearly half of all on-duty firefighter deaths in the U.S.—a proportion that has steadily increased over the past three decades, according to a Cedars-Sinai Health Sciences University study.</span></p><p><span>The findings, published in the journal </span><a href="https://urldefense.com/v3/__https:/protect.checkpoint.com/v2/r01/___https:/*urldefense.com/v3/__https:/*www.jacc.org/doi/10.1016/j.jacadv.2026.103383__;!!KOmnBZxC8_2BBQ!0RQHL2MF50cOqW1gWnYmW7PoPPIsDP1BnuGKowNsI8hM-aV-LXmbuxmBSmgiQokKvAnk9zVCyR2QhaDjaid6$___.YzJ1OmFjYzI6YzpvOmJmZmZjODUxY2NiYzhhNTYwMmJjODM5MDBhZjdkMmE4Ojc6YzczNDphM2ViOTE4YTA3ZjJlZjNiYjE4MDc4MTcwMWQ0YmU4MDRlZmY3OTM4NDI5MmM2NTIxNWY3MjhjZWMyZjA0ZWMwOmg6VDpG__;Ly8!!KOmnBZxC8_2BBQ!xjmtB0BsNR1bcqapAGCcU3c35agqGZMCeYxvYwguEzXnYMSmJnPHix3WvyhPigaztXbKJJa6czx4hWdZvIeE$" target="_blank" rel="noreferrer noopener"><i><span>JACC: Advances</span></i></a><span>, <img class="image_resized image-style-align-right" style="width:250px;" src="https://content.presspage.com/uploads/2110/d11f8c8e-ea77-4688-8118-7b6ef6a6e24e/800_alan-kwan-md-cedars-sinai.jpg?x=1792534315572" alt="Alan Kwan, MD" width="250" />suggest that annual health screenings may miss heart conditions that put firefighters at risk of sudden cardiac death. National screening recommendations primarily rely on exercise stress testing, which may not detect some heart conditions.</span></p><p><span>“Our research shows there may be a blind spot when it comes to routine heart screenings for firefighters in the U.S.,” said </span><a href="https://researchers.cedars-sinai.edu/Alan.Kwan?ppn=Y3Mtb3JnOmNlZGFycy1zaW5haTpwcm92aWRlcjpwcm92aWRlci1iaW8tcGFnZTphbGFuLWt3YW4tMzMxMTcyOA%3D%3D&prevPageName=cs-org%3Acedars-sinai%3Anewsroom%3Aintensive-blood-pressure-treatment-may-help-some-middle-aged-women"><span>Alan Kwan, MD</span></a><span>, assistant professor of Cardiology in the </span><a href="https://www.cedars-sinai.org/programs/heart.html"><span>Smidt Heart Institute at Cedars-Sinai</span></a><span> and senior author of the study. “Identifying heart conditions when they can be treated is key to addressing these new findings.”</span></p><p><span>Investigators found that many on-duty firefighter deaths involved coronary artery disease, also known as narrowing of arteries that feed the heart. But a greater number were tied to something harder to detect: an enlargement of heart muscle mass.</span></p><p><span>Heart muscle enlargement, which can take various shapes and forms, is not readily detected by standard exercise stress tests that firefighters undergo as part of their yearly physical. As firefighters train, they build heart muscle, which may represent athletic cardiac changes but also may mask heart muscle changes caused by dangerous cardiac conditions.</span></p><p><span><img class="image_resized image-style-align-right" style="width:250px;" src="https://content.presspage.com/uploads/2110/eb4db6ab-189f-42bf-9a75-2f0b60c75b64/800_susan-cheng-md-cedars-sinai.jpg?x=1792534330771" alt="Susan Cheng, MD, MMSc, MPH" width="250" />“It’s possible that national firefighter health guidelines need to be updated to include screening for excess heart muscle mass,” said study author </span><a href="https://researchers.cedars-sinai.edu/Susan.Cheng?adobe_mc=MCMID%3D75360244188131661941566734971363994374%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1754577108&prevPageName=cs-org%3Acedars-sinai%3Anewsroom%3Asusan-cheng-md-mmsc-mph-to-lead-department-of-cardiology-at-cedars-sinai"><span>Susan Cheng, MD, MMSc, MPH</span></a><span>, chair of the Department of Cardiology in the Smidt Heart Institute. “It’s not clear why firefighters appear to be at risk for this condition, and so we need to learn more through additional research.”</span></p><p><span>Investigators reviewed U.S. Fire Administration records documenting 3,401 on-duty firefighter deaths from 1990 through 2025 and found that 43% were cardiac in origin.</span></p><p><span>The team analyzed firefighter deaths during the years from 1990 through 2019, before the COVID-19 pandemic. Over that span, on-duty deaths fell overall, but the odds that any given death was heart-related increased by 2.2% each year. In the U.S. population at large, the trend ran the opposite direction: Cardiac deaths as a proportion of all deaths fell 1.3% per year.</span></p><p><span>“This trend suggests that prevention of on-duty cardiac death has not kept pace with other domains of firefighter safety,” Kwan said. “This work builds on prior research reporting that cardiac events are a major cause of death for firefighters. We plan to continue our study of firefighter health risks to inform prevention efforts.”</span></p><p><i><span>Additional Cedars-Sinai authors include Sandy Y. Joung, MBA, MSHS; Lori Martinez-Rubio, DDS, MS; Michelle Bravo, MSN, RN, PHN; Rahul Gupta, MD; Yeran Lee; Eli M. Friedman, MD; Evan Kransdorf, MD, PhD; and Joseph E. Ebinger, MD, MS.</span></i></p><p><i><span>Other authors include: Brian Claggett, PhD, and Stefanos Kales, MD, MPH.</span></i></p><p><i><span>Funding: The study was partially supported by the Spiegel Family Fund, the Smidt Discovery Fund of the Smidt Heart Institute, the Erika J. Glazer Family Foundation, NIH grant KL2TR001882, and R01AG099094.</span></i></p><p><span style="color:hsl(353,76%,49%);"><i><span><strong>Read More From the Cedars-Sinai Newsroom:</strong> </span></i></span><a href="https://www.cedars-sinai.org/newsroom/cedars-sinai-reports-heart-attacks-general-illness-spiked-after-la-fires/"><span style="color:hsl(353,76%,49%);"><i><span><strong>Cedars-Sinai Reports Heart Attacks, General Illness Spiked After LA Fires</strong></span></i></span></a></p>]]></description><category><![CDATA[alan-kwan-3311728,susan-cheng-763325,Heart,Heart Research,News,Stephanie Cajigal]]></category>
            <pubDate>Wed, 21 Oct 2026 11:01:00 -0700</pubDate>
            <pp:lastModified>Wed, 21 Oct 2026 00:54:11 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/2a00f19c-19e3-49f2-af5e-80539293851b/500_firefighter-cedars-sinai.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/2a00f19c-19e3-49f2-af5e-80539293851b/500_firefighter-cedars-sinai.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/2a00f19c-19e3-49f2-af5e-80539293851b/firefighter-cedars-sinai.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[A Cedars-Sinai study points to a gap in annual health screenings for firefighters. Photo by Getty.]]></pp:imageTitle><pp:imageDescription><![CDATA[Firefighter in full gear carries a rolled hose while running next to a firetruck.]]></pp:imageDescription></item><item>
                        <title>Arun Sharma, PhD, Appointed Ben Winters Chair in Regenerative Medicine</title>
                        <link>https://www.cedars-sinai.org/newsroom/arun-sharma-phd-appointed-ben-winters-chair-in-regenerative-medicine/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/arun-sharma-phd-appointed-ben-winters-chair-in-regenerative-medicine/</guid><pp:caseid>819221</pp:caseid><pp:subtitle>Chair Supports Cedars-Sinai Research in Stem Cell and Organoid Technology, Biomanufacturing in Space</pp:subtitle><description><![CDATA[<p><span>The first time </span><a href="https://researchers.cedars-sinai.edu/Arun.Sharma">Arun Sharma, PhD</a><span>, turned human stem cells into beating heart cells, he was an undergraduate on a summer internship.</span></p><p><span>“It was so hard to believe that was real, making these heart cells and seeing them beating in a dish, and I’m still making them 15 years later. </span>I tell everyone on my lab team, I don't ever forget the feeling of making these special cells for the first time,” <span>said Sharma, who recently became the Ben Winters Chair in Regenerative Medicine at Cedars-Sinai.</span></p><p><img class="image_resized image-style-align-right" style="width:526px;" src="https://content.presspage.com/uploads/2110/cf9022d4-4227-443d-909b-87f131d2274c/1920_arunsharmaphdatrightandpostdoctoralscientistpaullineschphdatworkinthesharmalabatcedars-sinai.photobycedars-sinai..jpg?x=1792014773474" alt="Arun Sharma, PhD, at right, and Paul Linesch, PhD, a collaborator from the Svendsen Lab at Cedars-Sinai. Photo by Cedars-Sinai." width="526" /><span>Sharma also has a fascination with space and its potential to advance research, and he is director of Cedars-Sinai’s </span><a href="https://www.cedars-sinai.edu/health-sciences-university/research/departments-institutes/regenerative-medicine/space-medicine.html">Center for Space Medicine Research</a><span>. He said the support provided through the chair will allow him to push his research—on Earth and in space—in new directions.</span></p><p><span>“Receiving this chair is a tremendous honor,” Sharma said. “Ben Winters and his wife, Elaine, were longtime benefactors of Cedars-Sinai, supporting the merger of Cedars of Lebanon and Mount Sinai and the institution’s research. Their children, John and Sherry, have carried on their legacy.”</span></p><p>Sharma’s lab specializes in turning induced pluripotent stem cells, which can be transformed into virtually any cell type, into cardiomyocytes, the muscle cells that make the heart beat. He uses these cardiomyocytes to create tiny clumps of cells called cardiac organoids, which mimic many of the heart’s functions. <span>Sharma is also the director of the </span><a href="https://www.cedars-sinai.edu/health-sciences-university/research/cores/shared-resources-lab.html"><span>Organoid and Organ Chip Shared Resources Laboratory</span></a><span> at Cedars-Sinai, which provides resources and training for researchers working with these cutting-edge technologies.</span></p><p>Using heart muscle cells made from stem cells, Sharma has helped <a href="https://www.cedars-sinai.org/newsroom/a-path-to-heart-safe-chemotherapy/">advance research</a> aimed at making chemotherapy safer for the heart. He’s also been sending stem cells and cardiac organoids into space for more than a decade, bringing two of his passions together.</p><p>Sharma grew up in Huntsville, Alabama, known as “Rocket City” because it played a vital role in the development of the U.S. space program. His father, a recently retired physics professor at Alabama A&M University, nurtured his love of science.</p><p>“One of my earliest memories is waking up to the sound of rocket engines being tested,” Sharma said. “I guess that’s where I first fell in love with space.”</p><p>Sharma was inspired to pair cardiac biology with stem cell biology when he learned as an undergraduate at Duke University that the human heart has very limited capacity to regenerate when it is damaged.</p><p>“Maybe one day we can use the cardiomyocytes and organoids we create to repair the heart,” Sharma said.</p><p>Sharma earned his PhD from Stanford University, where he led the first long-duration cell culture experiment to take place on the International Space Station.</p><p><img class="image_resized image-style-align-left" style="width:200px;" src="https://content.presspage.com/uploads/2110/223ed21d-6c1c-4983-8512-e3d25d809af0/500_svendsen-clive.svendsenc.jpg?x=1792015047910" alt="Clive Svendsen, PhD" width="200" />When Sharma’s wife, a cardiologist, matched to Cedars-Sinai for her cardiology fellowship training, Sharma was excited to follow her, completing his postdoctoral training with <a href="https://researchers.cedars-sinai.edu/Clive.Svendsen">Clive Svendsen, PhD</a>, executive director of the Board of Governors Regenerative Medicine Institute. Sharma also participated in the Cardiovascular Postdoctoral Training Program with <a href="https://researchers.cedars-sinai.edu/Eduardo.Marban">Eduardo Marb<span>á</span>n, MD, PhD</a>, and <a href="https://researchers.cedars-sinai.edu/Joshua.Goldhaber">Joshua Goldhaber, MD</a>, in the Smidt Heart Institute.</p><p><span>A Career Development Award from the American Heart Association allowed Sharma to establish his own laboratory at Cedars-Sinai. And Svendsen encouraged him to apply for grants from NASA that have helped fund six missions to the International Space Station thus far.</span></p><p><span>“Arun is a tour de force with a phenomenal ability to conduct research and communicate science,” Svendsen said. “His passion for space resulted in the launch of our Center for Space Medicine Research, and his ability to engage and train young scientists fuels a vibrant and successful laboratory environment. This chair reflects Arun’s commitment to leading-edge science on Earth and in space.”</span></p><p><span>Sharma’s major research goals are to advance the development of organoids to faithfully represent the human heart and other organs, and to manufacture those organoids in space.</span></p><p><span>“Organoid technology is improving rapidly, but there are ways to make them even more advanced,” Sharma said. “Organoids grow best when they are floating, and in space, everything floats. So my goals intersect.”</span></p><p><span style="color:hsl(353,76%,49%);"><i><span><strong>Cedars-Sinai Health Sciences University is advancing groundbreaking research and educating future leaders in medicine, biomedical sciences and allied health sciences. </strong></span></i></span><a href="https://www.cedars-sinai.edu/health-sciences-university.html?adobe_mc=MCMID%3D79521921680015491943235909713257507329%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1733161540"><span style="color:hsl(353,76%,49%);"><i><span><strong><u>Learn more</u></strong></span></i></span></a><span style="color:hsl(353,76%,49%);"><i><span><strong> about the university.</strong></span></i></span></p>]]></description><category><![CDATA[Christina Elston,RMI,Regenerative Medicine,Exclude,Faculty News]]></category>
            <pubDate>Tue, 20 Oct 2026 07:00:00 -0700</pubDate>
            <pp:lastModified>Thu, 22 Oct 2026 20:51:30 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/90a149fd-e2aa-4f91-8e22-621cf23fbcb8/500_cedars-sinaiscientistarunsharmaphdhasbeennamedthebenwinterschairinregenerativemedicine.photobycedars-sinai..jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/90a149fd-e2aa-4f91-8e22-621cf23fbcb8/500_cedars-sinaiscientistarunsharmaphdhasbeennamedthebenwinterschairinregenerativemedicine.photobycedars-sinai..jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/90a149fd-e2aa-4f91-8e22-621cf23fbcb8/cedars-sinaiscientistarunsharmaphdhasbeennamedthebenwinterschairinregenerativemedicine.photobycedars-sinai..jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Cedars-Sinai scientist Arun Sharma, PhD, has been named the Ben Winters Chair in Regenerative Medicine. Photo by Cedars-Sinai.]]></pp:imageTitle><pp:imageDescription><![CDATA[A scientist, Arun Sharma, stands in his lab in a white lab coat.]]></pp:imageDescription></item><item>
                        <title>The Race to Predict and Prevent Sudden Cardiac Arrest</title>
                        <link>https://www.cedars-sinai.org/newsroom/the-race-to-predict-and-prevent-sudden-cardiac-arrest/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/the-race-to-predict-and-prevent-sudden-cardiac-arrest/</guid><pp:caseid>818413</pp:caseid><pp:subtitle>AI Could Help Identify Cardiac Arrest Risk Years in Advance; Wearable-Device Data Could Detect Warning Signs Hours Before Cardiac Arrest Occurs</pp:subtitle><description><![CDATA[<p><span>Can artificial intelligence and consumer wearable devices help identify who is at risk of sudden cardiac arrest years before it happens—or in the hours leading up to it?</span></p><p><span><img class="image_resized image-style-align-right" style="width:240px;" src="https://content.presspage.com/uploads/2110/177b9a0e-e963-46a3-8a4e-176f07a337c9/800_chugh-sumeet.chughs-1280x1280.jpeg?x=1791409732543" alt="Sumeet Chugh, MD" width="240" />Supported by more than $5 million in new funding from the National Institutes of Health (NIH) and the American Heart Association (AHA), </span><a href="https://www.cedars-sinai.edu/health-sciences-university.html"><span>Cedars-Sinai Health Sciences University</span></a><span> investigators </span><a href="https://researchers.cedars-sinai.edu/Sumeet.Chugh"><span>Sumeet Chugh, MD</span></a><span>, and </span><a href="https://researchers.cedars-sinai.edu/Kyndaron.Reinier"><span>Kyndaron Reinier, PhD, MPH</span></a><span>, are building on two decades of collaborative research to improve long-term risk prediction and spot warning signs shortly before sudden cardiac arrest strikes.</span></p><p><span>“We’re cautiously optimistic that incorporating AI tools and wearables data will improve prevention of cardiac arrest and outcomes for this lethal condition,” said Chugh, who directs the </span><a href="https://www.cedars-sinai.edu/health-sciences-university/research/departments-institutes/cardiology/cardiac-arrest-prevention.html"><span>Center for Cardiac Arrest Prevention</span></a><span> and the </span><a href="https://www.cedars-sinai.edu/health-sciences-university/research/departments-institutes/biomedical-sciences/artificial-intelligence-medicine.html"><span>Artificial Intelligence in Medicine Research Center</span></a><span> at Cedars-Sinai.</span></p><p><span>Out-of-hospital sudden cardiac arrest affects about 1,000 people in the U.S. </span><a href="https://www.sca-aware.org/about-sca" target="_blank" rel="noreferrer noopener"><span>each day</span></a><span>. Unlike a heart attack—a circulation problem caused by a blocked artery—</span><a href="https://www.heart.org/en/health-topics/cardiac-arrest/about-cardiac-arrest" target="_blank" rel="noreferrer noopener"><span>cardiac arrest</span></a><span> is an electrical failure in which the heart suddenly develops a chaotic rhythm and stops pumping blood. Without immediate CPR and defibrillation, death follows within minutes.</span></p><p><span>“Because many cases occur without warning, and cardiac arrest is fatal in about 90% of cases, improving risk identification and prevention is critical,” said Reinier, associate director of Epidemiology in the Center for Cardiac Arrest Prevention.</span></p><p><span>To mark Sudden Cardiac Arrest Awareness Month in October, the </span><i><span>Cedars-Sinai Newsroom</span></i><span> spoke with Chugh and Reinier about the latest advances in cardiac arrest </span><a href="https://www.cedars-sinai.org/newsroom/two-studies-advance-sudden-cardiac-arrest-prediction/"><span>prediction</span></a><span> and prevention.</span></p><h2><span><strong>Why is sudden cardiac arrest so difficult to predict?</strong></span></h2><p><span><strong>Reinier:</strong> For up to half of patients, cardiac arrest is the first sign of underlying heart disease. Historically, clinicians relied on left ventricular ejection fraction, or LVEF—a measure of heart pumping function—to gauge risk. But LVEF has become less predictive as treatments for reduced heart function have improved. Also, many people who suffer cardiac arrest never had severely reduced LVEF. So, better risk predictors are essential.</span></p><p><span><strong>Chugh:</strong> Implantable defibrillators—which act like personal paramedics, delivering a shock within seconds when they detect a dangerous heart rhythm—were once effective at protecting people with weak heart function. In the past, implanting 100 defibrillators based on LVEF saved 10 to 15 lives a year. Today, that number is closer to three to five. LVEF simply isn’t catching enough high-risk patients anymore.</span></p><h2><span><strong>What has earlier research revealed about prediction and prevention?</strong></span></h2><p><span><strong>Chugh:</strong> Over two decades of community-based research in <img class="image_resized image-style-align-right" style="width:240px;" src="https://content.presspage.com/uploads/2110/eadb7a44-7ab9-42aa-b8c3-2e110b692d8b/800_kyndaron-reinier-phd-mph-cedars-sinai.jpg?x=1791409953845" alt="Kyndaron Reinier, PhD, MPH. Photo courtesy of Kyndaron Reinier, PhD, MPH." width="240" />Oregon and California allowed us to study cardiac arrest in approximately 2 million people. With help from local paramedics, police, firefighters and the coroner, we identified nearly every cardiac arrest that occurred. We combined the data collected by paramedics with the individuals’ electronic health record to develop a unique learning health system. This resource helped Dr. Reinier and the Center for Cardiac Arrest Prevention team develop a ventricular fibrillation risk score, called VFRisk, that outperformed LVEF in identifying at-risk people in those populations.</span></p><p><span>Paramedics also collected blood samples, which revealed genetic and protein patterns unique to cardiac arrest patients.</span></p><p><span><strong>Reinier: </strong>VFRisk uses 13 variables, including electrocardiogram [ECG] measures, heart structure imaging from echocardiograms, and clinical history, such as cardiovascular risk factors and other medical conditions. We also evaluated warning symptoms—like chest pain, shortness of breath and palpitations—alongside blood proteins. We’ve </span><a href="https://www.cedars-sinai.org/newsroom/cedars-sinai-investigators-move-closer-to-predicting-sudden-cardiac-arrest/"><span>proved</span></a><span> that combining dynamic risk (how a person’s heart health changes over time) and static risk (a single snapshot in time) can provide a clearer, earlier warning.</span></p><h2><span><strong>How does your new research build on these findings?</strong></span></h2><p><span><strong>Chugh:</strong> The new grants allow us to test new tools in a real-world health system setting. For our NIH-funded study, we’re using de-identified electronic health records from the O.S.C.A.R. [Observational Study of Cardiac Arrest Risk] cohort—about 400,000 Los Angeles County residents treated at Cedars-Sinai—to evaluate how well VFRisk predicts events over time and determine whether adding dynamic risk markers improves risk prediction.</span></p><h2><span><strong>How can AI help?</strong></span></h2><p><span><strong>Chugh:</strong> Conventional tools can analyze numbers and text well, but it is much more difficult to integrate digital ECG signals, moving echocardiogram images, biological samples and health records. AI can unify complex information from disparate sources and identify subtle patterns that would be difficult to detect by examining only a few individual markers. We will compare AI-based methods with conventional approaches to determine whether they improve prediction.</span></p><h2><span><strong>Where do wearable devices fit into the picture?</strong></span></h2><p><span><strong>Reinier:</strong> The AHA-funded study uses wearables to track near-term risk. Over three years, we will monitor 600 high-risk O.S.C.A.R. patients identified by their VFRisk and provide them with a fitness tracker that logs heart rate, heart-rate variability, oxygen saturation and activity levels. By establishing personal baselines, we can analyze rolling 48-hour windows for subtle deviations before an event occurs. Paired with clinical history and AI analysis, wearable data could signal when an event is imminent.</span></p><h2><span><strong>What is the bottom line for the future of cardiac arrest prevention?</strong></span></h2><p><span><strong>Reinier: </strong>By broadening risk markers, we hope to pinpoint high-risk individuals earlier while reassuring low-risk patients. Eventually, if wearable data and symptoms indicate rising short-term risk, we could provide clearer guidance on when to seek urgent care.</span></p><p><span>In the immediate term, if you witness a cardiac arrest, </span><a href="https://www.cedars-sinai.org/newsroom/quick-action-saves-dancer-after-sudden-cardiac-arrest/"><span>fast action</span></a><span> is essential: Call 911, start CPR and use an automated external defibrillator [AED] if available.</span></p><p><span style="color:hsl(353,76%,49%);"><i><span><strong>Cedars-Sinai Health Sciences University is advancing groundbreaking research and educating future leaders in medicine, biomedical sciences and allied health sciences. </strong></span></i></span><a href="https://www.cedars-sinai.edu/health-sciences-university.html"><span style="color:hsl(353,76%,49%);"><i><span><strong>Learn more</strong></span></i></span></a><span style="color:hsl(353,76%,49%);"><i><span><strong> about the university.</strong></span></i></span></p>]]></description><category><![CDATA[News,Heart,Artificial Intelligence,Kristin Reynolds,sumeet-chugh-1385885,Heart Research]]></category>
            <pubDate>Mon, 19 Oct 2026 06:00:00 -0700</pubDate>
            <pp:lastModified>Thu, 15 Oct 2026 21:53:21 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/cb3c98b2-4bb1-45b0-b9c4-0edd5b77fe94/500_smart-watch-cedars-sinai.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/cb3c98b2-4bb1-45b0-b9c4-0edd5b77fe94/500_smart-watch-cedars-sinai.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/cb3c98b2-4bb1-45b0-b9c4-0edd5b77fe94/smart-watch-cedars-sinai.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Cedars-Sinai investigators are studying how artificial intelligence and consumer wearables can help detect sudden cardiac arrest risk before an event occurs. Photo by Getty.]]></pp:imageTitle><pp:imageDescription><![CDATA[Older man with white hair and beard looks at his smartwatch to check his pulse after exercising outdoors]]></pp:imageDescription></item><item>
                        <title>Weight Loss Drugs May Protect Against Heart Failure</title>
                        <link>https://www.cedars-sinai.org/newsroom/weight-loss-drugs-may-protect-against-heart-failure/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/weight-loss-drugs-may-protect-against-heart-failure/</guid><pp:caseid>818415</pp:caseid><pp:subtitle>Low Doses of GLP-1s Provide Powerful Heart Health Benefits Independent of Weight Control, Preclinical Research Finds</pp:subtitle><description><![CDATA[<p><span>Weight loss drugs known as GLP-1s may help protect against heart failure even at doses too low to produce significant weight loss, according to a laboratory study led by Cedars-Sinai Health Sciences University investigators.</span></p><p><span><img class="image_resized image-style-align-right" style="width:230px;" src="https://content.presspage.com/uploads/2110/4a23fa7c-bff1-400e-b2d2-4831941a098a/800_david-lefer-cedars-sinai.jpg?x=1791566272729" alt="David Lefer, PhD. Photo courtesy of David Lefer, PhD." width="230" />“Our findings provide a strong mechanistic rationale for studying GLP-1 medicines as potential treatments for heart failure,” said </span><a href="https://researchers.cedars-sinai.edu/David.Lefer"><span>David Lefer, PhD</span></a><span>, director of Translational Research in the Department of Cardiac Surgery in the </span><a href="https://www.cedars-sinai.edu/health-sciences-university/research/departments-institutes/smidt-heart-institute.html"><span>Smidt Heart Institute</span></a><span> at Cedars-Sinai and co-senior author of the study.</span></p><p><span>The study, published in the </span><a href="https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag732/8862375?searchresult=1" target="_blank" rel="noreferrer noopener"><i><span>European Heart Journal</span></i></a><span>, investigated the drugs’ effects on heart failure with preserved ejection fraction. The incurable disorder, in which the heart pumps out blood normally but is too stiff to fill properly, accounts for more than half of the roughly 6.7 million heart failure cases in the U.S. each year, according to the American College of Cardiology.</span></p><p><span>Investigators administered low doses of semaglutide, a GLP-1 drug, to laboratory rats and minipigs with a condition that mimics a subtype of heart failure with preserved ejection fraction that is associated with obesity. They found that while the drug didn’t reduce overall body weight, it significantly reduced the heart’s stiffness. The drug also reduced heart enlargement and tissue scarring. The researchers were encouraged to observe that the drug also cleared damaging fat around the heart and liver.</span></p><p><span>“This opens the door to potentially prescribing GLP-1s at low doses to achieve major cardiovascular protection while minimizing common side effects,” said </span><a href="https://researchers.cedars-sinai.edu/Traci.Goodchild"><span>Traci Goodchild, PhD</span></a><span>, professor of Cardiac Surgery in the Smidt Heart Institute and co-senior author of the study.</span></p><p><span>The authors emphasized that the study’s findings do not diminish the well-established benefits of weight loss for the heart. Instead, the results indicate that GLP-1 therapy may provide additional, direct cardiovascular benefits independent of weight loss.</span></p><p><span>“These data suggest that low-dose semaglutide has powerful protective effects on the heart independent of its impact on weight loss,” said Mahmoud Elbatreek, PhD, a project scientist in the Department of Cardiac Surgery in the Smidt Heart Institute and lead author of the study.</span></p><p><i><span>Additional Cedars-Sinai authors include Zhen Li, Xiaoman Yu, Miguel Huerta, Xinheng Zhang, Hsin-Jung R. Yang and Michael E. Bowdish.</span></i></p><p><i><span>Additional authors include Natalie D. Gehred, Tatiana Gromova, Jingshu Chen, Naoto Muraoka, Martin Borch Jensen, Vinay Kartha, Chris Carrico, Timothy D. Allerton, Sanjiv J. Shah, Kathleen C. Woulfe, Timothy A. McKinsey, Edwin Yoo, David J. Polhemus and Thomas M. Vondriska</span></i><span>.</span></p><p><i><span>Funding: This study was supported by NIH HL181016 (D.J.L.), NIH HL105699 (T.M.V.), NIH HL174996 (T.M.V. and D.J.L.), NIH HL159428 (T.T.G.). D.J.L. was supported by the California Institute for Regenerative Medicine (CIRM, PDEV-19141). N.D.G. was supported by the American Heart Association Predoctoral Fellowship PRE1026591. T.A.M. was supported by the National Institutes of Health grants R01HL171711 and HL181226 and an American Heart Association Collaborative Sciences Award (24CSA1255857). H.-J.R.Y. was supported by National Institutes of Health grants 1R01HL165211 and1R01HL181091. D.J.P. was supported by a (NIH) Ruth L. Kirschstein National Research Service Award Institutional Training Grant (5T32HL007227).</span></i></p><p><i><span>Disclosure of interest:</span></i><span> </span><i><span>J.C., N.M., M.B.J., V.K., and C.C. work for Gordian Biotechnology. S.J.S. is a consultant for Abbott, Alleviant, Amgen, Aria CV, AstraZeneca, Axon Therapies, Bayer, Boehringer-Ingelheim, Boston Scientific, Bristol Myers Squibb, Corvia, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eli Lilly, Imara, Impulse Dynamics, Intellia, Ionis, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Regeneron, Rivus, Shifamed, Tenax, Tenaya, and Ultromics. T.A.M. is a co- founder of Myracle Therapeutics, is on the scientific advisory boards of Eikonizo Therapeutics and Revier Therapeutics and is a consultant for Augustine Therapeutics. All other authors declare no disclosure of interest for this contribution.</span></i></p><p><span style="color:hsl(353,76%,49%);"><i><span><strong>Cedars-Sinai Health Sciences University is advancing groundbreaking research and educating future leaders in medicine, biomedical sciences and allied health sciences. </strong></span></i></span><a href="https://www.cedars-sinai.edu/health-sciences-university.html"><span style="color:hsl(353,76%,49%);"><i><span><strong>Learn more</strong></span></i></span></a><span style="color:hsl(353,76%,49%);"><i><span><strong> about the university.</strong></span></i></span></p>]]></description><category><![CDATA[Exclude,Research,Heart Failure Research,Heart Research,Heart,Newsroom Author]]></category>
            <pubDate>Tue, 13 Oct 2026 07:00:00 -0700</pubDate>
            <pp:lastModified>Thu, 15 Oct 2026 02:57:28 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/a85290a2-1209-4d80-809e-cd00031f8703/500_glp-1-cedars-sinai.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/a85290a2-1209-4d80-809e-cd00031f8703/500_glp-1-cedars-sinai.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/a85290a2-1209-4d80-809e-cd00031f8703/glp-1-cedars-sinai.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[In a laboratory study, researchers found semaglutide significantly improved the heart&amp;rsquo;s performance. Photo by Getty.]]></pp:imageTitle><pp:imageDescription><![CDATA[GLP-1 injection pen and medication vial for subcutaneous use on yellow background.]]></pp:imageDescription></item><item>
                        <title>Cedars-Sinai Cancer ‘Smart Bomb’ to Get Development Boost</title>
                        <link>https://www.cedars-sinai.org/newsroom/cedars-sinai-cancer-smart-bomb-to-get-development-boost/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/cedars-sinai-cancer-smart-bomb-to-get-development-boost/</guid><pp:caseid>818702</pp:caseid><pp:subtitle>Nanotechnology Characterization Laboratory Will Test and Study the Cedars-Sinai Therapy Intended for Brain Metastatic Breast Cancer</pp:subtitle><description><![CDATA[<p><span>An experimental nanoparticle developed by Cedars-Sinai Health Sciences University investigators, which delivers cancer treatment directly to tumors in the brain, has been selected for evaluation by the Nanotechnology Characterization Laboratory (NCL). The program, funded by the National Cancer Institute, is designed to help promising nanotechnologies advance toward clinical trials.</span></p><p><span>The therapeutic nanoparticle, called HerDox2.0, was developed by </span><a href="https://researchers.cedars-sinai.edu/Lali.Medina-Kauwe"><span>Lali Medina-Kauwe, PhD</span></a><span>, professor of </span><a href="https://www.cedars-sinai.edu/health-sciences-university/research/departments-institutes/biomedical-sciences.html"><span>Biomedical Sciences</span></a><span> at Cedars-Sinai and associate director of Basic Research at Cedars-Sinai Cancer.</span></p><p><span>“Acceptance into the elite Nanotechnology Characterization Laboratory program will provide thorough testing of HerDox2.0 by top experts in the field, moving us toward our goal of submitting it to the Food and Drug Administration as an Investigational New Drug,” Medina-Kauwe said.</span></p><p><span>The particle works like a cancer “smart bomb,” connecting with a protein called HER3, which helps it cross the protective blood-brain barrier and target and penetrate tumor cells. Medina-Kauwe has been working on the particle for decades and most recently described it in a 2025 paper in </span><a href="https://www.cedars-sinai.org/newsroom/lab-study-shows-tumor-invading-protein-delivers-therapy-straight-to-the-brain/"><i><span>Nature Nanotechnology</span></i></a><i><span>.</span></i></p><p><span>“We’ve put a huge amount of preclinical work into this, so I knew the technology was ready. Having the program help move it to the next stage is a huge jump for us,” Medina-Kauwe said. “The program will provide advanced-level analysis that otherwise would have required hiring a third party at a cost of hundreds of thousands of dollars.”</span></p><p><span>The Nanotechnology Characterization Laboratory analysis will help determine the physical and chemical properties of the formulation, evaluate the particle’s compatibility with and stability in human blood, assess potential immune responses the particle might elicit, and evaluate general toxicity of the formulation. Testing will also evaluate whether the particle can be manufactured consistently and in larger-scale batches for clinical use.</span></p><p><span><img class="image-style-align-left" src="https://content.presspage.com/uploads/2110/8493835a-56de-43bc-8781-73ed862f61e3/500_robertfiglinmd.jpg?x=1791570142754" alt="Robert Figlin, MD" width="200" />The Nanotechnology Characterization Laboratory, </span><span style="padding:0in;">operated at the Frederick National Laboratory for Cancer Research,</span><span> was founded in 2004 in collaboration with the Food and Drug Administration and the National Institute of Standards and Technology to expedite the development of promising nanotech therapies and diagnostics. To date, the laboratory has tested more than 1,000 nanomaterials and worked with more than 250 academic researchers and companies.</span></p><p><span>“We are happy to welcome Dr. Medina-Kauwe’s team to the NCL’s Assay Cascade Characterization Program,” said Marina Dobrovolskaia, PhD, NCL co-director and director of Operations.</span></p><p><span>Acceptance into the program required a written application describing key features of the particle, followed by a live presentation to a panel of nanotechnology, pharmacological and pharmaceutical experts regarding the particle’s possible path to clinical use.</span></p><p><span>“Even as we are offering patients leading-edge therapies, we are looking to new treatments on the horizon,” said </span><a href="https://researchers.cedars-sinai.edu/Robert.Figlin"><span>Robert Figlin, MD</span></a><span>, associate dean of Cedars-Sinai Cancer Care. “Acceptance of HerDox2.0 into this prestigious program highlights the level of translational work Dr. Medina-Kauwe and her team are doing to bring novel therapies to our patients.”</span></p><p><span>Medina-Kauwe said HerDox2.0 has advantages over currently available therapies, as well as some in development. And while it has potential against several cancer types, breast cancer that has spread to the brain will be the team’s first target if the therapy makes it to clinical trials.</span></p><p><span>“The best treatment currently available for brain metastatic breast cancer is systemic chemotherapy, which can be hard on the body,” Medina-Kauwe said. “And metastatic tumors are generally resistant to chemotherapy. Our work so far has shown that our particle penetrates tumor cells but spares healthy tissue. We’re focusing on these tumors first because we believe we can make a big difference for patients.”</span></p><p><span style="color:hsl(353,76%,49%);"><i><span><strong>Cedars-Sinai Health Sciences University is advancing groundbreaking research and educating future leaders in medicine, biomedical sciences and allied health sciences. </strong></span></i></span><a href="https://www.cedars-sinai.edu/health-sciences-university.html?adobe_mc=MCMID%3D79521921680015491943235909713257507329%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1733161540"><span style="color:hsl(353,76%,49%);"><i><span><strong><u>Learn more</u></strong></span></i></span></a><span style="color:hsl(353,76%,49%);"><i><span><strong> about the university.</strong></span></i></span></p><p><span><img class="image_resized" style="width:901px;" src="https://content.presspage.com/uploads/2110/17c7b891-d313-42f0-b0ea-75b85f7285bc/thisillustrationshowshowtheherdox2.0nanoparticleisformedwithachemotherapydrugatitscenter.imagecourtesymedina-kauwelabatcedars-sinai..jpg?x=1791569600626" alt="This illustration shows how the HerDox2.0 nanoparticle is formed with a chemotherapy drug at its center. Image courtesy Medina-Kauwe Lab at Cedars-Sinai." width="901" /></span></p>]]></description><category><![CDATA[Christina Elston,Cancer Research,Cancer,Exclude,Research,Faculty News]]></category>
            <pubDate>Mon, 12 Oct 2026 07:00:00 -0700</pubDate>
            <pp:lastModified>Sat, 10 Oct 2026 01:25:44 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/8d48c456-5b2d-423a-b977-607926149d51/500_lalimedina-kauwephdprofessorofbiomedicalsciencesatcedars-sinaiandassociatedirectorofbasicresearchatcedars-sinaicancerdevelopedanexperimentalnanoparticlethatworkslikeacancerlsquosmartbomb.rdquophotobycedars-sinai..jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/8d48c456-5b2d-423a-b977-607926149d51/500_lalimedina-kauwephdprofessorofbiomedicalsciencesatcedars-sinaiandassociatedirectorofbasicresearchatcedars-sinaicancerdevelopedanexperimentalnanoparticlethatworkslikeacancerlsquosmartbomb.rdquophotobycedars-sinai..jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/8d48c456-5b2d-423a-b977-607926149d51/lalimedina-kauwephdprofessorofbiomedicalsciencesatcedars-sinaiandassociatedirectorofbasicresearchatcedars-sinaicancerdevelopedanexperimentalnanoparticlethatworkslikeacancerlsquosmartbomb.rdquophotobycedars-sinai..jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Lali Medina-Kauwe, PhD, professor of Biomedical Sciences at Cedars-Sinai and associate director of Basic Research at Cedars-Sinai Cancer, developed an experimental nanoparticle that works like a cancer &amp;lsquo;smart bomb.&amp;#039; Photo by Cedars-Sinai.]]></pp:imageTitle><pp:imageDescription><![CDATA[A female scientist, Lali Medina-Kauwe, PhD, standing in a lab.]]></pp:imageDescription></item><item>
                        <title>Cedars-Sinai Establishes Center for Autonomous Robotic Surgery</title>
                        <link>https://www.cedars-sinai.org/newsroom/cedars-sinai-establishes-center-for-autonomous-robotic-surgery/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/cedars-sinai-establishes-center-for-autonomous-robotic-surgery/</guid><pp:caseid>818603</pp:caseid><pp:subtitle>New Center Brings Together Surgical and Engineering Expertise to Advance the Next Generation of Robotic Surgery</pp:subtitle><description><![CDATA[<p>Cedars-Sinai has launched the Center for Autonomous Robotic Surgery, a new initiative bringing surgeons and engineers together to develop the next generation of surgical robots capable of performing certain surgical tasks autonomously while working alongside surgeons in the operating room.</p><p><img class="image-style-align-right" style="width:200px;" src="https://content.presspage.com/uploads/2110/3a95bf2b-fbb1-49a4-bc2d-d72a3af16974/500_andrew-hung-md-cedars-sinai.jpeg?x=1791518868902" width="200" alt="Andrew J. Hung, MD" /><a href="https://www.cedars-sinai.org/provider/andrew-hung-2646283.html">Andrew J. Hung, MD</a>, a urologist and minimally invasive robotic surgery specialist in the Cedars-Sinai <a href="https://www.cedars-sinai.org/programs/urology.html">Department of Urology</a>, will serve as co-director of the new center. Partnering with Hung as co-director is <a href="https://researchers.cedars-sinai.edu/Michael.Yip">Michael C. Yip, PhD</a>, <span> </span>who joins Cedars-Sinai from the University of California, San Diego (UCSD), and holds a joint faculty appointment in Urology and Computational Biomedicine.</p><p>At UCSD, Yip directed the Advanced Robotics and Controls Laboratory and developed expertise in surgical robotics, machine learning and autonomous systems. Together, Hung and Yip form a surgeon-scientist partnership designed to bridge the gap between the operating room and the engineering lab.</p><p>“For too long, the development of surgical robots has happened at a distance from the operating room, but the Center for Autonomous Robotic Surgery changes that,” said Hung, an internationally recognized leader in the integration of AI and machine learning into robotic surgery. “As surgeons, we know what good surgery looks like. By embedding clinical expertise directly into the engineering process, we can build autonomous systems that surgeons will trust and patients will benefit from. This is where the future of robotic surgery will be built.”</p><p>Hung’s experience in robotic surgery and research into <a href="https://www.cedars-sinai.org/newsroom/ai-analyzes-surgical-technique-to-improve-prostate-cancer-care/">AI-driven surgical performance metrics</a> will help guide how autonomous systems function in the operating room. Yip’s engineering science innovation will make the vision possible.</p><p><img class="image-style-align-right" style="width:200px;" src="https://content.presspage.com/uploads/2110/39943302-c594-4432-8d90-5d953c440916/500_michael-yip-phd-cedars-sinai.jpeg?x=1791518885023" width="200" alt="Michael C. Yip, PhD" />Together, they plan to develop the next generation of surgical robots and surgeon-driven autonomous systems designed to augment a surgeon’s clinical judgment rather than replace it, making it possible to treat more complex diseases and reach more patients. The goal is to make surgery safer, more precise and more available.</p><p>“Surgical robotics has reached a turning point,” Yip said. “We now have the tools, from machine learning to advanced sensing, to build systems that genuinely understand the surgical environment and be able to autonomously support the surgical team in real time. Co-creating this center at Cedars-Sinai gives me the opportunity to bring the leading edge in surgical robot intelligence into clinical practice, working directly with physicians who are treating patients every day to make sure it is translated responsibly and effectively.”</p><p>As the co-directors embark on this new initiative for Cedars-Sinai, Hung and Yip are recruiting clinicians, engineers and data scientists to join the center’s multidisciplinary team building the future of robotic surgery.</p><p>“The launch of the Center for Autonomous Robotic Surgery marks a pivotal moment for surgical innovation at Cedars-Sinai,” said <a href="https://researchers.cedars-sinai.edu/Jeffrey.Golden?prevPageName=cs-org%3Acedars-sinai%3Anewsroom%3Acedars-sinai-animal-care-and-use-program-recognized">Jeffrey A. Golden, MD</a>, executive vice dean of Research and Education and director of the Burns and Allen Research Institute. “Dr. Hung and Dr. Yip represent exactly the kind of partnership we need to move this field forward. Their respective leadership will give the Center for Autonomous Robotic Surgery a rare ability to develop autonomous systems that are both scientifically rigorous and grounded in real patient care.”</p><p><span style="color:hsl(353,76%,49%);"><i><span><strong>Read more from Cedars-Sinai Stories and Insights: </strong></span></i></span><a href="https://www.cedars-sinai.org/stories-and-insights/innovation-and-research/how-ai-is-turning-surgery-from-art-into-science"><span style="color:hsl(353,76%,49%);"><i><span><strong>How AI Is Turning Medical Intuition Into Evidence</strong></span></i></span></a></p>]]></description><category><![CDATA[Exclude,Faculty News,AI,Surgery,Urology,Computational Biomedicine,andrew-hung-2646283,Jillian Scholten]]></category>
            <pubDate>Mon, 12 Oct 2026 06:00:00 -0700</pubDate>
            <pp:lastModified>Sat, 10 Oct 2026 01:25:18 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/d03adbeb-1f48-4624-b7d9-53cdac3858d0/500_robotic-surgery-cedars-sinai-2.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/d03adbeb-1f48-4624-b7d9-53cdac3858d0/500_robotic-surgery-cedars-sinai-2.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/d03adbeb-1f48-4624-b7d9-53cdac3858d0/robotic-surgery-cedars-sinai-2.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[The Center for Autonomous Robotic Surgery at Cedars-Sinai aims to build the future of robotic surgery, making it more accessible for patients. Photo by Cedars-Sinai.]]></pp:imageTitle><pp:imageDescription><![CDATA[Surgeons in an operating room utilizing a surgical robot for an operation.]]></pp:imageDescription></item><item>
                        <title>Cedars-Sinai Cancer Advances Leadership Roles</title>
                        <link>https://www.cedars-sinai.org/newsroom/cedars-sinai-cancer-advances-leadership-roles/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/cedars-sinai-cancer-advances-leadership-roles/</guid><pp:caseid>818289</pp:caseid><pp:subtitle>Robert Figlin, MD, and Andrew Hendifar, MD, Assume New Positions to Advance Cancer Care, Research</pp:subtitle><description><![CDATA[<p>Two <a href="https://www.cedars-sinai.edu/health-sciences-university/research/departments-institutes/cancer.html">Cedars-Sinai Cancer</a> leaders are assuming new roles to help advance cancer care, education and research for patients in Los Angeles and beyond. <a href="https://researchers.cedars-sinai.edu/Robert.Figlin">Robert Figlin, MD</a>, is now associate dean of Cedars-Sinai Cancer Care, and <a href="https://researchers.cedars-sinai.edu/Andrew.Hendifar">Andrew Hendifar, MD</a>, is interim director of Cedars-Sinai Cancer.</p><p><img class="image_resized image-style-align-left" style="width:225px;" src="https://content.presspage.com/uploads/2110/e4daabdb-7380-416a-9d3d-b7053afc548e/800_ravi-thadhani-md-mph-cedars-sinai.jpg?x=1791323100607" alt="Ravi Thadhani, MD, MPH" width="225" />“We look forward to the continued contributions of Dr. Figlin and Dr. Hendifar,” said <a href="https://www.cedars-sinai.org/about/leadership/executive-management/ravi-thadhani-md-mph.html">Ravi Thadhani, MD, MPH</a>, <span>executive vice president, chief physician executive and dean of the Medical Faculty at Cedars-Sinai</span>. “We are confident their talent and leadership will continue to spur the growth and vision of Cedars-Sinai Cancer as one of the nation’s leading destinations for cancer care, research and education.”</p><p>As associate dean, Figlin, formerly interim director of Cedars-Sinai Cancer, will serve as a senior adviser and institutional leader. Drawing on his experience, he will guide the advancement of strategic and clinical cancer priorities across Cedars-Sinai Health System and assist with key physician and leadership recruitment efforts and national outreach.</p><p>“I look forward to building on the work we have done to promote research excellence that translates into leading-edge therapies for cancer patients,” Figlin said. “To support such work, strategic direction is key.”</p><p>Under Figlin’s leadership as interim director, Cedars-Sinai Cancer increased clinical volumes, expanded access to clinical trials and advanced the integration of cancer services across health system hospitals. He was instrumental in establishing the Investigator Initiated Trials Program in Cedars-Sinai Cancer and offering oversight for the Investigator Initiated Trials Incubator.</p><p>Through his work in clinical trials, <img class="image_resized image-style-align-left" style="width:225px;" src="https://content.presspage.com/uploads/2110/8493835a-56de-43bc-8781-73ed862f61e3/800_robertfiglinmd.jpg?x=1791323142957" alt="Robert Figlin, MD" width="225" />Figlin shifted the treatment landscape for renal cell carcinoma, the most common type of kidney cancer. His pioneering work in immunotherapy testing proved that the immune system could eradicate kidney cancer and achieve long-term survival. He has also been a principal investigator on pivotal trials of targeted therapies that block enzymes responsible for driving cancer cells to multiply, and in trials establishing combination therapies as a preferred first-line treatment.</p><p><span>Figlin is the Steven Spielberg Family Chair in Hematology Oncology and a professor of Medicine and Biomedical Sciences. He formerly served as chair and associate director of the Department of Medical Oncology and Therapeutics Research as well as associate director for Clinical Research at City of Hope Comprehensive Cancer Center. He also held an endowed chair in urologic oncology at the David Geffen School of Medicine at UCLA.</span></p><p><span>A member of multiple national professional organizations, Figlin has also published more than 430 peer-reviewed articles in major medical journals and authored and edited multiple textbooks on kidney cancer.</span></p><p>He currently serves as the editor of <i>Oncology News Central </i>and the <i>Kidney Cancer Journal.</i></p><p><img class="image_resized image-style-align-left" style="width:225px;" src="https://content.presspage.com/uploads/2110/e5c02c59-ac93-43e1-873b-2245af59b1fd/800_andrewhendifarmd.jpg?x=1791323169913" alt="Andrew Hendifar, MD" width="225" />As interim director of Cedars-Sinai Cancer, Hendifar will continue building the academic cancer program based on excellence in clinical care, research and teaching. He will deepen the integration of cancer services at Cedars-Sinai Medical Center, Cedars-Sinai Medical Network and health system affiliates.</p><p>“I look forward to supporting the physicians, scientists and clinical care specialists who make up Cedars-Sinai Cancer,” Hendifar said. “By continuing to advance scientific discovery, precision medicine and patient-centered and community-informed approaches, we can redefine cancer care.”</p><p>Hendifar brings extensive clinical, research and management experience to this interim leadership role.</p><p>He has been a principal investigator on Phase III clinical trials and published in the highest-impact journals, including a Phase III study in <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2605555" target="_blank" rel="noreferrer noopener"><i>The New England Journal of Medicine</i></a> in May about an experimental treatment that nearly doubled survival time for patients with advanced pancreatic cancer.</p><p>Hendifar has led key studies on integrating artificial intelligence into pancreatic cancer care, and he is a principal investigator on multiple trials focusing on novel therapeutic strategies and targeting cancer wasting syndrome.</p><p>He currently serves as a professor of Medicine, medical director of the Cancer Clinical Trials Office and medical director of the Gastrointestinal Oncology Disease Research Group at the Cedars-Sinai Samuel Oschin Comprehensive Cancer institute.</p><p>Hendifar began his career at Cedars-Sinai in 2012, was a founding director of the Hematology and Oncology Fellowship Program and has served on several Cedars-Sinai committees, including those for the Internal Review Board, Pharmacy and Therapeutics, and Medical Oncology/Cancer Center leadership, as well as the Medical Executive Committee. </p><p>In addition to his medical and research accomplishments, Hendifar has executive managerial experience as chief medical officer for the Pancreatic Cancer Action Network and holds a master’s degree in health systems management from Tulane University, where he earned his medical degree. He has served as a member of the National Institutes of Health (NIH) Neuroendocrine Tumor Task Force and on the steering committee for the Precision Promise Consortium.</p><p><span style="color:hsl(353,76%,49%);"><i><span><strong>Cedars-Sinai Health Sciences University is advancing groundbreaking research and educating future leaders in medicine, biomedical sciences and allied health sciences. </strong></span></i></span><a href="https://www.cedars-sinai.edu/health-sciences-university.html?adobe_mc=MCMID%3D79521921680015491943235909713257507329%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1733161540"><span style="color:hsl(353,76%,49%);"><i><span><strong><u>Learn more</u></strong></span></i></span></a><span style="color:hsl(353,76%,49%);"><i><span><strong> about the university.</strong></span></i></span></p>]]></description><category><![CDATA[Exclude,Faculty News,Cancer,Christina Elston,robert-figlin-1071249,andrew-hendifar-546093]]></category>
            <pubDate>Wed, 07 Oct 2026 07:00:00 -0700</pubDate>
            <pp:lastModified>Wed, 07 Oct 2026 01:14:52 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/e0ffab1e-6d68-4437-ab64-90747739cc99/500_cedars-sinaicancernamesrobertfiglinmdassociatedeanofcancercareandandrewhendifarmdinterimdirectortoadvancecareresearchandeducation..jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/e0ffab1e-6d68-4437-ab64-90747739cc99/500_cedars-sinaicancernamesrobertfiglinmdassociatedeanofcancercareandandrewhendifarmdinterimdirectortoadvancecareresearchandeducation..jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/e0ffab1e-6d68-4437-ab64-90747739cc99/cedars-sinaicancernamesrobertfiglinmdassociatedeanofcancercareandandrewhendifarmdinterimdirectortoadvancecareresearchandeducation..jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Cedars-Sinai Cancer names Robert Figlin, MD, associate dean of cancer care and Andrew Hendifar, MD, interim director, to advance care, research and education.]]></pp:imageTitle><pp:imageDescription><![CDATA[An outdoor view of two hospital buildings at an angle to each other, with garden beds with greenery in the foreground.]]></pp:imageDescription></item><item>
                        <title>Michael Buchman Named Chief Investment Officer of Cedars-Sinai</title>
                        <link>https://www.cedars-sinai.org/newsroom/michael-buchman-named-chief-investment-officer-of-cedars-sinai/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/michael-buchman-named-chief-investment-officer-of-cedars-sinai/</guid><pp:caseid>818149</pp:caseid><pp:subtitle>Former Conrad N. Hilton Foundation Investment Leader Will Oversee Cedars-Sinai’s $8 Billion Investment Portfolio</pp:subtitle><description><![CDATA[<p><span>Michael Buchman, JD, MBA, has been named chief investment officer of </span><a href="https://www.cedars-sinai.org/home.html"><span>Cedars-Sinai</span></a><span>, overseeing an $8 billion investment portfolio to support the institution’s mission of advancing the </span><a href="http://cedars-sinai.org/community.html"><span>health of the community</span></a><span>.</span></p><p style="margin-left:0in;"><span>Buchman joins Cedars-Sinai from the Conrad N. Hilton Foundation, where he spent 18 years in a variety of investment roles, including leadership positions for the last decade. He <img class="image_resized image-style-align-right" style="width:334px;" src="https://content.presspage.com/uploads/2110/2399698f-9a9d-4ff5-a2d8-3733c8900039/800_michael-buchman-cedars-sinai.jpg?x=1791244118659" alt="Michael Buchman, JD, MBA, will oversee an investment portfolio that supports Cedars-Sinai's mission of advancing the health of the community. Photo courtesy of Michael Buchman." width="334" />served since 2021 as vice president and chief investment officer managing the foundation’s $8.3 billion investment portfolio.</span></p><p style="margin-left:0in;"><span>At the Hilton foundation, he reported directly to the CEO and worked closely with the investment committee and board of directors to successfully craft investment strategy, including asset allocation, risk management, manager selection and operations.</span></p><p><span>“I am excited to join Cedars-Sinai and look forward to continue stewarding and growing its investment portfolio in service of its mission,” Buchman said. “Investing Cedars-Sinai’s assets by partnering with outstanding investment managers will generate returns that enable us to enhance health and healthcare in Los Angeles and beyond.”</span></p><p style="margin-left:0in;"><span>In his new role, Buchman will oversee Cedars-Sinai’s investment strategy, objectives and policies as established by the board of director’s investment committee, and he will advise on investment portfolio risk and exposure while further developing the investment team.</span></p><p><span>Earlier in his career, Buchman held positions in finance, real estate and law at Citigroup Global Investment Bank and real estate asset-management firm Broadway Partners. He also worked at the law firms Fried Frank Harris Shriver & Jacobson and Skadden Arps Slate Meagher & Flom.</span></p><p><span>Buchman earned his JD from the University of Pennsylvania Law School and an MBA and bachelor’s degree in economics from the Wharton School of the University of Pennsylvania.</span></p><p><span>“Michael is the ideal leader to strategically grow our investment portfolio and enable us to better serve all those who need Cedars-Sinai,” said David Wrigley, executive vice president and chief financial officer of Cedars-Sinai Health System.</span></p><p><span>For Buchman, joining Cedars-Sinai on Dec. 1 marks a homecoming of sorts. He was born at Cedars-Sinai Medical Center, as were each of his three children.</span></p><p><span>“As a native Angeleno, I have seen firsthand the impact Cedars-Sinai has across the city,” he said. “I am thrilled to play my part in ensuring a vibrant Cedars-Sinai for years to come.</span></p><p><span style="color:hsl(353,76%,49%);"><i><span><strong>More from Cedars-Sinai Stories and Insights: </strong></span></i></span><a href="https://www.cedars-sinai.org/stories-and-insights/healthy-living/inspiring-community-health-by-meeting-patients-needs"><span style="color:hsl(353,76%,49%);"><i><strong>Inspiring Community Health by Meeting Patients' Needs</strong></i></span></a></p>]]></description><category><![CDATA[Exclude,Faculty News,Sally Stewart]]></category>
            <pubDate>Tue, 06 Oct 2026 12:00:00 -0700</pubDate>
            <pp:lastModified>Tue, 06 Oct 2026 16:55:17 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/1a4596ad-1a69-4779-8b3d-671be71d59e9/500_cedars-sinai-medical-center-3.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/1a4596ad-1a69-4779-8b3d-671be71d59e9/500_cedars-sinai-medical-center-3.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/1a4596ad-1a69-4779-8b3d-671be71d59e9/cedars-sinai-medical-center-3.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Michael Buchman, JD, MBA, will join Cedars-Sinai Dec. 1 as the health system&amp;rsquo;s chief investment officer.  Photo by Cedars-Sinai.]]></pp:imageTitle><pp:imageDescription><![CDATA[A landscape view of Cedars-Sinai Medical Center towers as seen from a distance through palm tree fronds.]]></pp:imageDescription></item><item>
                        <title>Bernice Coleman, PhD, Inducted as New York Academy of Medicine Fellow</title>
                        <link>https://www.cedars-sinai.org/newsroom/bernice-coleman-phd-inducted-as-new-york-academy-of-medicine-fellow/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/bernice-coleman-phd-inducted-as-new-york-academy-of-medicine-fellow/</guid><pp:caseid>817696</pp:caseid><pp:subtitle>Nurse Scientist Recognized for Advancing Nursing Science, Improving Healthcare and Mentoring the Next Generation of Nurse Scientists</pp:subtitle><description><![CDATA[<p><a href="https://researchers.cedars-sinai.edu/Bernice.Coleman"><span>Bernice Coleman, PhD, ACNP</span></a><span>, director of Nursing Research and Quality Improvement and assistant professor of Biomedical Sciences at Cedars-Sinai, has been inducted as a fellow of the New York Academy of Medicine.</span></p><p><span>Coleman joined Cedars-Sinai in 1987 as a clinical nurse specialist in cardiac surgery. Her research spans bench to bedside to community—with work on genomic transplant disparities, family caregivers and church-based preventive blood pressure education. She earned a master’s degree from the Yale University School of Nursing and a doctorate from the UCLA School of Nursing.</span></p><p><span>“Dr. Coleman’s induction as a fellow of the New York Academy of Medicine is a well-deserved recognition of her impact on nursing, patient care and the advancement of health,” said </span><a href="https://www.cedars-sinai.org/about/leadership/david-marshall-jd-dnp-rn-faan.html"><span>David Marshall, JD, DNP, RN</span></a><span>. “Her leadership, clinical expertise, research and commitment to mentoring others exemplify the kind of influence that strengthens both our profession and the communities we serve. We are proud to celebrate this important achievement and the example she continues to set for colleagues and future generations.”</span></p><p><span>Founded in 1847, the </span><a href="https://nyam.org/" target="_blank" rel="noreferrer noopener"><span>New York Academy of Medicine</span></a><span> is committed to helping all people live healthier, longer lives through innovative research and collaboration. With more than 1,700 distinguished fellows and members, the academy brings together leading experts to translate ideas into policy and real-world impact.</span></p><p><span>The </span><i><span>Cedars-Sinai Newsroom</span></i><span> spoke with Coleman about the significance of the fellowship, her commitment to advancing nursing science and the leadership lessons she hopes to pass on to others.</span></p><h2><span><strong>What does becoming a fellow of the New York Academy of Medicine mean to you personally and professionally?</strong></span></h2><p><span>It is a tremendous honor. Personally, I am deeply grateful to be welcomed into a community with such a long history of advancing health through science, evidence, innovation and service.</span></p><p><span>Professionally, it is especially meaningful because the academy brings together leaders from many disciplines who share a commitment to improving health and addressing some of the most complex healthcare challenges affecting people in the United States. I see the fellowship not simply as recognition, but as an opportunity to contribute.</span></p><h2><span><strong>How did you react when you learned you had been selected?</strong></span></h2><p><span>I was surprised, humbled and very grateful. As your career progresses, you don’t necessarily stop to think about individual recognition because you are usually focused on the next patient, the next research question, the next grant or helping someone else move their work forward. So this caused me to reflect for a moment on the journey and all the people who have been part of it. It was very special.</span></p><h2><span><strong>What aspects of your experience or work contributed to this recognition?</strong></span></h2><p><span>My career has really been driven by curiosity and built at the intersection of clinical practice, research and leadership.</span></p><p><span>Much of my scholarship has grown directly from questions I encountered caring for patients after cardiac surgery or heart transplantation and patients experiencing mechanical circulatory support. That has led to work in transplant outcomes and genomics, caregiver support, health disparities and, more recently, the responsible use of artificial intelligence in healthcare.</span></p><p><span>Another important part of my work has been strengthening nursing science itself—mentoring nurses, developing research infrastructure, advancing the role of clinically based nurse scientists, and helping nurses translate important clinical questions into evidence that can improve care.</span></p><h2><span><strong>What inspired you to enter your field?</strong></span></h2><p><span>I began as a licensed practical nurse and advanced to an acute care nurse practitioner. Clinical practice has always been the foundation of my work.</span></p><p><span>My involvement in heart transplantation and mechanical circulatory support exposed me to extraordinarily complex patients and families and to questions that we simply could not answer with the evidence available at the time.</span></p><p><span>That curiosity led me toward research. I wanted to understand the biological bases for why some patients experienced different outcomes, how biology and genetics might contribute, how we could better support families, and how nurses could generate the evidence needed to improve care.</span></p><p><span>Over time, my career evolved from asking those questions at the bedside to building research programs and helping other nurses ask and answer their own important clinical questions.</span></p><h2><span><strong>Which accomplishments or experiences have been most meaningful to you?</strong></span></h2><p><span>The most meaningful accomplishments are those where I can see that the work has opened a door for someone else or has the potential to change care.</span></p><p><span>My research in heart transplantation and genomics has been important to me because it grew directly from a brother-in-law who died after his heart transplant, and clinical questions about differences in patient outcomes.</span></p><p><span>My work supporting caregivers of patients living with mechanical circulatory support is equally meaningful because these families assume enormous responsibilities that healthcare systems do not always adequately recognize.</span></p><p><span>I am also very proud of the work we have done to advance clinically based nurse scientists and to create opportunities for nurses to conduct, present and publish their work. Helping create national </span><a href="https://www.nln.org/detail-pages/news/2026/06/09/nln-declares-nurse-scientist-day-on-june-14--the-anniversary-of-the-establishment-of-the-national-institute-of-nursing-research" target="_blank" rel="noreferrer noopener"><span>Nurse Scientist Day</span></a><span>, which launched in June 2026, was especially meaningful because it celebrates an entire profession of scientists across the United States whose contributions deserve greater visibility.</span></p><h2><span><strong>How does your current role connect with the mission of the New York Academy of Medicine?</strong></span></h2><p><span>There is a very natural connection. The academy emphasizes using evidence, interdisciplinary collaboration and innovation to improve population health and help people live healthier, longer lives.</span></p><p><span>In my current role, I am trying to do those same things within a healthcare system—identify important clinical problems, generate evidence, translate that evidence into practice, develop the next generation of nurse scientists through supporting PhD nurses at Cedars-Sinai in a research fellowship, and bring disciplines together around problems that cannot be solved by one profession alone.</span></p><p><span>Whether the issue is health disparities, transplantation, genomics, caregiver wellbeing or artificial intelligence, the ultimate question is always: How can this work improve health and healthcare?</span></p><h2><span><strong>What impact do you hope your work will have?</strong></span></h2><p><span>Ultimately, I hope my work demonstrates that research can be both scientifically rigorous and immediately relevant to the people we care for.</span></p><p><span>For patients and families, I hope it leads to more individualized, equitable and supportive care. For Cedars-Sinai, I hope it strengthens a culture in which clinical questions become opportunities for inquiry and improvement.</span></p><p><span>And for nursing, I want nurses and nurse scientists to recognize that their perspective is essential and valuable in solving some of healthcare’s most difficult problems and that they should have a seat at every table where those solutions are being developed.</span></p><p style="margin-left:0px;"><span style="color:hsl(353,76%,49%);"><i><span style="margin:0px;text-align:left;"><strong>Cedars-Sinai Health Sciences University is advancing groundbreaking research and educating future leaders in medicine, biomedical sciences and allied health sciences. </strong></span></i></span><a href="https://www.cedars-sinai.edu/health-sciences-university.html?adobe_mc=MCMID%3D79521921680015491943235909713257507329%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1733161540&prevPageName=cs-org%3Acedars-sinai%3Anewsroom%3Acedars-sinai-names-director-of-congenital-heart-program"><span style="color:hsl(353,76%,49%);"><i><span style="margin:0px;"><strong><u>Learn more</u></strong></span></i></span></a><span style="color:hsl(353,76%,49%);"><i><span style="margin:0px;text-align:left;"><strong> about the university.</strong></span></i></span></p>]]></description><category><![CDATA[Faculty News,Nursing,bernice-coleman-881571,Newsroom Author,Exclude]]></category>
            <pubDate>Mon, 05 Oct 2026 11:15:00 -0700</pubDate>
            <pp:lastModified>Mon, 05 Oct 2026 19:57:20 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/45df1744-8d7b-4c2b-bdef-baba9b035e1a/500_bernicecolemanoct.2026.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/45df1744-8d7b-4c2b-bdef-baba9b035e1a/500_bernicecolemanoct.2026.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/45df1744-8d7b-4c2b-bdef-baba9b035e1a/bernicecolemanoct.2026.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Bernice Coleman, PhD, ACNP, has been inducted as a fellow of the New York Academy of Medicine. Photo by Cedars-Sinai.]]></pp:imageTitle><pp:imageDescription><![CDATA[A nurse scientist, Bernice Coleman, PhD, NP, in a blue blazer with a white shirt standing outside.]]></pp:imageDescription></item><item>
                        <title>Cedars-Sinai Names Director of Congenital Heart Program</title>
                        <link>https://www.cedars-sinai.org/newsroom/cedars-sinai-names-director-of-congenital-heart-program/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/cedars-sinai-names-director-of-congenital-heart-program/</guid><pp:caseid>817923</pp:caseid><pp:subtitle>Andrew Y. Shin, MD, Will Lead an Integrated Congenital Heart Program Spanning Fetal Diagnosis Through Childhood, Adolescence and Adulthood</pp:subtitle><description><![CDATA[<p><span>Cedars-Sinai has named Andrew Y. Shin, MD, as director of Congenital Heart within the Department of Cardiology in the </span><a href="https://www.cedars-sinai.org/programs/heart.html">Smidt Heart Institute at Cedars-Sinai</a><span>. Dr. Shin will also serve as director of Pediatric Cardiology and have an appointment in the Department of Pediatrics in </span><a href="https://www.cedars-sinai.org/programs/pediatrics.html">Cedars-Sinai Guerin Children’s</a><span>.</span></p><p><span>Dr. Shin will lead the continued development of an integrated congenital heart program spanning fetal diagnosis through childhood, adolescence and adulthood.</span></p><p><span>“We are delighted to have Dr. Shin working across the Smidt Heart Institute, Guerin Children’s and our multidisciplinary programs,” said </span><a href="https://researchers.cedars-sinai.edu/Eduardo.Marban">Eduardo Marbán, MD, PhD</a><span>, executive director of the Smidt Heart Institute at Cedars-Sinai.</span></p><p><a href="https://researchers.cedars-sinai.edu/Susan.Cheng?adobe_mc=MCMID%3D75360244188131661941566734971363994374%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1754577108&prevPageName=cs-org%3Acedars-sinai%3Anewsroom%3Asusan-cheng-md-mmsc-mph-to-lead-department-of-cardiology-at-cedars-sinai">Susan Cheng, MD, MMSc, MPH</a><span>, chair of the Department of Cardiology in the Smidt Heart Institute at Cedars-Sinai, said Dr. Shin will “advance clinical excellence, programmatic growth, research and education while strengthening the connections and continuum of care for all our patients affected by fetal, pediatric or adult congenital heart disease.”</span></p><p><span>Dr. Shin joins Cedars-Sinai from Stanford University, where he is clinical professor of Pediatrics. As a Stanford faculty member, he spent nearly two decades building programs at the intersection of pediatric and adult congenital heart care. Dr. Shin served as executive medical director for Innovations and Clinical Effectiveness, medical director for Quality and Outcomes in the Moore Children’s Heart Center, and medical director of Systems Utilization Research.</span></p><p><span>“Dr. Shin is widely respected by colleagues across the field not only for his academic and clinical accomplishments but also for his generous and thoughtful mentorship of students, medical trainees and faculty,” said </span><a href="https://researchers.cedars-sinai.edu/Ophir.Klein">Ophir Klein, MD, PhD</a><span>, executive director of Guerin Children’s and executive vice dean of Children’s Health. “We are eager for him to lead the next chapter of our growth and impact in congenital heart care.”</span></p><p><span>Beyond his prominent roles at Stanford, Dr. Shin also is recognized nationally for his leadership as an investigator, educator and innovator in congenital heart disease.</span></p><p><span>He has led a multicenter consortium of hospitals across North America investigating interventions aimed at reducing variation in hospital length of stay. His scholarship has addressed outcomes following congenital heart surgery, pediatric cardiac critical care, clinical decision support, and the use of mathematical modeling and systems engineering to address complex challenges in healthcare delivery.</span></p><p><span>Dr. Shin earned his medical degree from the University of California, San Francisco (UCSF), and completed his pediatrics residency, chief residency and fellowship training in pediatric cardiology and pediatric critical care medicine at Boston Children’s Hospital and Harvard Medical School.</span></p><p><span>“I look forward to partnering with Cedars-Sinai leadership to develop a vanguard integrated, lifespan model of congenital heart care,” Dr. Shin said.</span></p><p><span>Dr. Shin said the Cedars-Sinai program will accelerate the translation of innovation into better patient outcomes by integrating exceptional clinical care with data science, advanced analytics and emerging technologies.</span></p><p><span>The program will draw on the broader capabilities of the Smidt Heart Institute, Guerin Children’s and Cedars-Sinai to create a comprehensive approach to congenital cardiovascular disease across the lifespan.</span></p><p style="margin-left:0px;"><span style="color:hsl(353,76%,49%);"><i><span style="margin:0px;text-align:left;"><strong>Cedars-Sinai Health Sciences University is advancing groundbreaking research and educating future leaders in medicine, biomedical sciences and allied health sciences. </strong></span></i></span><a href="https://www.cedars-sinai.edu/health-sciences-university.html?adobe_mc=MCMID%3D79521921680015491943235909713257507329%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1733161540"><span style="color:hsl(353,76%,49%);"><i><span style="margin:0px;"><strong><u>Learn more</u></strong></span></i></span></a><span style="color:hsl(353,76%,49%);"><i><span style="margin:0px;text-align:left;"><strong> about the university.</strong></span></i></span></p>]]></description><category><![CDATA[Exclude,Faculty News,Heart,Congenital Heart,Congenital Heart Disease,Pediatric Heart,Pediatrics,cedars-sinai guerin children&#039;s,Guerin Childrens,Cara Martinez]]></category>
            <pubDate>Fri, 02 Oct 2026 11:31:29 -0700</pubDate>
            <pp:lastModified>Sat, 24 Oct 2026 00:51:52 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/2e73a17e-ea64-43c1-816c-3ee07a9fc16a/500_andy-y-shin-md-cedars-sinai.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/2e73a17e-ea64-43c1-816c-3ee07a9fc16a/500_andy-y-shin-md-cedars-sinai.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/2e73a17e-ea64-43c1-816c-3ee07a9fc16a/andy-y-shin-md-cedars-sinai.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Andrew Y. Shin, MD, will lead an integrated congenital heart program at Cedars-Sinai, spanning fetal diagnosis through adulthood. Photo courtesy of Andrew Y. Shin, MD.]]></pp:imageTitle><pp:imageDescription><![CDATA[A physician-leader, Andrew Y. Shin, MD, in a gray suit jacket and white collared shirt, standing outside in front of green leaves.]]></pp:imageDescription></item><item>
                        <title>Bert Mandelbaum, MD, Named US Soccer Chief Medical Officer</title>
                        <link>https://www.cedars-sinai.org/newsroom/bert-mandelbaum-md-named-us-soccer-chief-medical-officer/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/bert-mandelbaum-md-named-us-soccer-chief-medical-officer/</guid><pp:caseid>814769</pp:caseid><pp:subtitle>Cedars-Sinai Orthopedic Surgeon Brings Decades of Experience in Athlete Health, Injury Prevention and Performance to National Role</pp:subtitle><description><![CDATA[<p><span>Orthopedic surgeon and prominent sports medicine expert </span><a href="https://www.cedars-sinai.org/provider/bertr-mandelbaum-819188.html"><span>Bert Mandelbaum, MD</span></a><span> has been named chief medical officer of the </span><a href="https://www.ussoccer.com/" target="_blank" rel="noreferrer noopener"><span>U.S. Soccer Federation</span></a><span>.</span></p><p><span><img class="image-style-align-right image_resized" style="width:224px;" src="https://content.presspage.com/uploads/2110/938984a0-b55e-4202-9056-82e5b9e06018/800_mandelbaum-bert.mandelbaumb.jpg?x=1789744875542" width="224" alt="Bert Mandelbaum, MD" />Mandelbaum was appointed interim chief medical officer earlier this year and served in the role during the </span><a href="https://www.cedars-sinai.org/newsroom/world-cup-medicine-keeping-us-soccer-healthy/"><span>2026 FIFA World Cup</span></a><span>. He will continue to lead the federation’s medical strategy, oversee its network of physicians and guide efforts related to clinical care, athlete wellness, injury prevention and long-term performance.</span></p><p><span>Mandelbaum has worked with U.S. Soccer since 1989 and has supported the U.S. Men’s National Team at every FIFA World Cup since 1994. A veteran of nine FIFA World Cups and six Olympic and Paralympic Games, he has extensive experience caring for elite athletes on the world’s largest sporting stages.</span></p><p><span>Mandelbaum is vice chair of Network Development at </span><a href="https://www.cedars-sinai.org/programs/ortho.html"><span>Cedars-Sinai Orthopaedics and Sports Medicine</span></a><span> and serves as medical director of the Cedars-Sinai FIFA Medical Centre of Excellence, one of only three </span><a href="https://inside.fifa.com/health-and-medical/centers-of-excellence" target="_blank" rel="noreferrer noopener"><span>FIFA Medical Centres of Excellence</span></a><span> in the United States.</span></p><p><span>“U.S. Soccer has been part of my life for more than three decades, so stepping into this role is both an honor and a responsibility,” Mandelbaum said. “This is an opportunity to help shape how medicine, health and performance are integrated across an entire national system. It’s about building systems that last and creating standards that improve care not only for elite athletes, but for people at every level of sport and throughout their lives.”</span></p><p><span>As chief medical officer, Mandelbaum will help establish and advance medical policies and standards across U.S. Soccer. His responsibilities will include supporting the health and performance of national team athletes, strengthening collaboration among medical professionals and developing strategies focused on injury prevention, recovery, resilience and longevity.</span></p><p><span>Mandelbaum’s approach to athlete care is grounded in what he calls “play span”—a philosophy focused on preserving performance and extending an individual’s ability to participate in the activities they value. The approach emphasizes building capacity and resilience, rather than simply treating injuries after they occur.</span></p><p><span>“It’s not only about whether someone can perform today,” Mandelbaum said. “Can we increase their capacity and resiliency? Can we prevent injury and help them maintain their performance over time? We look at how someone lives, eats, thinks, trains, recovers and performs.”</span></p><p><span>Through the Cedars-Sinai FIFA Medical Centre of Excellence, Mandelbaum and his colleagues collaborate with sports medicine leaders </span><a href="https://www.cedars-sinai.org/newsroom/cedars-sinai-experts-attend-world-health-expo-in-dubai/"><span>around the world</span></a><span> to advance research, education and clinical care for athletes.</span></p><p><span>“Dr. Mandelbaum has been a trusted and invaluable partner to U.S. Soccer for more than 30 years, helping shape an environment where athlete health, safety and performance are always at the forefront,” said Oguchi Onyewu, U.S. Soccer assistant sporting director.<strong> </strong>“His expertise spans the highest levels of the sport, but what stands out most is his unwavering commitment to supporting athletes throughout every stage of their journey. His experience, innovation and vision for the future of sports medicine make him exceptionally qualified to lead our medical program.”</span></p><p><span>Mandelbaum hopes his work will contribute to lasting improvements in athlete care and create models that benefit broader communities.</span></p><p><span>“Ultimately, the impact will not be measured only in wins or championships,” he said. “It will be measured in healthier people, better care models and stronger communities.”</span></p><p><span style="color:hsl(353,76%,49%);"><i><span><strong>Read more from Cedars-Sinai Stories and Insights: </strong></span></i></span><a href="https://www.cedars-sinai.org/stories-and-insights/healthy-living/preventing-injuries-to-young-soccer-players"><span style="color:hsl(353,76%,49%);"><i><span><strong>Preventing Injuries to Young Soccer Players</strong></span></i></span></a><span> </span><br /><br /> </p>]]></description><category><![CDATA[Faculty News,bert-mandelbaum-819188,Sports Medicine]]></category>
            <pubDate>Fri, 18 Sep 2026 09:05:00 -0700</pubDate>
            <pp:lastModified>Fri, 18 Sep 2026 18:01:15 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/0828e0ff-fb6a-44dc-9f83-33e1578781d3/500_mandelbaumincenterwith2026teamusamedicalstaff.jpeg?10000" length="0" type="image/jpeg" />
                <pp:image>https://content.presspage.com/uploads/2110/0828e0ff-fb6a-44dc-9f83-33e1578781d3/500_mandelbaumincenterwith2026teamusamedicalstaff.jpeg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/0828e0ff-fb6a-44dc-9f83-33e1578781d3/mandelbaumincenterwith2026teamusamedicalstaff.jpeg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Bert Mandelbaum, MD, (center) of Cedars-Sinai Orthopaedics and Sports Medicine has been named chief medical officer of U.S. Soccer. Photo by Cedars-Sinai.]]></pp:imageTitle><pp:imageDescription><![CDATA[Group photo of the medical team of the United States Mens national soccer team.]]></pp:imageDescription></item><item>
                        <title>Experimental Study Points to Systemic Sclerosis Treatment</title>
                        <link>https://www.cedars-sinai.org/newsroom/experimental-study-points-to-systemic-sclerosis-treatment/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/experimental-study-points-to-systemic-sclerosis-treatment/</guid><pp:caseid>806129</pp:caseid><pp:subtitle>Cedars-Sinai Investigators Tested a Novel Drug That Targets an Immune System Pathway and Could Become a New Treatment for the Life-Threatening Disease</pp:subtitle><description><![CDATA[<p><span>Investigators at </span><a href="https://www.cedars-sinai.org/about/health-sciences-university.html"><span>Cedars-Sinai Health Sciences University</span></a><span> used an experimental drug to reverse the effects of systemic sclerosis, a serious autoimmune disease. The study, conducted in a laboratory, was published in </span><a href="https://doi.org/10.1172/jci.insight.197716" target="_blank" rel="noreferrer noopener"><i><span>JCI Insight</span></i></a><i><span>.</span></i></p><p><span><img class="image-style-align-right image_resized" style="width:220px;" src="https://content.presspage.com/uploads/2110/45319f57-f61c-4828-91cf-696a7c168881/800_eduardo-marban-md-cedars-sinai-1500.jpg?x=1788469927398" width="220" alt="Eduardo Marbán, MD, PhD" />Systemic sclerosis, also called </span><a href="https://www.cedars-sinai.org/health-topics/scleroderma"><span>scleroderma</span></a><span>, is a chronic, life-threatening condition that scars the skin, lungs, heart and other organs. Because there is no cure or known cause for the disease, which affects about 100,000 people in the U.S., treatments focus on relieving symptoms.</span></p><p><span>“That’s why we are so excited about our findings,” said </span><a href="https://researchers.cedars-sinai.edu/Eduardo.Marban"><span>Eduardo Marbán, MD, PhD</span></a><span>, executive director of the </span><a href="https://www.cedars-sinai.org/programs/heart.html"><span>Smidt Heart Institute</span></a><span> </span>at Cedars-Sinai<span> and corresponding author of the study. “The basic immune system pathway driving systemic sclerosis is blocked by this new drug, making it a potential future therapy.”</span></p><p><span>Investigators tested the experimental drug, called TY1, on immune cells collected from patients with systemic sclerosis. They found that the drug reduced inflammation and DNA damage in those cells. When they administered TY1 to laboratory mice with a condition that mimics systemic sclerosis, investigators found that heart function and physical activity improved, and scar formation in organs was reduced.</span></p><p><span>TY1, which was developed at Cedars-Sinai, is a synthetic version of a type of noncoding ribonucleic acid (RNA), a molecule that regulates cellular processes. After using TY1 to reduce tissue damage in laboratory experiments addressing heart attacks, as </span><a href="https://www.cedars-sinai.org/newsroom/experimental-drug-repairs-dna-damage-caused-by-disease/"><span>reported last year</span></a><span>, investigators sought to determine if TY1 might have a similar effect on autoimmune disorders.<img class="image_resized image-style-align-right" style="width:220px;" src="https://content.presspage.com/uploads/2110/5345244c-1805-45a0-9f85-35710a34d5ad/800_ahmed-ibrahim-cedars-sinai.jpg?x=1788469956641" alt="Ahmed Ibrahim, PhD, MPH" width="220" /></span></p><p><span>“We chose to test TY1 in systemic sclerosis because the science of how the drug works makes sense and also because it is such a devastating disease,” said </span><a href="https://researchers.cedars-sinai.edu/Ahmed.Ibrahim"><span>Ahmed Ibrahim, PhD, MPH</span></a><span>, associate professor of Cardiology at Cedars-Sinai and a co-investigator of the study.</span></p><p><span>Investigators are currently preparing an investigational new drug application to the U.S. Food and Drug Administration, the first step toward obtaining approval for studying TY1 in people with systemic sclerosis.</span></p><p><span>"This innovative study illustrates how doing careful research on one disease can lead to key discoveries on another — in this case, from conditions that can stiffen the heart to scleroderma, a rare disease that hardens the skin and internal organs in patients who have waited decades for better treatment options,” said </span><a href="https://researchers.cedars-sinai.edu/Susan.Cheng"><span>Susan Cheng, MD</span></a><span>, chair of the Department of Cardiology in the Smidt Heart Institute.</span></p><p><i><span>Additional Cedars-Sinai authors include Salwa Soussi, Alessandra Ciullo, Kara Tsi, Weixin Liu, Liang Li, Mario Fournier, Thassio Mesquita, Alberto Marchevsky, Nunzio Bottini and Francesco Boin.</span></i></p><p><i><span>Xaviar Jones, MD, is the first author of the paper and is currently completing his residency training at Yale University.</span></i></p><p><i><span>Funding: This work is the result of National Institutes of Health funding, in whole or in part, and is subject to the NIH Public Access Policy. Through acceptance of this federal funding, the NIH has been given a right to make the work publicly available in PubMed Central. Supported funding for this study include grants NIH (R01HL164588 to EM, and T32HL116273 to EM, which supported XMJ), and the California Institute for Regenerative Medicine (TRAN1-15317 to AGI).</span></i></p><p><i><span>Disclosures:<strong> </strong>EM owns founder’s equity in Capricor. AI owns stock in Capricor. Capricor has no relationship with this project, nor any licensing rights to the discoveries reported here. All other authors declare no competing interests.</span></i></p><p><span style="color:hsl(353,76%,49%);"><i><span><strong>Cedars-Sinai Health Sciences University is advancing groundbreaking research and educating future leaders in medicine, biomedical sciences and allied health sciences. </strong></span></i></span><a href="https://www.cedars-sinai.edu/health-sciences-university.html"><span style="color:hsl(353,76%,49%);"><i><span><strong>Learn more</strong></span></i></span></a><span style="color:hsl(353,76%,49%);"><i><span><strong> about the university.</strong></span></i></span></p>]]></description><category><![CDATA[Heart,Heart Research,Autoimmunity,Research,Exclude,Newsroom Author,eduardo-marban-817236,susan-cheng-763325]]></category>
            <pubDate>Tue, 08 Sep 2026 09:00:00 -0700</pubDate>
            <pp:lastModified>Wed, 09 Sep 2026 00:58:31 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/00d64cdf-c425-493b-aea7-f1b54a4becc7/500_rna-strand-cedars-sinai.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/00d64cdf-c425-493b-aea7-f1b54a4becc7/500_rna-strand-cedars-sinai.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/00d64cdf-c425-493b-aea7-f1b54a4becc7/rna-strand-cedars-sinai.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Developed at Cedars-Sinai, TY1 is a synthetic version of a type of noncoding RNA, a molecule that regulates cellular processes. Image by Getty.]]></pp:imageTitle><pp:imageDescription><![CDATA[Digital illustration of ribonucleic acid (RNA) strands consisting of nucleotides.]]></pp:imageDescription></item><item>
                        <title>AFib in the Summer: Know the Triggers</title>
                        <link>https://www.cedars-sinai.org/newsroom/afib-in-the-summer-know-the-triggers/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/afib-in-the-summer-know-the-triggers/</guid><pp:caseid>801698</pp:caseid><pp:subtitle>Q&amp;A With Electrophysiologist Archana Ramireddy, MD, to Mark National Atrial Fibrillation Awareness Month</pp:subtitle><description><![CDATA[<p><span>People with atrial fibrillation should take extra precautions during hot weather, when dehydration and alcohol consumption can trigger symptoms and make the common heart rhythm disorder more difficult to manage, according to experts in the </span><a href="https://www.cedars-sinai.edu/health-sciences-university/research/departments-institutes/smidt-heart-institute.html"><span>Smidt Heart Institute</span></a><span> at Cedars-Sinai.</span></p><p><span><img class="image-style-align-right image_resized" style="width:370px;" src="https://content.presspage.com/uploads/2110/800_archana-ramireddy-md-cedars-sinai.jpeg?x=1788298836258" width="370" alt="Archana Ramireddy, MD" /></span><a href="https://www.heart.org/en/health-topics/atrial-fibrillation" target="_blank" rel="noreferrer noopener"><span>Atrial fibrillation</span></a><span>, or AFib, is a condition in which the heart’s upper chambers beat irregularly, often causing a rapid heartbeat. Some people with AFib also experience chest discomfort, shortness of breath or heart palpitations. Others may notice only mild fatigue during activity. And still others may feel no </span><a href="https://www.heart.org/en/health-topics/atrial-fibrillation/what-are-the-symptoms-of-atrial-fibrillation" target="_blank" rel="noreferrer noopener"><span>symptoms</span></a><span> at all. AFib also increases the </span><a href="https://www.cedars-sinai.org/health-topics/atrial-fibrillation-and-stroke-prevention"><span>risk of stroke</span></a><span>.</span></p><p><span>“That’s why it’s especially important to carefully manage AFib in the summer, when people may spend more time in the sun, lose fluids through sweating, and drink more alcohol on vacation, at barbecues and at other outdoor social gatherings,” said </span><a href="https://www.cedars-sinai.org/provider/archana-ramireddy-1902414.html"><span>Archana Ramireddy, MD</span></a><span>, a clinical electrophysiologist in the Smidt Heart Institute. “Older adults are especially affected by the heat, even if it may not seem obvious at first.”</span></p><p><span>In recognition of AFib Awareness Month in September—when Southern California often experiences some of its hottest weather—the </span><i><span>Cedars-Sinai Newsroom</span></i><span> spoke with Ramireddy about steps people with AFib can take to stay healthy.</span></p><h2><span><strong>What summer factors can trigger an AFib episode?</strong></span></h2><p><span>Hot weather can put added stress on the heart, but heat itself isn’t necessarily the primary concern. Dehydration is of special concern because people lose fluids through sweating. Older adults may be particularly susceptible to heat-related dehydration because the body’s ability to conserve fluids and regulate temperature can decline with age. Alcohol is another concern because it is a well-recognized trigger for AFib, and people tend to drink more during the summer while vacationing, spending time outdoors and attending social gatherings.</span></p><h2><span><strong>Should people with AFib drink plain water to stay hydrated, or do they need electrolytes?</strong></span></h2><p><span>Plain water is usually the best choice. Electrolyte drinks may be helpful in some circumstances, although individual needs vary based on heat exposure, activity level, how much a person has been sweating, and underlying health conditions.</span></p><h2><span><strong>What are the signs of dehydration?</strong></span></h2><p><span>Signs of dehydration can include dark urine, dizziness, dry mouth, fatigue, confusion and a rapid heartbeat. If symptoms are prolonged or severe, or if a person also is experiencing chest discomfort or shortness of breath, they should seek medical attention.</span></p><h2 style="margin-left:0in;"><span><strong>Is coffee off-limits for people with AFib?</strong></span></h2><p style="margin-left:0in;"><span>One cup of coffee a day generally isn’t a concern. Even two cups may be acceptable, although for some patients I recommend switching extra servings to decaf or half-caf. It’s most important that people pay attention to their own bodies. If caffeine consistently triggers symptoms, cutting back is recommended. I’m far more concerned about the consumption of multiple energy drinks, because high doses of caffeine and other ingredients in these drinks can increase the risk of arrhythmias.</span></p><h2><span><strong>Is it safe for people with AFib to exercise in the summer?</strong></span></h2><p><span>I encourage regular exercise for my patients with AFib. If physical activity consistently triggers episodes, the underlying AFib should be evaluated and treated rather than simply avoiding exercise. That said, it’s best to avoid strenuous exercise during the hottest part of the day and to stay well-hydrated if outside in the heat. To combat overheating, seek air conditioning, drink plenty of water, take a cool shower or use cool towels.</span></p><h2><span><strong>What if a person thinks they may have AFib?</strong></span></h2><p><span>If a person has heart palpitations and isn’t sure what is causing them, capturing an episode can be key for diagnosis and treatment. This is where wearable devices, such as smartwatches, can play a role. If a device can record an ECG, or electrocardiogram, during an episode, a </span><a href="https://www.cedars-sinai.org/find-a-doctor.html?input=&offset=0&limit=25&retrieveFacets=true&facets=%5B%7B%22fieldId%22%3A%22c_linkedPrograms.name%22%2C%22options%22%3A%5B%7B%22matcher%22%3A%22%24eq%22%2C%22value%22%3A%22Heart%22%7D%5D%7D%5D"><span>physician</span></a><span> can review the tracing to determine whether it is consistent with AFib. Wearable devices have helped us identify more patients sooner, allowing us to begin treatment sooner. Preventing stroke is a major goal of AFib treatment. People who have been diagnosed with AFib should work with their healthcare team to determine whether further evaluation by a cardiac electrophysiologist is appropriate.</span></p><p><span style="color:hsl(353,76%,49%);"><i><span><strong>Read more from Cedars-Sinai Stories and Insights: </strong></span></i></span><a href="https://www.cedars-sinai.org/stories-and-insights/expert-advice/atrial-fibrillation-warning-signs"><span style="color:hsl(353,76%,49%);"><i><span><strong>Atrial Fibrillation—Know the Warning Signs</strong></span></i></span></a></p>]]></description><category><![CDATA[archana-ramireddy-1902414,News,Heart,Kristin Reynolds]]></category>
            <pubDate>Wed, 02 Sep 2026 07:00:00 -0700</pubDate>
            <pp:lastModified>Wed, 02 Sep 2026 00:36:28 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/5e869199-abba-4624-86b1-153751c93213/500_summer-heat-afib-cedars-sinai.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/5e869199-abba-4624-86b1-153751c93213/500_summer-heat-afib-cedars-sinai.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/5e869199-abba-4624-86b1-153751c93213/summer-heat-afib-cedars-sinai.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[People with atrial fibrillation, or AFib, should take extra care in hot weather, as more time in the sun and dehydration can trigger symptoms and make the condition harder to manage, according to Archana Ramireddy, MD, an electrophysiologist in the Smidt Heart Institute at Cedars-Sinai. Photo by Getty.]]></pp:imageTitle><pp:imageDescription><![CDATA[A woman cools off on a park bench with a bottle of water.]]></pp:imageDescription></item><item>
                        <title>Cedars-Sinai Promotes Four to Senior Vice President</title>
                        <link>https://www.cedars-sinai.org/newsroom/cedars-sinai-promotes-four-to-senior-vice-president/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/cedars-sinai-promotes-four-to-senior-vice-president/</guid><pp:caseid>787276</pp:caseid><pp:subtitle>Advancements Spotlight Cedars-Sinai’s Focus on Enhancing Patient Care and Access Amid Steady Growth of the Organization</pp:subtitle><description><![CDATA[<p><span>Cedars-Sinai has promoted four leaders to senior vice president, reflecting their expanded scopes of responsibility for improving patient care and access as the organization continues to grow.</span></p><p><span>The promotions of Jennifer Blaha, MBA; Clare Lee, MBA; Lisa Maqueira; and Alen Voskanian, MD, MBA, represent an intentional investment in leadership capacity to meet Cedars-Sinai’s core mission of delivering the highest-quality care to patients in Los Angeles and beyond.</span></p><p><span>“These four leaders exemplify the operational excellence and strategic acumen required to deliver on our care vision,” said </span><a href="https://www.cedars-sinai.org/about/leadership/executive-management/peter-l-slavin.html"><span>Peter L. Slavin, MD</span></a><span>, president and CEO of Cedars-Sinai Medical Center and Cedars-Sinai Health System. “Collectively, these promotions expand the portfolio of responsibilities held by leaders who have shown, time and again, that operational excellence and exceptional patient care are complementary priorities.”</span></p><p><span>Blaha, senior vice president of Surgical Services, joined Cedars-Sinai 17 years ago from GE Healthcare, where she served as a senior consultant, and has since risen through senior operational roles across the institution before being named vice president of Operations in 2018.</span></p><p><span>In her new role, she will oversee the service lines of Neurosurgery, Neurology, Orthopaedics, Surgery, Transplant and Urology, along with Peri-Procedural Services, including Anesthesia and OR Operations.</span></p><p><span>Blaha has built a strong record of improving clinical quality, patient satisfaction and operational efficiency across the surgical service lines she now leads. She was one of 22 healthcare leaders selected nationally for the Carol Emmott Fellowship, a competitive program advancing women in healthcare leadership.</span></p><p><span>Lee, senior vice president of Medical Services, brings 34 years of healthcare experience, including 21 years at the executive level, to her new role. She joined Cedars-Sinai in 2018 as vice president of Operations. Prior to Cedars-Sinai, Lee was chief operating officer at Dignity Health Mercy General Hospital in Sacramento and vice president of Operations at Houston Methodist.</span></p><p><span>In her new role, she will oversee the service lines of Medicine, OB/GYN, Pediatrics and Psychiatry, along with Imaging, Lab and Pathology, and Emergency Services. Over her career, she has transformed clinical operations within the service lines under her purview, cultivating strong leaders and driving significant improvements across clinical and operational areas.</span></p><p><span>Maqueira, senior vice president of Finance and chief revenue cycle officer, joined Cedars-Sinai in 2011 as director of Professional Billing and Revenue Cycle Services, leading the transformation of professional billing operations. She was promoted to vice president of Revenue Cycle and Managed Care Operations in 2016, taking on expanded responsibility for managed care operations and contracting, professional compliance, government incentives, and centralized scheduling for Cedars-Sinai Medical Network.</span></p><p><span>Maqueira was named vice president of Finance and chief revenue cycle officer in 2022, leading the organization’s integrated revenue cycle strategy across hospitals and physician networks. With 33 years of revenue cycle experience, she has consistently delivered stronger collections, improved charge capture and greater operational efficiency. </span>In her new role, she is accountable for setting and executing a strategic vision to advance exceptional patient and provider experience while strengthening financial performance.</p><p><span>Voskanian, senior vice president and chief operating officer of Ambulatory Clinics, joined Cedars-Sinai in 2018 from VITAS Healthcare, where he was regional medical director. He served as medical director of Cedars-Sinai Medical Group and later as vice president and chief operating officer of Cedars-Sinai Medical Network.</span></p><p><span>A practicing physician who continues to care for patients, Voskanian has helped lead ambulatory strategy and the growth and integration of specialty practices, contributing to substantial growth in weekly patient volumes during his tenure as chief operating officer. Working closely with clinical and administrative leaders, he has also advanced a dyad leadership model that strengthens collaboration, improves operational performance and supports physicians and staff in delivering high-quality care.</span></p><p><span style="color:hsl(353,76%,49%);"><i><span><strong>Read more from Cedars-Sinai Stories and Insights: </strong></span></i></span><a href="https://www.cedars-sinai.org/stories-and-insights/innovation-and-research/new-cedars-sinai-ceo-shares-vision-for-growth-and-priorities"><span style="color:hsl(353,76%,49%);"><i><span><strong>New Cedars-Sinai CEO Shares Vision for Growth and Priorities</strong></span></i></span></a></p>]]></description><category><![CDATA[Exclude,Faculty News,Cara Martinez]]></category>
            <pubDate>Thu, 20 Aug 2026 07:00:00 -0700</pubDate>
            <pp:lastModified>Thu, 20 Aug 2026 01:37:49 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/61a78bd1-29e2-4f36-8c0f-4c5e54979af0/500_healing-garden-sculpture-rain-cedars-sinai.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/61a78bd1-29e2-4f36-8c0f-4c5e54979af0/500_healing-garden-sculpture-rain-cedars-sinai.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/61a78bd1-29e2-4f36-8c0f-4c5e54979af0/healing-garden-sculpture-rain-cedars-sinai.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[The promotions represent an intentional investment in leadership capacity to meet Cedars-Sinai&amp;rsquo;s core mission of providing patients with the highest-quality care. Photo by Cedars-Sinai.]]></pp:imageTitle><pp:imageDescription><![CDATA[Exterior of Cedars-Sinai medical center on a rainy day. Large building in background with large, silver sculpture in foreground.]]></pp:imageDescription></item><item>
                        <title>Cedars-Sinai Investigators Uncover Earliest Changes in Coronary Heart Disease</title>
                        <link>https://www.cedars-sinai.org/newsroom/cedars-sinai-investigators-uncover-earliest-changes-in-coronary-heart-disease/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/cedars-sinai-investigators-uncover-earliest-changes-in-coronary-heart-disease/</guid><pp:caseid>785460</pp:caseid><pp:subtitle>Studying Proteins Helps Scientists Uncover Earliest Biological Changes in Atherosclerosis, Which Could Lead to New Heart Disease Prevention Methods</pp:subtitle><description><![CDATA[<p><span>Researchers have identified molecular changes that appear to trigger atherosclerosis years before inflammation—the long-recognized hallmark of the disease—takes hold, according to a </span><a href="https://www.cedars-sinai.edu/health-sciences-university.html"><span>Cedars-Sinai Health Sciences University</span></a><span>-led study.</span></p><p><span><img class="image_resized image-style-align-right" style="width:225px;" src="https://content.presspage.com/uploads/2110/a6c05c6b-0be8-44b0-a1df-9166b49e9c1f/800_sarah-parker-phd-cedars-sinai.jpg?x=1786478013733" alt="Sarah Parker, PhD" width="225" />The multi-institutional study offers one of the clearest pictures of what happens during the earliest stages of disease. The findings could help researchers develop new ways to detect and prevent heart disease before plaque builds up inside arteries.</span></p><p><span>“We analyzed proteins and gene activity in coronary artery tissue from young adults who died of trauma and had no known </span><a href="https://www.cedars-sinai.org/health-topics/coronary-heart-disease"><span>coronary artery disease</span></a><span>, and we found that more than half already had preclinical atherosclerosis,” said study first author </span><a href="https://researchers.cedars-sinai.edu/Sarah.Parker"><span>Sarah Parker, PhD</span></a><span>, an associate professor of </span><a href="https://www.cedars-sinai.org/programs/heart/specialties/general-cardiology.html"><span>Cardiology</span></a><span> and Biomedical Sciences and co-director of the </span><a href="https://www.cedars-sinai.edu/health-sciences-university/research/cores/proteomics-metabolomics.html"><span>Proteomics and Metabolomics Core</span></a><span> at Cedars-Sinai Health Sciences University. “This suggests that changes in cellular metabolism and communication begin before the inflammation long considered a hallmark of the disease.”</span></p><p><span>Published in the </span><a href="https://academic.oup.com/eurheartj/article/47/28/3840/8676655" target="_blank" rel="noreferrer noopener"><i><span>European Heart Journal</span></i></a><span>, the study findings point to previously unrecognized molecular pathways—and a potential “master regulator” called MLXIPL—that could become targets for therapies aimed at preventing plaque from developing.</span></p><p><span>The </span><i><span>Cedars-Sinai Newsroom</span></i><span> spoke with Parker about the findings and how </span><a href="https://www.cedars-sinai.org/newsroom/cedars-sinai-scientists-track-bodys-most-elusive-proteins/"><span>proteomics</span></a><span>—the study of proteins—is helping researchers rethink the earliest stages of heart disease.</span></p><h2><span><strong>Why are proteins so important in understanding heart disease?</strong></span></h2><p><span>Proteins are the molecules that make cells function. They tell us how the body’s cells are responding to risk factors like cholesterol, blood pressure or smoking. Two people can have identical cholesterol levels, yet only one develops plaque. Proteins may help explain why. They provide a much more direct picture of what's happening inside the artery wall and may reveal why some people are more vulnerable to heart disease than others.</span></p><h2><span><strong>What did this most recent study reveal about the earliest stages of atherosclerosis?</strong></span></h2><p><span>Previous studies had shown that the earliest artery lesions can appear in the first decade of life. What we haven’t understood is what causes those early changes to progress into dangerous plaques that lead to heart attacks. In studying coronary artery tissue before people ever developed symptoms, we were able to capture some of the earliest molecular changes that appear to set the disease in motion. One of the biggest surprises was that we saw changes in cellular metabolism and communication before we saw the classic inflammatory signals traditionally associated with atherosclerosis.</span></p><p><span>To be clear, inflammation remains a defining feature of advanced atherosclerosis. What our study suggests is that important molecular changes begin much earlier. If we want to prevent plaque from forming, we need to understand those earliest changes—not just what happens after inflammation has already taken hold.</span></p><h2 style="margin-left:0in;"><span><strong>Explain MLXIPL, the potential ‘master regulator’ you identified.</strong></span></h2><p style="margin-left:0in;"><span>We performed a master regulator analysis to identify the genes that may be coordinating these early events. Some of the regulators we found were exactly what we expected. But one stood out. MLXIPL is a transcription factor gene involved in cellular metabolism. Previous genetic studies have linked it to coronary artery disease through its role in the liver. Our findings suggest it may also play an important role directly within the artery wall. When we altered MLXIPL activity in lab-grown human artery tissue, we saw the protein changes we predicted. That makes it an exciting candidate for future therapies that interrupt disease before plaque develops.</span></p><h2><span><strong>How could these findings change atherosclerosis prevention?</strong></span></h2><p><span>Today, we estimate cardiovascular risk using factors such as high cholesterol, diabetes, smoking, age and family history. By the time plaque is visible on imaging, disease often is well underway. We hope to identify protein biomarkers in the blood that reveal what’s happening inside the artery wall much earlier. One day, a simple blood test could identify people who would benefit from preventive treatment before symptoms develop.</span></p><p><span>That said, our findings do not change current prevention recommendations. Managing cholesterol, blood pressure, diabetes, smoking, exercise and diet remain essential.</span></p><h2><span><strong>This study relied on a decades-long collaboration. Why was that essential?</strong></span></h2><p><span>This is a collaboration more than 20 years in the making. The project was spearheaded by proteomics pioneer </span><a href="https://researchers.cedars-sinai.edu/Jennifer.VanEyk"><span>Jennifer Van Eyk</span></a><span>. (Van Eyk, PhD, is director of the </span><a href="https://www.cedars-sinai.edu/health-sciences-university/research/departments-institutes/biomedical-sciences/advanced-clinical-biosystems.html"><span>Advanced Clinical Biosystems Research Institute</span></a><span> in the </span><a href="https://www.cedars-sinai.edu/health-sciences-university/research/departments-institutes/smidt-heart-institute.html"><span>Smidt Heart Institute</span></a><span> at Cedars-Sinai and co-director of the Proteomics and Metabolomics Core.)</span></p><p><span>Our collaborators included investigators from many other institutions across the country. What began as a small group has grown into an ecosystem of investigators, trainees and collaborators. This kind of large-scale molecular study simply isn’t possible without that level of long-term partnership and shared expertise.</span></p><p><span style="color:hsl(353,76%,49%);"><i><span><strong>Cedars-Sinai Health Sciences University is advancing groundbreaking research and educating future leaders in medicine, biomedical sciences and allied health sciences. </strong></span></i></span><a href="https://www.cedars-sinai.edu/health-sciences-university.html"><span style="color:hsl(353,76%,49%);"><i><span><strong>Learn more</strong></span></i></span></a><span style="color:hsl(353,76%,49%);"><i><span><strong> about the university.</strong></span></i></span></p>]]></description><category><![CDATA[News,Kristin Reynolds,Heart,Heart Research]]></category>
            <pubDate>Wed, 12 Aug 2026 06:00:00 -0700</pubDate>
            <pp:lastModified>Tue, 11 Aug 2026 22:43:55 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/ed6c8957-e6eb-42b5-859e-97baecf9a97d/500_multi-channel-pipette-cedars-sinai.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/ed6c8957-e6eb-42b5-859e-97baecf9a97d/500_multi-channel-pipette-cedars-sinai.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/ed6c8957-e6eb-42b5-859e-97baecf9a97d/multi-channel-pipette-cedars-sinai.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Analyzing proteins and gene activity in human coronary artery tissue, Cedars-Sinai Health Sciences University investigators identified molecular changes that occur before the inflammation traditionally associated with atherosclerosis, offering new insights into how heart disease begins. Photo by Getty.]]></pp:imageTitle><pp:imageDescription><![CDATA[Scientist using multi-channel pipette to fill multiwell plate for analysis of antibodies.]]></pp:imageDescription></item><item>
                        <title>Partnership Advances Care, Prevention for Beach Volleyball Athletes</title>
                        <link>https://www.cedars-sinai.org/newsroom/partnership-advances-care-prevention-for-beach-volleyball-athletes/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/partnership-advances-care-prevention-for-beach-volleyball-athletes/</guid><pp:caseid>782481</pp:caseid><pp:subtitle>Cedars-Sinai Orthopaedics and Sports Medicine and the California Beach Volleyball Association Renew Collaboration to Provide Expert Care, Injury Prevention Resources and Education</pp:subtitle><description><![CDATA[<p>Beach volleyball athletes throughout California will continue to have access to expert orthopedic care, sports medicine expertise and injury prevention resources through a renewed partnership between <a href="https://www.cedars-sinai.org/programs/ortho.html">Cedars-Sinai Orthopaedics and Sports Medicine</a> and the California Beach Volleyball Association (CBVA).</p><p>Cedars-Sinai will continue as the organization's Official Healthcare Partner, reaffirming its commitment to supporting the health, performance and recovery of beach volleyball athletes throughout California.</p><p>Founded in 1962, the nonprofit hosts nearly 1,000 tournaments annually across more than 20 California locations, serving approximately 8,000 active members spanning youth, amateur and elite competition.</p><p>“Our continued partnership with the California Beach Volleyball Association reflects Cedars-Sinai’s commitment to helping athletes stay healthy,” said <a href="https://www.cedars-sinai.org/provider/mark-vrahas-2181749.html"><span style="margin:0px;">Mark Vrahas, MD</span></a><span style="margin:0px;text-align:left;">, chair of </span><span style="margin:0px;">Cedars-Sinai Orthopaedics and Sports Medicine.</span> “Together, we’re giving players of every age and skill level access to expert care that helps prevent injuries, supports recovery and keeps them enjoying the sport they love.”</p><p>Through the collaboration, Cedars-Sinai Orthopaedics and Sports Medicine will provide athletes with access to orthopedic specialists, sports medicine physicians and <a href="https://cbva.com/info/cedars" target="_blank" rel="noreferrer noopener">injury prevention</a> resources designed to help players perform safely and recover effectively.</p><p>Beach volleyball places unique demands on the body, requiring explosive movement, agility and endurance. Cedars-Sinai sports medicine physicians regularly treat shoulder, knee, ankle and hand injuries, while emphasizing evidence-based injury prevention strategies that help keep competitors in the game.</p><p>“Whether treating professional athletes or weekend competitors, our goal is always the same: helping patients return safely to the activities they love,” said <a href="https://www.cedars-sinai.org/provider/joshua-scott-864782.html">Joshua Scott, MD</a>, orthopedic specialist at Cedars-Sinai Orthopaedics and Sports Medicine. “We're excited to continue working with the association to provide guidance on injury prevention, performance optimization and comprehensive musculoskeletal care throughout the season.”</p><p>A nonprofit organization, the <a href="https://cbva.com/" target="_blank" rel="noreferrer noopener">California Beach Volleyball Association</a> is dedicated to nurturing, promoting and growing the sport through organized tournaments and opportunities for players of all ages and abilities to compete. The organization has helped grow the sport and foster healthy competition for generations of athletes.</p><p>“CBVA has been putting on tournaments on California sand for more than 60 years, and keeping our players healthy has always been part of our job,” said Kathy Hubbell, the group’s executive director. “Partnering with Cedars-Sinai gives our athletes—from the kids just learning to bump and serve to the dedicated weekend players who never miss a tournament—access to real experts when they need them. That kind of support is hard to find for a sport like ours, and it makes a difference.”</p><p><span style="color:hsl(353,76%,49%);"><i><span><strong>Read more from Cedars-Sinai Stories and Insights: </strong></span></i></span><a href="https://www.cedars-sinai.org/stories-and-insights/healthy-living/proper-precautions-can-net-safety-benefits-for-beach-volleyball"><span style="color:hsl(353,76%,49%);"><i><span><strong>Proper Precautions Can Net Safety Benefits for Beach Volleyball Players</strong></span></i></span></a></p>]]></description><category><![CDATA[Faculty News,Sports Medicine,Melissa Vizcarra,Orthopaedics,Pediatric Orthopaedics]]></category>
            <pubDate>Thu, 06 Aug 2026 08:00:00 -0700</pubDate>
            <pp:lastModified>Wed, 30 Sep 2026 22:35:02 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/f441bbee-b85f-4f26-ba7b-6417f6cee550/500_649217342_18579652822045067_7813944529891970675_n.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/f441bbee-b85f-4f26-ba7b-6417f6cee550/500_649217342_18579652822045067_7813944529891970675_n.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/f441bbee-b85f-4f26-ba7b-6417f6cee550/649217342_18579652822045067_7813944529891970675_n.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[From injury prevention to rehabilitation, Cedars-Sinai sports medicine experts help beach volleyball athletes maintain performance and safely return after injury. Photo courtesy of the CBVA.]]></pp:imageTitle><pp:imageDescription><![CDATA[Female volleyball players playing beach volleyball in the sand with a rollercoaster in the background.]]></pp:imageDescription></item><item>
                        <title>Cedars-Sinai Pulmonary Hypertension Clinic Receives Care Designation</title>
                        <link>https://www.cedars-sinai.org/newsroom/cedars-sinai-pulmonary-hypertension-clinic-receives-care-designation/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/cedars-sinai-pulmonary-hypertension-clinic-receives-care-designation/</guid><pp:caseid>784979</pp:caseid><pp:subtitle>Pulmonary Hypertension Association Names Cedars-Sinai a Center of Comprehensive Care</pp:subtitle><description><![CDATA[<p><span>The Pulmonary Hypertension Association has named Cedars-Sinai a Center of Comprehensive Care.</span></p><p><span><img class="image-style-align-right" style="width:200px;" src="https://content.presspage.com/uploads/2110/7f69de7f-b93c-432b-a059-c6dc9a70f7c7/500_yuri-matusov-md-cedars-sinai.jpg?x=1785872055875" width="200" alt="Yuri Matusov, MD" />The designation from the condition’s oldest patient organization is awarded to programs with the infrastructure and experience needed to provide high-quality care to people with pulmonary hypertension, a type of high blood pressure that occurs in arteries of the lungs.</span></p><p><a href="https://www.cedars-sinai.org/health-topics/primary-pulmonary-hypertension-pph?query=Pulmonary+hypertension&utm_source=search"><span>Pulmonary hypertension</span></a><span> can make it difficult for blood to circulate through the lungs, forcing the heart to work harder. In severe cases, the condition can lead to heart failure. People with pulmonary hypertension often need care from several specialists. </span></p><p>The <a href="https://www.cedars-sinai.org/locations/pulmonary-medicine-140.html"><span>Cedars-Sinai Pulmonary Hypertension Clinic</span></a> <span>includes six physicians and one nurse practitioner. The pulmonary hypertension program combines cardiology and pulmonology, which allows patients to access multidisciplinary care from experts in the disease. Providers care for more than 250 patients each year and address multiple aspects of the disease, including </span>diagnosis, medication management, symptom control and disease progression.</p><p><span>“At Cedars-Sinai, pulmonary hypertension specialists collaborate with colleagues in rheumatology, congenital heart disease, critical care medicine, lung transplantation and other specialties to create treatment plans tailored to patients,” said </span><a href="https://researchers.cedars-sinai.edu/Yuri.Matusov">Yuri Matusov, MD</a><span>, assistant professor of Medicine at Cedars-Sinai. “We are proud to care for an extraordinarily diverse patient population, some of whom come from very far away for their care.”</span></p><p><span>The association noted several outstanding aspects of the Cedars-Sinai Pulmonary Hypertension Clinic including:</span></p><ul><li><span><img class="image_resized image-style-align-right" style="width:200px;" src="https://content.presspage.com/uploads/2110/d37f7481-6484-4654-adb3-ffe5d10d34c7/500_dael-geft-md-cedars-sinai.jpg?x=1785872071127" alt="Dael Geft, MD" width="200" />A team that collaborates and provides timely evaluation and management of people who are hospitalized and continues to provide consistent care when they leave the hospital.</span></li><li><span>Monthly conferences with specialists in the Southern California region that allow for the review of complex pulmonary hypertension cases, knowledge-sharing and regional care coordination.</span></li><li><span>For people with advanced disease, access to top-notch heart, lung and thoracic transplant programs.</span></li><li><span>A research program led by doctors investigating potential treatments.</span></li></ul><p><span>“We are honored for our clinic to have received this designation, the highest recognition available to pulmonary hypertension programs in the United States,” said </span><a href="https://researchers.cedars-sinai.edu/Dael.Geft?adobe_mc=MCMID%3D15143042538955239740718824350024281938%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1783698820&previousPageName=cs-org%253Acedars-sinai%253Aother&adobe_mc=MCMID%3D15143042538955239740718824350024281938%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1783698822"><span>Dael Geft, MD</span></a><span>, assistant professor of Cardiology in the </span><a href="https://www.cedars-sinai.org/programs/heart.html"><span>Smidt Heart Institute</span></a><span> </span>at Cedars-Sinai<span>. “Ultimately, the greatest reward is helping our patients live longer, healthier and more fulfilling lives.”</span></p><p style="margin-left:0in;"><span style="color:hsl(353,76%,49%);"><i><span><strong>Read more on the Cedars-Sinai Newsroom:  </strong></span></i></span><a href="https://www.cedars-sinai.org/newsroom/unique-cell-based-approach-for-pulmonary-arterial-hypertension-shown-to-be-safe/"><span style="color:hsl(353,76%,49%);"><i><span><strong>Unique Cell-Based Approach for Pulmonary Arterial Hypertension Shown to Be Safe</strong></span></i></span></a></p>]]></description><category><![CDATA[Heart,Stephanie Cajigal,Pulmonology,yuri-matusov-3575306,dael-geft-1278388,Exclude,Faculty News]]></category>
            <pubDate>Wed, 05 Aug 2026 07:00:00 -0700</pubDate>
            <pp:lastModified>Tue, 04 Aug 2026 23:27:54 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/c65acbbc-27af-4938-a54f-541233d39fe2/500_pulmonary-hypertension-cedars-sinai.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/c65acbbc-27af-4938-a54f-541233d39fe2/500_pulmonary-hypertension-cedars-sinai.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/c65acbbc-27af-4938-a54f-541233d39fe2/pulmonary-hypertension-cedars-sinai.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[The Pulmonary Hypertension Association noted several outstanding aspects of the Cedars-Sinai Pulmonary Hypertension Clinic. Photo by Getty.]]></pp:imageTitle><pp:imageDescription><![CDATA[Older man with white beard holds his chest while speaking to a doctor.]]></pp:imageDescription></item><item>
                        <title>Continuously Building a Culture of Belonging</title>
                        <link>https://www.cedars-sinai.org/newsroom/continuously-building-a-culture-of-belonging/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/continuously-building-a-culture-of-belonging/</guid><pp:caseid>777709</pp:caseid><pp:subtitle>Chief Diversity, Inclusion and Wellbeing Officer Nicole Mitchell Discusses How Cedars-Sinai Advances Inclusive Care, Accessibility and Belonging</pp:subtitle><description><![CDATA[<p><span>Cedars-Sinai has again been designated as a “Best Place to Work for Disability Inclusion” and as a “Healthcare Equality Index Leader,” reflecting the organization's ongoing commitment to fostering an inclusive environment for employees, patients and the communities it serves.</span></p><p><span><img class="image_resized image-style-align-right" style="width:358px;" src="https://content.presspage.com/uploads/2110/4d9af602-1b2c-4b98-911b-426c59dbe1f7/800_28733-corp-nicolemitchellndashofficialportrait001-1280x1280.jpeg?x=1785432454397" alt="Nicole Mitchell" width="358" />The “Best Place to Work for Disability Inclusion” designation from the 2026 Disability Index recognizes organizations for workplace policies and practices that support disability inclusion, while the “Healthcare Equality Index” label from the Human Rights Campaign Foundation recognizes healthcare organizations that demonstrate a commitment to equitable, inclusive care for LGBTQIA+ patients, visitors and employees.</span></p><p><span>“These recognitions reflect our commitment to ensuring our people and our communities experience Cedars-Sinai in a way that aligns with our values and our mission,” said Nicole Mitchell, chief </span><a href="https://www.cedars-sinai.org/diversity-and-inclusion.html"><span>diversity, inclusion and wellbeing</span></a><span> officer at Cedars-Sinai. “We are proud to once again be recognized but also recognize that this work is never finished.”</span></p><p><span>The </span><i><span>Cedars-Sinai Newsroom</span></i><span> spoke with Mitchell about what these recognitions mean and how inclusion continues to shape the organization's culture, workplace and patient care.</span></p><h2><span>What do these recognitions represent for Cedars-Sinai?</span></h2><p><span>These recognitions are meaningful because they reflect years of intentional work and accountability. They are not about receiving an award or checking a box. Instead, they are an external reflection of our commitment to creating an environment where people feel seen, supported and able to thrive.</span></p><p><span>More importantly, they reinforce our commitment to ensuring our people and our communities experience Cedars-Sinai in a way that aligns with our values and our mission to elevate the health status of the communities we serve. When people experience belonging, trust and inclusion, it strengthens our culture and helps us deliver the exceptional care that is at the heart of our mission.</span></p><h2><span>How do inclusion and accessibility affect Cedars-Sinai's commitment to providing the highest level of patient care?</span></h2><p><span>At Cedars-Sinai, inclusion is not separate from our mission. It is connected to how we care for patients, support our workforce and engage with our communities.</span></p><p><span>This work is reflected in everything from leadership development and employee education to accessibility initiatives and the everyday interactions people have across our organization. It also includes programs and resources that help our employees build community and help our caregivers provide more inclusive, affirming care. Ultimately, it's about creating environments where people can fully participate and where their lived experiences are valued and respected.</span></p><p><span>While these recognitions acknowledge important progress, what matters most is the experience people have every day when they walk through our doors—whether as patients, family members, employees, physicians, learners or community members.</span></p><h2><span>What are some examples of how these values are reflected in the experiences of our patients, workforce and community?</span></h2><p><span>For patients and families, inclusive care helps build trust, strengthen communication and create meaningful partnerships in healthcare decisions. When people feel heard, respected and understood, they are more empowered to participate in their care. That commitment is reflected in ongoing efforts to create welcoming, affirming care experiences, provide education that equips caregivers to meet the diverse needs of patients, and foster an environment where every individual feels valued and respected.</span></p><p><span>For our workforce, belonging means creating a culture where employees can contribute fully, share different perspectives and feel supported in doing their best work. Employee resource groups—including Supporting Purposeful Accessibility, Community and Equity [SPACE] and Pride, Respect, Inclusivity, Solidarity and Meaningful Support [PRISMS]—play an important role in building community, elevating lived experiences and helping us better understand the needs of employees with apparent and non-apparent disabilities, LGBTQIA+ employees, and allies.</span></p><p><span>We know this work is a team effort. Inclusion cannot live within one office or one department. It must be reflected in our systems, our decisions and our daily practices across the organization.</span></p><h2><span>How does Cedars-Sinai ensure that inclusion remains part of our culture and daily operations?</span></h2><p><span>One of the strengths of our Office of Diversity, Inclusion and Wellbeing is that we approach this work every day through both a strategic and human lens.</span></p><p><span>The frameworks provided through the Disability Index and Healthcare Equality Index help us measure progress and identify opportunities to continue growing. But lasting change happens when inclusion becomes part of how we lead, collaborate, make decisions and care for one another every day.</span></p><p><span>We remain focused on strengthening education, creating opportunities for connection and belonging, increasing accessibility, and embedding inclusive practices into how we show up for our patients and one another. Our goal is not simply to achieve or maintain recognition. It is to continue building an environment where people feel they belong because inclusion is part of who we are as an organization.</span></p><p><span style="color:hsl(353,76%,49%);"><i><span><strong>Read more from Cedars-Sinai Stories and Insights: </strong></span></i></span><a href="https://www.cedars-sinai.org/stories-and-insights/innovation-and-research/residency-programs-move-toward-greater-diversity"><span style="color:hsl(353,76%,49%);"><i><span><strong>Residency Programs Move Toward Greater Diversity</strong></span></i></span></a></p>]]></description><category><![CDATA[Health Equity,Faculty News,Community,Community Benefit,LGBTQ]]></category>
            <pubDate>Thu, 30 Jul 2026 11:30:00 -0700</pubDate>
            <pp:lastModified>Fri, 31 Jul 2026 04:15:36 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/b31db4bd-3d33-438f-a954-a5fe087e66a5/500_060224-outloudmusicfestival-forpress-danielmacadangdang-8.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/b31db4bd-3d33-438f-a954-a5fe087e66a5/500_060224-outloudmusicfestival-forpress-danielmacadangdang-8.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/b31db4bd-3d33-438f-a954-a5fe087e66a5/060224-outloudmusicfestival-forpress-danielmacadangdang-8.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[More than 300 Cedars-Sinai employees, family members and friends marched in the 2024 WeHo Pride Parade, showing support for the LGBTQIA+ community.  Photo courtesy of WeHo Pride.]]></pp:imageTitle><pp:imageDescription><![CDATA[Cedars-Sinai employees march in a Pride parade carrying a Cedars-Sinai banner while waving rainbow and transgender pride flags. Spectators line both sides of the street.]]></pp:imageDescription></item><item>
                        <title>Quick Action Saves Dancer After Sudden Cardiac Arrest</title>
                        <link>https://www.cedars-sinai.org/newsroom/quick-action-saves-dancer-after-sudden-cardiac-arrest/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/quick-action-saves-dancer-after-sudden-cardiac-arrest/</guid><pp:caseid>777711</pp:caseid><pp:subtitle>Bystanders, Emergency Responders and Cedars-Sinai Experts Helped G’bari Gilliam Survive, Receive a Heart Transplant</pp:subtitle><description><![CDATA[<p><span>G’bari Gilliam was living the life he had dreamed about since childhood. The professional hip-hop dancer had moved to Los Angeles, built a successful career and was rehearsing for his next performance one afternoon in March 2026 when his heart suddenly stopped.</span></p><p><span>Gilliam, 32, suffered sudden cardiac arrest, an electrical malfunction of the heart that causes it to abruptly stop beating. The odds were stacked against him: Sudden cardiac arrest kills about 90% of those who experience it outside of a hospital. Survival depended on a chain of people acting within minutes.</span></p><p><span><img class="image_resized image-style-align-right" style="width:225px;" src="https://content.presspage.com/uploads/2110/06568747-100d-448e-8676-11673d7a2b85/800_kransdorfevan.kransdorfe-1280x1280.jpeg?x=1785194632976" alt="Evan Kransdorf, MD" width="225" />A fellow dancer immediately started CPR. Other dancers ran out of the dance studio in search of an </span><a href="https://www.cedars-sinai.org/health-topics/automated-external-defibrillator?query=sudden+cardiac+arrest&utm_source=search"><span>automated external defibrillator (AED)</span></a><span> and found one at a nearby dentist’s office. A speech pathologist who had just completed CPR recertification and happened to be nearby used the AED to revive Gilliam’s heartbeat.</span></p><p><span>Paramedics then rushed Gilliam to the Cedars-Sinai Emergency Department, where he had another cardiac arrest. Surgeons placed Gilliam on extracorporeal membrane oxygenation (ECMO), a form of advanced life support that temporarily took over the work of his heart, giving it time to recover—or, if necessary, bridging him to a transplant.</span></p><p><span>Cedars-Sinai experts say Gilliam’s case illustrates the importance of bystander CPR and quick medical response.</span></p><p><span>“The key to G’bari surviving sudden cardiac arrest was the fast-acting individuals who provided CPR, facilitated the use of an AED, and the Cedars-Sinai Emergency Department and cardiothoracic surgery teams who began ECMO within the hospital,” said </span><a href="https://researchers.cedars-sinai.edu/Evan.Kransdorf?prevPageName=cs-org%3Acedars-sinai%3Anewsroom%3Asudden-cardiac-arrest-genetic-cause-more-common-in-younger-people&adobe_mc=MCMID%3D15143042538955239740718824350024281938%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1773769890&previousPageName=cs-org%253Acedars-sinai%253Aother&adobe_mc=MCMID%3D15143042538955239740718824350024281938%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1783466719"><span>Evan Kransdorf, MD, PhD</span></a><span>, assistant professor of Cardiology in the Smidt Heart Institute and one member of Gilliam’s team of physicians and surgeons.</span></p><p><span><img class="image_resized image-style-align-right" style="width:225px;" src="https://content.presspage.com/uploads/2110/004cecc1-9e89-43f8-9027-55025e5619f9/800_pedro-catarino-md-smidt-heart-institute-cedars-sinai.jpg?x=1785194783286" alt="Pedro Catarino, MD" width="225" />During cardiac arrest, blood stops circulating, explained </span><a href="https://www.cedars-sinai.org/provider/pedro-catarino-915128.html"><span>Pedro Catarino, MD</span></a><span>, a cardiothoracic surgeon in the </span><a href="https://www.cedars-sinai.org/programs/heart.html"><span>Smidt Heart Institute at Cedars-Sinai</span></a><span>.</span></p><p><span>“The cells of the body, particularly the brain, will die within a few minutes without circulation,” Catarino said. “Gilliam’s heart was in and out of a rhythm that doesn’t sustain circulation, so the surgery team put him on emergency life support.”</span></p><p><span>Gilliam’s heart had ceased working, so he was listed in the organ donation system. After 12 days on life support, Gilliam received the news every transplant candidate hopes for: A donor heart had become available.</span></p><p><span>“Heart transplantation offers a new chance at life for patients like Gilliam,” Catarino said. “Gilliam is an athlete and can look forward to going back to his career with a heart that has a long lifespan.”</span></p><p><span>A pathology report showed Gilliam had a severe form of </span><a href="https://www.cedars-sinai.org/health-topics/hypertrophic-cardiomyopathy?query=hypertrophic+cardiomyopahty&utm_source=search"><span>hypertrophic cardiomyopathy</span></a><span>, an inherited condition that causes the heart muscle to thicken so that the heart cannot contract and pump blood properly. The condition likely caused Gilliam’s sudden cardiac arrest, his medical experts say.</span></p><p><span>“Many people with hypertrophic cardiomyopathy don’t have symptoms, and athletes who are used to pushing themselves to be out of breath might not realize they have it,” Kransdorf said.</span></p><p><span><img class="image_resized image-style-align-right" style="width:450px;" src="https://content.presspage.com/uploads/2110/e5b1f997-cca4-4b36-b0f4-eab398d433a0/800_gbari-with-care-team.jpg?x=1785194593149" alt="G'bari Gilliam, seated, surrounded by family and members of his care team." width="450" />Geneticists in the Smidt Heart Institute tested samples of Gilliam’s heart and found that he had a genetic variant associated with hypertrophic cardiomyopathy. Experts encourage anyone with a family history to be screened for the condition, which affects about </span><a href="https://www.cdc.gov/heart-disease-family-history/about/about-hypertrophic-cardiomyopathy-hcm-and-family-health-history-of-sudden-death.html" target="_blank" rel="noreferrer noopener"><span>1 in 500 people</span></a><span>. Gilliam’s close family members are undergoing genetic testing.</span></p><p><span>Gilliam, whose credits include performing with Bad Bunny and on </span><i><span>Jimmy Kimmel Live!</span></i><span>, is now in physical therapy and preparing to return to dance.</span></p><p><span>“With dancing, it feels like I'm able to be my most authentic self and be the most vulnerable version of myself. It makes me feel alive,” he said.</span></p><p><span>Prior to his medical emergency, Gilliam’s schedule consisted of dance classes and gym training five days a week. He hopes to return to intense days and to continue teaching dance to elementary school students and choreographing dancers on TV and film sets. His mother and girlfriend are supporting him, as are many friends, family members and fellow dancers.</span></p><p><span>“What I learned from this experience is everyone should be trained in CPR because you never know what's going to happen,” Gilliam said. “Even more so, be a person of service. If you have the opportunity to help someone, do it.”</span></p><p><span style="color:hsl(353,76%,49%);"><i><span><strong>Read more from Cedars-Sinai Stories and Insights—</strong></span></i></span><a href="https://www.cedars-sinai.org/newsroom/sudden-cardiac-arrest-genetic-cause-more-common-in-younger-people/"><span style="color:hsl(353,76%,49%);"><i><span><strong>Sudden Cardiac Arrest: Genetic Cause More Common in Younger People</strong></span></i></span></a></p>]]></description><category><![CDATA[News,Heart,Heart Transplant,evan-kransdorf-834994,pedro-catarino-915128,Stephanie Cajigal,Soshea Leibler,Homepage]]></category>
            <pubDate>Tue, 28 Jul 2026 06:00:00 -0700</pubDate>
            <pp:lastModified>Fri, 25 Sep 2026 21:07:03 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/7ece6611-e6d2-4d15-a242-d99b90c01083/500_gbari-gilliam-with-family-cedars-sinai.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/7ece6611-e6d2-4d15-a242-d99b90c01083/500_gbari-gilliam-with-family-cedars-sinai.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/7ece6611-e6d2-4d15-a242-d99b90c01083/gbari-gilliam-with-family-cedars-sinai.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[gbari-gilliam-with-family-cedars-sinai]]></pp:imageTitle><pp:imageDescription><![CDATA[Heart transplant patient, G&amp;#039;bari Gilliam, sits on a white couch between his mother (left) and girlfriend (right).]]></pp:imageDescription></item><item>
                        <title>Cedars-Sinai Appoints Ravi Thadhani, MD, MPH, as Inaugural Chief Physician Executive, Dean of the Medical Faculty</title>
                        <link>https://www.cedars-sinai.org/newsroom/cedars-sinai-appoints-ravi-thadhani-md-mph-as-inaugural-chief-physician-executive-dean-of-the-medical-faculty/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/cedars-sinai-appoints-ravi-thadhani-md-mph-as-inaugural-chief-physician-executive-dean-of-the-medical-faculty/</guid><pp:caseid>767689</pp:caseid><pp:subtitle>Distinguished Physician-Scientist Will Oversee Clinical, Academic and Education Enterprises</pp:subtitle><description><![CDATA[<p><a href="https://www.cedars-sinai.org/about/leadership/executive-management/ravi-thadhani-md-mph.html"><span>Ravi Thadhani, MD, MPH</span></a><span>, a distinguished leader in academic medicine and a widely respected physician, scientist and educator, has been appointed to the inaugural role of executive vice president, chief physician executive and dean of the Medical Faculty, effective Sept. 1.</span></p><p><span>In this new senior leadership position, Thadhani will oversee the academic and clinical enterprises at Cedars-Sinai, further unifying the organization's care delivery, research and education missions. He will lead a broad team of leaders, including department chairs, institute directors, executive vice deans, vice deans and chief medical officers.</span></p><p><span>Thadhani succeeds </span><a href="https://www.cedars-sinai.org/about/leadership/executive-management/shlomo-melmed-mbchb.html"><span>Shlomo Melmed, MB, ChB</span></a><span>, who served as dean of the Medical Faculty and executive vice president of Medicine and Health Sciences for 28 years. Melmed will transition to the role of dean emeritus of the Medical Faculty and executive adviser to Cedars-Sinai President and CEO </span><a href="https://www.cedars-sinai.org/about/leadership/executive-management/peter-l-slavin.html"><span>Peter L. Slavin, MD</span></a><span>.</span></p><p><span>“Dr. Thadhani is the ideal leader to succeed Dr. Melmed,” Slavin said. “His extensive background in organizational leadership, commitment to clinical medicine and academic excellence and robust scientific record position him to advance every dimension of our enterprise.”</span></p><p><span>Thadhani most recently served as executive vice president of Clinical Affairs and chief medical officer for Cedars-Sinai Medical Center and Cedars-Sinai Health System. In his new role, he will retain oversight of clinical quality and safety, medical affairs, and medical standards of care for the medical center and health system, while assuming additional responsibility for all academic and education programs, including Cedars-Sinai Health Sciences University and the Burns and Allen Research Institute.</span></p><p><span>Thadhani began his career at Massachusetts General Hospital and Harvard Medical School. He served as vice dean for Research and Education at Cedars-Sinai Medical Center from 2017 to 2019 before returning to Harvard as professor of medicine and serving as chief academic officer and dean for Faculty Affairs at Mass General Brigham and Harvard Medical School.</span></p><p><span>In 2022, he was named executive vice president for health affairs at Emory University as well as vice chair of the Emory Healthcare Board of Directors and executive director of Emory’s Woodruff Health Sciences Center, which includes Emory’s schools of medicine, public health and nursing.</span></p><p><span>Thadhani is the author or co-author of more than 300 scientific manuscripts published in leading academic journals, including </span><i><span>The New England Journal of Medicine</span></i><span>, </span><i><span>The Lancet</span></i><span> and the</span><i><span> Journal of the American Medical Association.</span></i></p><p><span>A leading expert in nephrology and preeclampsia, one of the leading causes of maternal and perinatal morbidity and mortality, Thadhani played a central role with Cedars-Sinai collaborators in developing the first Food and Drug Administration-approved test to predict the condition.</span></p><p><span>His research contributions have earned recognition at the highest levels of science and medicine. Earlier this year, he was elected a Fellow of the American Association for the Advancement of Science (AAAS), following his election last year to the National Academy of Medicine.</span></p><p><span>“I am deeply honored to step into this role at such a pivotal moment for Cedars-Sinai,” Thadhani said. “I am grateful to Dr. Melmed for the extraordinary foundation he has built, and I look forward to working closely with our talented leaders and faculty to forge the next chapter of our academic and clinical mission.”</span></p><p><span style="color:hsl(353,76%,49%);"><i><strong>Read more from the Cedars-Sinai Newsroom: </strong></i></span><a href="https://www.cedars-sinai.org/newsroom/physician-scientist-ravi-thadhani-md-mph-named-aaas-fellow/" target="_blank" rel="noreferrer noopener"><span style="color:hsl(353,76%,49%);"><i><strong>Physician-Scientist Ravi Thadhani, MD, MPH, Named AAAS Fellow</strong></i></span></a></p>]]></description><category><![CDATA[Exclude,Faculty News,Cara Martinez]]></category>
            <pubDate>Fri, 24 Jul 2026 07:00:00 -0700</pubDate>
            <pp:lastModified>Thu, 23 Jul 2026 16:42:40 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/92c1b197-779e-4431-abf7-568c762d7b4d/500_ravi-thadhani-md-mph-cedars-sinai2.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/92c1b197-779e-4431-abf7-568c762d7b4d/500_ravi-thadhani-md-mph-cedars-sinai2.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/92c1b197-779e-4431-abf7-568c762d7b4d/ravi-thadhani-md-mph-cedars-sinai2.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Thadhani will oversee the academic and clinical enterprises at Cedars-Sinai, further unifying the organization&amp;#039;s care delivery, research and education missions. Photo by Cedars-Sinai.]]></pp:imageTitle><pp:imageDescription><![CDATA[A man in a white lab coat, Ravi Thadhani, MD, MPH, stands outside on the plaza level of Cedars-Sinai Medical Center.]]></pp:imageDescription></item><item>
                        <title>Why the Heart’s Metabolism Fascinates This Scientist</title>
                        <link>https://www.cedars-sinai.org/newsroom/why-the-hearts-metabolism-fascinates-this-scientist/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/why-the-hearts-metabolism-fascinates-this-scientist/</guid><pp:caseid>763848</pp:caseid><pp:subtitle>Cedars-Sinai’s Anja Karlstaedt, MD, PhD, Is Mapping How the Heart Feeds Itself — and Her Discoveries Could Lead to New Treatments for Heart Failure</pp:subtitle><description><![CDATA[<p>The heart runs an around-the-clock fuel operation, burning almost any nutrient it can get to keep pumping. Understanding this fuel operation is the central focus of scientist <a href="https://researchers.cedars-sinai.edu/Anja.Karlstaedt">Anja Karlstaedt, MD, PhD,</a> and her team. Their work could lead to new treatments for the millions of p<span>eople with conditions that impair their heart function.</span></p><p><span>A new study led by Karlstaedt and published in </span><a href="https://urldefense.com/v3/__https:/www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.125.076453__;!!KOmnBZxC8_2BBQ!yJDawQIXy2K690fA7c1F2DL4rVnweE2zl4ueopDbCguX0slOVDRJGsOd7Gn_rqZgRVvMBnUVgnNqESG1KsGyH7k8ivwN$" target="_blank" rel="noreferrer noopener"><i><span>Circulation</span></i></a><i><span> </span></i><span>reports that a specific enzyme plays an important role in keeping the heart beating. The discovery could help scientists create drugs that mimic the enzyme’s role and help people with heart failure, a condition in which the heart becomes too weak to pump blood properly.  </span></p><p><span>Karlstaedt, assistant professor of Cardiology in the </span><a href="https://www.cedars-sinai.org/programs/heart.html"><span>Smidt Heart Institute</span></a><span> at Cedars-Sinai, has spent more than a decade studying heart metabolism—the chemical process that powers the heart. She spoke with the</span><i><span> Cedars-Sinai Newsroom</span></i><span> about her dedication to uncovering treatments for the millions diagnosed with heart failure every year.</span></p><h2><strong>How is the heart’s metabolism different from the metabolism of other parts of the body?</strong></h2><p><span>There are thousands of tiny molecules called metabolites—including amino acids, glucose and fatty acids—that act as an energy source to help cells function properly. The heart is the only organ that can use almost any metabolite.</span></p><p><span>The heart is also unique because it never stops beating. It's not like other muscles, which can rest. Fueling heart cells requires fine-tuned, organized chemical reactions. The system functions perfectly until something disrupts it, and metabolism is at its center. </span></p><h2><strong>What was one of the major discoveries that led to your current work?</strong><span><strong> </strong></span></h2><p><span>My colleagues and I </span><a href="https://www.pnas.org/doi/10.1073/pnas.1601650113" target="_blank" rel="noreferrer noopener"><span>published a study in </span>2016</a><span> in which we discovered that the heart uses unusual fuel-processing routes to adapt to metabolites released by cancer cells. It’s like in a city where you have streets and traffic moves along those streets. </span>If a construction site suddenly blocks a street, traffic finds another way around. The heart does the same thing.</p><p><span>We also found that in response to cancer-related metabolic stress, the heart suddenly started using an unusual enzyme called </span>ATP-dependent citrate lyase, or ACL. This enzyme drives the process that creates fatty acids, something we didn’t think happened in heart cells. But when we blocked ACL, the heart could not pump well. That told us this enzyme might be much more important for the heart than previously thought.</p><h2><span><strong>Could you describe your recent discovery?</strong></span></h2><p>We found that when ACL slows down, heart function drops. <span>To make this discovery, we studied heart tissue samples from people with healthy hearts and people with failing hearts. </span>We also observed ACL in the hearts of laboratory mice. When ACL activity decreased, meaning it no longer efficiently produced fatty acids, the heart tried to adapt by taking up more sugar and rewiring parts of its metabolism. But those changes did not fully protect the heart. Instead, the heart had less available energy and did not pump as well.</p><p><span>To dig deeper, we used CardioNet, our computational model of heart metabolism. The model pinpointed another enzyme, IDH1, that compensates for the loss of ACL. When we reduced IDH1 in our model, the heart could pump better. </span>We're now studying whether future heart failure therapies could target IDH1.</p><h2><span><strong>What do you hope to accomplish as this work progresses?</strong></span></h2><p>Heart failure can look similar from one patient to another, but the underlying metabolic changes may be different. <span>We hope to use our computational model to predict which fuel pathways are disrupted in people with heart failure and which treatments can get the heart working better. </span>We are not there yet, but this study is an important step toward understanding heart failure as a disease of both mechanics and metabolism.</p><p><span style="color:hsl(353,76%,49%);"><i><span><strong>Cedars-Sinai Health Sciences University is advancing groundbreaking research and educating future leaders in medicine, biomedical sciences and allied health sciences. </strong></span></i></span><a href="https://www.cedars-sinai.edu/health-sciences-university.html?adobe_mc=MCMID%3D79521921680015491943235909713257507329%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1733161540"><span style="color:hsl(353,76%,49%);"><i><span><strong>Learn more</strong></span></i></span></a><span style="color:hsl(353,76%,49%);"><i><span><strong> about the university.</strong></span></i></span></p>]]></description><category><![CDATA[Stephanie Cajigal,News,Heart,Heart Research,Heart Failure Research]]></category>
            <pubDate>Tue, 21 Jul 2026 06:00:00 -0700</pubDate>
            <pp:lastModified>Tue, 21 Jul 2026 01:32:21 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/4be38de3-1063-4088-a275-4aa4f7094e8c/500_anja-karlstaedt-md-phd-cedars-sinai.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/4be38de3-1063-4088-a275-4aa4f7094e8c/500_anja-karlstaedt-md-phd-cedars-sinai.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/4be38de3-1063-4088-a275-4aa4f7094e8c/anja-karlstaedt-md-phd-cedars-sinai.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Anja Karlstaedt, MD, PhD, a scientist in the Smidt Heart Institute at Cedars-Sinai, led a team that discovered the important role a specific enzyme plays in keeping the heart pumping. Photo by Cedars-Sinai.]]></pp:imageTitle><pp:imageDescription><![CDATA[A female scientist wearing latex gloves takes samples from a tray to insert into machine in lab.]]></pp:imageDescription></item><item>
                        <title>Two Studies Advance Sudden Cardiac Arrest Prediction</title>
                        <link>https://www.cedars-sinai.org/newsroom/two-studies-advance-sudden-cardiac-arrest-prediction/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/two-studies-advance-sudden-cardiac-arrest-prediction/</guid><pp:caseid>763224</pp:caseid><pp:subtitle>Warning Symptoms, Recurrent Heart Events May Identify People at Risk for This Often-Deadly Event</pp:subtitle><description><![CDATA[<p><span style="color:#000000;">Two studies from investigators at </span><a href="https://www.cedars-sinai.edu/health-sciences-university.html?prevPageName=cs-org%3Acedars-sinai%3Anewsroom&adobe_mc=MCMID%3D84485544739783459593277987900948470512%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1781634342&previousPageName=cs-org%253Acedars-sinai%253Aother"><span>Cedars-Sinai Health Sciences University</span></a><span style="color:#000000;"> move the medical field closer to solving a longstanding challenge: predicting who is at risk for sudden cardiac arrest. </span></p><p><span style="color:#000000;"><img class="image-style-align-right image_resized" style="width:240px;" src="https://content.presspage.com/uploads/2110/eadb7a44-7ab9-42aa-b8c3-2e110b692d8b/800_kyndaron-reinier-phd-mph-cedars-sinai.jpg?x=1784135260568" width="240" alt="Kyndaron Reinier, PhD, MPH. Photo courtesy of Kyndaron Reinier, PhD, MPH." />“The majority of people who have a sudden cardiac arrest outside of a hospital will die, so the best protection is being aware of risk,” said </span><a href="https://researchers.cedars-sinai.edu/Kyndaron.Reinier"><span>Kyndaron Reinier, PhD, MPH</span></a><span style="color:#000000;">, associate director of Epidemiology in the </span><span>Center for Cardiac Arrest Prevention</span><span style="color:#000000;"><span> in the </span></span><a href="https://www.cedars-sinai.org/programs/heart.html"><span>Smidt Heart Institute at Cedars-Sinai</span></a><span style="color:#000000;"> and an author of both studies. </span></p><p><span style="color:#000000;">Sudden cardiac arrest happens when a problem with the heart’s electrical system causes the heart to stop beating. It is different from a heart attack, which is caused by a lack of blood flow to the heart. More than </span><a href="https://cpr.heart.org/en/resources/cpr-facts-and-stats" target="_blank" rel="noreferrer noopener"><span>350,000 people</span></a><span style="color:#000000;"> experience sudden cardiac arrest outside of a hospital in the U.S. each year, and only about 10% survive. </span></p><p><span style="color:#000000;">Experts know that people with low left ventricular ejection fraction, when the heart’s main pumping chamber is weak and pumps less than it should, are at higher risk for sudden cardiac arrest. But this marker has become less effective and other indicators are needed to capture more people at risk.</span></p><p><span>“More than two-thirds of people who have cardiac arrest don’t have </span><span style="color:#000000;"><span>low left ventricular ejection fraction</span></span><span>, so using this marker alone misses too many people,” Reinier said. </span></p><p><span style="color:#000000;">A study published in the journal </span><a href="https://www.ahajournals.org/doi/10.1161/CIRCEP.125.014647" target="_blank" rel="noreferrer noopener"><i><span>Circulation: Arrhythmia and Electrophysiology</span></i></a><span style="color:#000000;"> reports that warning symptoms combined with clinical history could predict imminent sudden cardiac arrest. A second study, published in the </span><a href="https://www.ahajournals.org/doi/10.1161/JAHA.125.049853?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed" target="_blank" rel="noreferrer noopener"><i><span>Journal of the American Heart Association</span></i></a><span style="color:#000000;"><i> (JAHA)</i>, reports that having more than one cardiac event over time could signal rising risk. </span></p><h2><span style="color:hsl(0,0%,0%);"><strong>Reading Warning Symptoms</strong></span></h2><p class="p1"><span style="color:#000000;">In the <i>Circulation: Arrhythmia and Electrophysiology</i> study, investigators used machine learning to identify combinations of symptoms and medical history that best predicted sudden cardiac arrest in the near future. </span></p><p class="p1"><span style="color:#000000;"><img class="image-style-align-right image_resized" style="width:240px;" src="https://content.presspage.com/uploads/2110/177b9a0e-e963-46a3-8a4e-176f07a337c9/800_chugh-sumeet.chughs-1280x1280.jpeg?x=1784135313965" width="240" alt="Sumeet Chugh, MD" />The study included people enrolled in two separate, longstanding studies in Oregon and Ventura County, California, that were founded by </span><a href="https://researchers.cedars-sinai.edu/Sumeet.Chugh"><span style="background-color:#FFFFFF;"><span>Sumeet Chugh, MD</span></span></a><span style="background-color:#FFFFFF;"><span>,</span></span><span style="color:#000000;"> director of the </span><a href="https://www.cedars-sinai.edu/health-sciences-university/research/departments-institutes/cardiology/cardiac-arrest-prevention.html"><span>Center for Cardiac Arrest Prevention</span></a><span> in the </span><span style="color:#000000;">Smidt Heart Institute. The investigators compared 364 people who called 911 when experiencing symptoms such as chest pain and survived sudden cardiac arrest, with 313 people who called 911 for similar symptoms but did not experience sudden cardiac arrest.<span> </span></span></p><p class="p1"><span style="color:#000000;">The analysis found that people with sudden cardiac arrest were more likely to have a combination of shortness of breath and diagnosed coronary artery disease or heart failure than people who did not experience sudden cardiac arrest. Seizure-like symptoms without chest pain or shortness of breath were also more common in people who experienced sudden cardiac arrest.</span></p><p><span style="color:#000000;">The investigators also found that chest pain combined with coronary artery disease predicted imminent arrest in women, while chest pain combined with heart failure predicted it in men. </span></p><p><span style="color:#000000;">Warning symptoms most often occurred at least 15 minutes prior to the sudden cardiac arrest, a time frame that would make it possible to call 911. In </span><a href="https://www.acpjournals.org/doi/10.7326/M14-2342?__cf_chl_f_tk=TvmGlOsWXdkpUJH.m6vBZ8h4XOPUf_kxfDgAD_ASKag-1783029485-1.0.1.1-nANkA55OBLIduWWlS113NUXlGXyILfacHV79UQp_mb4" target="_blank" rel="noreferrer noopener"><span>earlier research</span></a><span style="color:#000000;">, the investigators found that 81% of people delayed their 911 call, reducing their chances of successful revival by ambulance paramedics. </span></p><p><span style="color:#000000;">These findings could be used to create risk-predicting algorithms for use by urgent care and emergency medicine providers, the investigators said. “While more research is needed, such risk prediction algorithms have the potential to avoid 911 call delays following warning symptoms of sudden cardiac arrest,” said Chugh, vice dean and chief AI health research officer at Cedars-Sinai.</span></p><h2><span style="color:hsl(0,0%,0%);"><strong>Tracking Risk Over Time</strong></span></h2><p><span style="color:#000000;">The <i>JAHA</i> study was carried out in the Observational Study of Cardiac Arrest Risk (O.S.C.A.R.) cohort at Cedars-Sinai, established by Chugh, that has been tracking the health of approximately 400,000 residents of Los Angeles County from 2017 onward. Of these, the investigators followed more than 6,700 people hospitalized at Cedars-Sinai for heart failure and more than 2,900 people hospitalized in the health system for acute coronary syndrome, when an artery blockage reduces blood flow to the heart. </span></p><p><span style="color:#000000;">Investigators found that patients in both groups who experienced a recurrent cardiovascular event faced a higher risk of sudden cardiac arrest. </span></p><p><span style="color:#000000;">Patients who had a second coronary artery blockage were more than three times as likely to experience sudden cardiac arrest as those without a recurrence. Patients who were hospitalized a second time for heart failure were nearly twice as likely to experience sudden cardiac arrest. Risk climbed with each additional heart failure hospitalization. The investigators compared the findings to what was found in participants of the Framingham Heart Study, which enrolled participants about 50 years earlier. The results were similar, however the heart failure result in that study did not reach statistical significance.</span></p><p><span style="color:#000000;">Reinier said that physicians should consider sudden cardiac arrest as being more likely when a </span><span>patient is hospitalized for a heart issue a second time.</span></p><p><span>“This may mean running additional tests,” Reinier said. “It may mean educating the patient about what cardiac arrest is and the importance of having a family member who knows to call 911 and start CPR immediately if their loved one collapses.”</span></p><h2><span style="color:hsl(0,0%,0%);"><strong>Moving Beyond Dead Ends</strong></span></h2><p><span style="background-color:#FFFFFF;">Chugh</span><span style="background-color:#FFFFFF;color:#000000;">, </span><span style="color:#000000;">senior author of both studies, said the combined findings point toward a more flexible approach to prediction.</span></p><p><span style="color:#000000;">“Near-term and long-term predictions are parallel approaches that can help us move past roadblocks we face in preventing death from this lethal heart event,” Chugh said.</span></p><p><span style="color:#000000;">Additional research, including studies in different populations, are needed to confirm whether the factors the investigators studied could be used in prediction tools, study authors said. </span></p><p><span style="color:#000000;">Cedars-Sinai investigators continue to study predictors of sudden cardiac arrest, and their work includes using </span><a href="https://www.cedars-sinai.org/newsroom/new-studies-ai-captures-electrocardiogram-patterns-that-could-signal-a-future-sudden-cardiac-arrest/"><span>AI to study patterns in heart tests called electrocardiograms</span></a><span style="color:#000000;"> and looking for </span><a href="https://www.cedars-sinai.org/newsroom/sudden-cardiac-arrest-genetic-cause-more-common-in-younger-people/"><span>genetic causes</span></a><span style="color:#000000;">. </span></p><p class="p1"><i><span>Additional Cedars-Sinai authors in the </span></i><span>Circulation</span><span style="color:#000000;">: Arrhythmia and Electrophysiology</span><i><span>study include Harpriya Chugh, BS; Vishnu Kadiyala, MD; Arayik Sargsyan, MPH; Audrey Uy-Evanado, MD; Kotoka Nakamura, PhD; Elizabeth Heckard, MS; Marco Mathias, BS.</span></i></p><p class="p1"><i><span>Other authors include Tristan Grogan, MS; David Elashoff, PhD; Angelo Salvucci, MD; and Jonathan Jui, MD, MPH.</span></i></p><p class="p1"><i><span>Funding: Dr. Chugh was funded by the National Heart Lung and Blood Institute, National Institutes of Health.</span></i></p><p class="p1"><i><span>Additional Cedars-Sinai authors in the</span></i><span> </span><span style="color:#000000;">Journal of the American Heart Association</span><span> </span><i><span>study include Marita Knudsen Pope, MD, PhD; Harpriya Chugh, BS, MSHS; Thien Tan Tri Tai Truyen, MD; Marco Mathias, BS; and Audrey Uy-Evanado, MD.</span></i></p><p class="p1"><i><span>Other authors include Honghuang Lin, PhD; Dan Atar, MD, Nichole Bosson, MD, MPH</span><span class="s1">, and </span><span>Emelia J. Benjamin, MD, ScM</span></i></p><p class="p1"><i><span>Funding: </span></i><span style="color:#222222;"><i>The Framingham Heart Study is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health. Dr. Benjamin is partially funded by The National Heart, Lung, and Blood Institute, National Institutes of Health.</i></span></p><p><span style="background-color:#FFFFFF;color:#C00000;"><i><strong>Cedars-Sinai Health Sciences University is advancing groundbreaking research and educating future leaders in medicine, biomedical sciences and allied health sciences. </strong></i></span><a href="https://www.cedars-sinai.edu/health-sciences-university.html?adobe_mc=MCMID%3D79521921680015491943235909713257507329%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1733161540"><span style="background-color:#FFFFFF;color:#C00000;"><i><strong>Learn more</strong></i></span></a><span style="background-color:#FFFFFF;color:#C00000;"><i><strong> about the university.</strong></i></span></p>]]></description><category><![CDATA[Exclude,Research,Stephanie Cajigal,sumeet-chugh-1385885,Heart,Heart Research]]></category>
            <pubDate>Thu, 16 Jul 2026 10:11:46 -0700</pubDate>
            <pp:lastModified>Thu, 16 Jul 2026 19:11:46 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/cea818a8-35d1-4fcc-be16-4c9112e5e11b/500_aed-on-wall-cedars-sinai.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/cea818a8-35d1-4fcc-be16-4c9112e5e11b/500_aed-on-wall-cedars-sinai.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/cea818a8-35d1-4fcc-be16-4c9112e5e11b/aed-on-wall-cedars-sinai.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Cedars-Sinai investigators are studying risk predictors of sudden cardiac arrest, which kills roughly 90% of those affected.  Photo by Getty.]]></pp:imageTitle><pp:imageDescription><![CDATA[An Automated External Defibrillator (AED) is securely mounted on a green tiled wall, ready for emergency use.]]></pp:imageDescription></item><item>
                        <title>Cedars-Sinai Appoints Electrophysiology Director</title>
                        <link>https://www.cedars-sinai.org/newsroom/cedars-sinai-appoints-electrophysiology-director/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/cedars-sinai-appoints-electrophysiology-director/</guid><pp:caseid>762010</pp:caseid><pp:subtitle>Michael Shehata, MD, Will Oversee Program That Provides Care to People With Heart Rhythm Disorders and Trains Future Specialists</pp:subtitle><description><![CDATA[<p><span style="color:#000000;">The<strong> </strong></span><a href="https://www.cedars-sinai.org/programs/heart.html"><span>Smidt Heart Institute</span></a><span style="color:#000000;"> at Cedars-Sinai has selected<strong> </strong></span><a href="https://www.cedars-sinai.org/provider/michael-shehata-128792.html"><span>Michael M. Shehata, MD</span></a><span>, as director of the Division of Cardiac Electrophysiology, a program that provides care to people with abnormal heart rhythms. </span></p><p class="p1"><span>Shehata is a cardiac electrophysiologist, a doctor who specializes in diagnosing and treating problems with the heart’s electrical system. He has experience with a broad spectrum of heart rhythm disorders and also cares for people with heart failure and survivors of cardiac arrest.</span></p><p style="margin-left:0in;"><span style="background-color:#FFFFFF;color:#111111;">“O</span><span>ver the past two decades, Dr. Shehata has emerged as a nationally recognized cardiac electrophysiologist and academic leader,” said </span><a href="https://researchers.cedars-sinai.edu/Susan.Cheng?adobe_mc=MCMID%3D75360244188131661941566734971363994374%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1754577108&prevPageName=cs-org%3Acedars-sinai%3Anewsroom%3Acedars-sinai-reports-heart-attacks-general-illness-spiked-after-la-fires"><span style="background-color:#FFFFFF;color:#DC1E34;">Susan Cheng, MD, MMSc, MPH</span></a><span style="background-color:#FFFFFF;color:#000000;">, </span><span>chair of the Department of Cardiology in the Smidt Heart Institute. “His leadership will mean continued progress in this important field.”</span></p><p><span style="background-color:#FFFFFF;color:#111111;">As a researcher, Shehata has led groundbreaking clinical trials for new types of pacemakers and other technologies for treating heart rhythm disorders. He also studies ways that AI can be used to personalize care. </span></p><p><span style="background-color:#FFFFFF;color:#111111;">Shehata’s most recent research includes a trial of a new treatment for atrial fibrillation, which occurs when the upper chambers of the heart beat out of sync with the lower chambers of the heart. The treatment, pulsed field ablation, </span><span style="background-color:#FFFFFF;color:#000000;">targets heart cells involved in an abnormal heart rhythm. The U.S. Food and Drug Administration approved several pulsed field ablation systems, including one studied by Shehata and other researchers, in 2024. </span></p><p><span style="background-color:#FFFFFF;color:#000000;">Shehata and colleagues have also studied leadless pacemakers, miniature devices that attach to the heart muscle and that, unlike traditional pacemakers, don’t require a battery and wires. </span></p><p><span style="background-color:#FFFFFF;color:#111111;">As division director, Shehata will oversee a program that provides research-backed care and trains new heart rhythm specialists. The program offers a two-year fellowship to medical school graduates seeking advanced knowledge and skills in electrophysiology. </span></p><p><span>“Through his leadership of the Interventional Electrophysiology Laboratory and the Clinical Cardiac Electrophysiology Fellowship Program, Dr. Shehata has expanded access to advanced therapies and enhanced the training of future electrophysiologists,” said</span><span style="background-color:#FFFFFF;color:#000000;"><span> </span></span><a href="https://researchers.cedars-sinai.edu/Eduardo.Marban?prevPageName=cs-org%3Acedars-sinai%3Anewsroom%3Asmidt-heart-institute-at-cedars-sinai-launches-sports-cardiology-program"><span style="background-color:#FFFFFF;color:#DC1E34;">Eduardo Marbán, MD, PhD</span></a><span style="background-color:#FFFFFF;color:#000000;">, executive director of the Smidt Heart Institute and the Mark S. Siegel Family Foundation Distinguished Professor.</span></p><p style="margin-left:0in;"><span>Shehata earned his medical degree from the University of California, San Diego, School of Medicine. He completed internal medicine residency training at UCLA and his cardiology fellowship training at Cedars-Sinai, where he was chief fellow. He also completed advanced fellowship training in cardiac electrophysiology at Cedars-Sinai. He served as faculty at UCLA before being recruited to join the cardiology faculty at Cedars-Sinai, where he is a professor of Cardiology. </span></p><p><span style="background-color:#FFFFFF;color:#000000;"><i>U.S. News & World Report</i> rates the Smidt Heart Institute a top 10 cardiovascular center in the U.S. and #1 in California. </span></p><p><span style="color:hsl(353,76%,49%);"><i><strong>Read more from Cedars-Sinai Stories and Insights: </strong></i></span><a href="https://www.cedars-sinai.org/newsroom/new-atrial-fibrillation-treatment-gets-dad-his-beat-back/"><span style="color:hsl(353,76%,49%);"><i><span><strong>New AFib Treatment Helps Dad Regain His Heart Rhythm</strong></span></i></span></a></p>]]></description><category><![CDATA[Exclude,Faculty News,Heart,Electrophysiology,michael-shehata-128792,Stephanie Cajigal]]></category>
            <pubDate>Thu, 02 Jul 2026 07:00:00 -0700</pubDate>
            <pp:lastModified>Wed, 01 Jul 2026 19:30:06 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/2e7a2d6d-4e79-44a2-9fc0-dc356a87178f/500_michael-shehata-md-cedars-sinai.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/2e7a2d6d-4e79-44a2-9fc0-dc356a87178f/500_michael-shehata-md-cedars-sinai.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/2e7a2d6d-4e79-44a2-9fc0-dc356a87178f/michael-shehata-md-cedars-sinai.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Michael Shehata, MD, is director of the Division of Electrophysiology in the Smidt Heart Institute at Cedars-Sinai.]]></pp:imageTitle><pp:imageDescription><![CDATA[A male physician, Michael Shehata, MD, in a white coat.]]></pp:imageDescription></item><item>
                        <title>Cedars-Sinai Selects New Otolaryngology Leader</title>
                        <link>https://www.cedars-sinai.org/newsroom/cedars-sinai-selects-new-otolaryngology-leader/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/cedars-sinai-selects-new-otolaryngology-leader/</guid><pp:caseid>761896</pp:caseid><pp:subtitle>Surgeon Mia Miller, MD, to Direct Division of Otolaryngology–Head and Neck Surgery</pp:subtitle><description><![CDATA[<p>Cedars-Sinai has selected <a href="https://www.cedars-sinai.org/provider/mia-miller-2556565.html">Mia E. Miller, MD</a>, to lead the Division of Otolaryngology–Head and Neck Surgery in the <a href="https://www.cedars-sinai.org/programs/general-surgery.html">Jim and Eleanor Randall Department of Surgery</a>.</p><p><img class="image_resized image-style-align-right" style="width:200px;" src="https://content.presspage.com/uploads/2110/bd067a16-917a-42ce-91d0-4e7f1a7f2919/500_mia-miller-md-cedars-sinai.jpg?x=1782861753793" alt="Mia E. Miller, MD" width="200" />An accomplished neurotologist and skull base surgeon, Miller joined Cedars-Sinai in 2021 and serves as director of Neurotology for the Cedars-Sinai Acoustic Neuroma and Lateral Skull Base Surgery Center. Her expertise includes otology, neurotology, cochlear implantation, vestibular schwannoma and acoustic neuroma care, lateral skull base surgery, Ménière’s disease, and hearing restoration.</p><p>“My vision is to continue to develop each of our subspecialties to the highest standard of rigorous academics and education paired with clinical excellence,” said Miller, also the <span style="color:#000000;">inaugural LuEllen Margaret Edwards Chair in Otology and Neurotology. "Every patient who comes to us deserves care from a team that is both deeply trained and fully committed to outstanding outcomes, and every trainee deserves an environment where they can grow into an exceptional clinician."</span></p><p>As an initial priority, Miller has hired Cedars-Sinai’s first otolaryngology PhD researcher to help lead the development of a hearing regeneration lab.</p><p><img class="image_resized image-style-align-right" style="width:200px;" src="https://content.presspage.com/uploads/2110/ed364105-2c4c-4580-9248-cc138382541c/500_cristina-ferrone-md-cedars-sinai.jpg?x=1782861781686" alt="Cristina R. Ferrone, MD" width="200" />"We are delighted for Dr. Miller to step into the role of division director," said <a href="https://www.cedars-sinai.org/provider/cristina-ferrone-41099.html">Cristina R. Ferrone, MD</a>, chair of the Department of Surgery at Cedars-Sinai. "Her expertise as a surgeon, dedication to education and clear vision make her an ideal leader for this team. We look forward to the many ways she will strengthen patient care and mentor the physicians of tomorrow."</p><p>Miller earned her bachelor’s degree from Harvard University and her medical degree from Harvard Medical School. She completed her surgical internship and residency in head and neck surgery at UCLA, followed by fellowship training in neurotology and skull base surgery at the University of California, San Diego (UCSD). Prior to joining Cedars-Sinai, Miller served as director of the Center for Balance and Falls at the University of California, San Francisco (UCSF), where she led clinical and research initiatives. She also spent seven years as an associate at the House Ear Clinic.</p><p>Miller succeeds Gene Liu, MD, in the role of division director.</p><p>“Over the course of his years at Cedars-Sinai, Dr. Liu made outstanding contributions to the Department of Surgery, and we are grateful for his leadership,” Ferrone said. “Through his recruitment of 19 surgeons across the network and the establishment of the ENT residency, he provided a strong foundation of excellence in the academic and clinical footprint of the division for Dr. Miller to build on.”</p><p><span style="color:hsl(353,76%,49%);"><i><strong>Read more from the Cedars-Sinai Newsroom—</strong></i></span><a href="https://www.cedars-sinai.org/newsroom/today-treating-hearing-loss-can-protect-your-brain-from-cognitive-decline/"><span style="color:hsl(353,76%,49%);"><i><strong>TODAY: Treating Hearing Loss Can Protect Your Brain From Cognitive Decline</strong></i></span></a></p>]]></description><category><![CDATA[Exclude,Faculty News,ENT,Skull Base Surgery,Surgery,mia-miller-2556565,Jillian Scholten]]></category>
            <pubDate>Wed, 01 Jul 2026 07:00:00 -0700</pubDate>
            <pp:lastModified>Thu, 23 Jul 2026 19:53:01 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/3d676c30-c438-4d98-9f99-271324f0ce53/500_cedars-sinai-plaza-exterior-shot.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/3d676c30-c438-4d98-9f99-271324f0ce53/500_cedars-sinai-plaza-exterior-shot.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/3d676c30-c438-4d98-9f99-271324f0ce53/cedars-sinai-plaza-exterior-shot.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Mia E. Miller, MD, inaugural holder of the LuEllen Margaret Edwards Chair in Otology and Neurotology, has been named director of the Division of Otolaryngology&amp;ndash;Head and Neck Surgery at Cedars-Sinai.]]></pp:imageTitle><pp:imageDescription><![CDATA[Exterior shot of Cedars-Sinai hospital with plants in foreground.]]></pp:imageDescription></item><item>
                        <title>The Heart of a Cancer Patient</title>
                        <link>https://www.cedars-sinai.org/newsroom/the-heart-of-a-cancer-patient/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/the-heart-of-a-cancer-patient/</guid><pp:caseid>758481</pp:caseid><pp:subtitle>Heart Valve Replacement and Management of Rare Neuroendocrine Tumors at Cedars-Sinai Give Patient New Lease on Life</pp:subtitle><description><![CDATA[<p><span>It was a fall day in 2024 and Ken Aster was hiking in Catalina, California, with his wife, Melissa Orr. They hiked together often but 64-year-old Aster—also an avid cyclist, surfer and pickleball player—was shocked to find he couldn’t keep up.</span></p><p><span>His labored breathing and exhaustion prompted him to see his physician, who ordered a battery of tests. Aster’s diagnosis: A rare cancer called a neuroendocrine tumor was causing a condition called carcinoid heart disease, and causing his heart to fail.</span></p><p><img class="image_resized image-style-align-right" style="width:219px;" src="https://content.presspage.com/uploads/2110/e5c02c59-ac93-43e1-873b-2245af59b1fd/800_andrewhendifarmd.jpg?x=1781807980701" alt="Andrew Hendifar, MD" width="219" /><span>With treatment at the Cedars-Sinai </span><a href="https://www.cedars-sinai.org/programs/cancer/specialties/gastrointestinal/carcinoid-neuroendocrine.html">Neuroendocrine Tumor Multidisciplinary Clinic</a>, <span>Aster is now back on the trail, his bike, his board and the court.</span></p><p>“I went from wondering how long I have to live to understanding that this can be managed,” Aster said. “I feel better than I have felt in years.”</p><p>Aster’s symptoms came on slowly over several months: crushing fatigue, bloating, loss of appetite and swelling in his legs and feet. Blood tests ordered by his primary doctor were normal, but a CT scan showed tumors in his liver, which were eventually diagnosed as stage 4 neuroendocrine cancer.</p><p>“We received the diagnosis the day we dropped the youngest of our four kids off at college,” Orr said. “We had other plans, so we just had to reset.”</p><p>Unable to sleep the night they got the news, Orr—who Aster said was his caregiver and support throughout this difficult time and credits with helping save his life—spent hours online. She clicked her way to the <a href="https://netrf.org/" target="_blank" rel="noreferrer noopener">Neuroendocrine Tumor Research Foundation</a>. The organization, a resource for research funding, patient education and support, directed the couple to <span> </span>the <a href="https://www.ncf.net/" target="_blank" rel="noreferrer noopener">Neuroendocrine Cancer Foundation</a>, which referred them to Cedars-Sinai and its multidisciplinary clinic.</p><p><img class="image_resized image-style-align-right" style="width:219px;" src="https://content.presspage.com/uploads/2110/17008b8d-ac41-4b78-a94b-70a2a2d24175/800_venkatesh-prashanth.venkateshp.jpg?x=1781808091595" alt="Prashanth Venkatesh, MD" width="219" />“We were concerned about Ken’s neuroendocrine tumors, which had spread to his liver and were making it difficult for his stomach to work normally,” said <a href="https://www.cedars-sinai.org/provider/andrew-hendifar-546093.html">Andrew Hendifar, MD</a>, who leads the clinic and is a professor of Medicine at Cedars-Sinai. “But we knew from experience that his heart failure would have to be treated first. We didn’t have a minute to lose.”</p><p>Neuroendocrine tumors begin in neuroendocrine cells, which connect the nervous system with the hormone-producing endocrine system. They can occur anywhere in the body.</p><p>Aster’s began in his small bowel and produced a hormone called serotonin, which thickened two of his heart valves and caused them to leak. The condition is called carcinoid heart disease.</p><p><a href="https://www.cedars-sinai.org/provider/prashanth-venkatesh-3320116.html">Prashanth Venkatesh, MD</a>, assistant professor of Cardiology in the <a href="https://www.cedars-sinai.edu/health-sciences-university/research/departments-institutes/smidt-heart-institute.html">Smidt Heart Institute</a> at Cedars-Sinai, is the cardiologist on the neuroendocrine team.</p><p>“The pulmonary valve, which sends blood from the heart to the lungs, is notoriously difficult to evaluate with standard imaging techniques because of its location in the chest and the relative rarity of pulmonary valve disease in adults,” Venkatesh said. “Significant pulmonary valve involvement in carcinoid heart disease is hence very easily missed.”</p><p><img class="image_resized image-style-align-right" style="width:219px;" src="https://content.presspage.com/uploads/2110/7c8d92b3-74e6-4982-a8b7-8676b1c2717e/800_makkar-rajendra.jpeg?x=1781808195572" alt="Raj Makkar, MD" width="219" />Venkatesh, a congenital heart specialist, often employs more extensive imaging techniques for patients born with structural heart defects. Aster’s results showed there was a leak in his pulmonary valve as well as a leak in his tricuspid valve. Both valves needed to be replaced.</p><p>“When there is a leaky valve, which we call regurgitation, some of the blood in the heart goes in the wrong direction,” said <a href="https://www.cedars-sinai.org/provider/rajendra-makkar-885543.html">Raj Makkar, MD</a>, vice president of Cardiovascular Innovation and Intervention at Cedars-Sinai and the Karsh Distinguished Chair in Interventional Cardiology in the Smidt Heart Institute. “With leaky pulmonary and tricuspid valves, the blood that is supposed to go into the lungs can leak back toward the upper chamber of the heart.”</p><p>Aster’s pulmonary valve was replaced via a minimally invasive procedure in which a catheter was threaded up through an artery in the groin to maneuver the valve into its proper place. Four weeks later, Makkar replaced Aster’s tricuspid valve using a similar procedure.<span> </span></p><p>“Patients with carcinoid heart disease are going through a lot because of the neuroendocrine tumor, and traditional valve replacement surgery puts them at higher risk for complications,” Makkar said. “We pioneered testing of transcatheter tricuspid valve replacement around five years ago, and this was the option we chose for Mr. Aster.”</p><p><img class="image_resized image-style-align-right" style="width:219px;" src="https://content.presspage.com/uploads/2110/5f753bde-8ca4-4bc5-80f2-8b6953f3f3bf/800_alexandra-gangi-md-cedars-sinai.jpg?x=1781808232763" alt="Alexandra Gangi, MD" width="219" />To address the neuroendocrine tumors on Aster’s liver, <a href="https://www.cedars-sinai.org/provider/alexandra-gangi-1031136.html">Alexandra Gangi, MD</a>, director of the Division of Surgical Oncology and co-director of the Neuroendocrine Tumor Multidisciplinary Clinc, chose another minimally invasive approach: tumor embolization.</p><p><span>“We accessed the tumors with a catheter, through the artery in the groin,” Gangi said. “This allows us to block off the blood flow to the specific arteries that feed the tumors. This starves the tumors, and results in shrinking and tumor control.”</span></p><p><span>So far, Aster has avoided surgery and chemotherapy because of the nature of neuroendocrine tumors and the expertise of his care team in sequencing his therapies based on his symptoms.</span></p><p><span>“I think the difference between metastatic neuroendocrine tumors and most other types of gastrointestinal cancers is that we’re playing the long game,” Gangi said. “We often do the least invasive thing and save more aggressive options for when we really need them. These tumors tend to recur, but prognosis is generally good and patients can live a long time with them.”</span></p><p><span>Additional treatment or surgical procedures might be on the horizon, but today, Aster is doing well.</span></p><p>“We feel very fortunate that we were able to identify this as early as we did and intervene in the way that we did,” Hendifar said. “A few years ago, even six months ago, Ken wouldn't have been a candidate for minimally invasive valve replacements. He would have required open-heart surgery, and I'm not sure if the outcome would have been as good.”</p><p>Aster describes his current health as “great.”</p><p>“I just started cycling again in January, 13 months after the second valve replacement,” Aster said. “Now I'm doing a 25-mile ride in the hills two or three times a week with no problem. My heart feels as normal as can be.”</p><p><span style="color:#dc1e34;"><i><span><strong>Cedars-Sinai Health Sciences University is advancing groundbreaking research and educating future leaders in medicine, biomedical sciences and allied health sciences. </strong></span></i></span><a href="https://www.cedars-sinai.edu/health-sciences-university.html?adobe_mc=MCMID%3D79521921680015491943235909713257507329%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1733161540"><span style="color:#dc1e34;"><i><span><strong><u>Learn more</u></strong></span></i></span></a><span style="color:#dc1e34;"><i><span><strong> about the university.</strong></span></i></span></p>]]></description><category><![CDATA[Christina Elston,News,GI Cancer,Heart,andrew-hendifar-546093,prashanth-venkatesh-3320116,rajendra-makkar-885543,alexandra-gangi-1031136]]></category>
            <pubDate>Mon, 22 Jun 2026 06:00:00 -0700</pubDate>
            <pp:lastModified>Sat, 14 Nov 2026 05:19:18 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/a143cfe0-0536-4681-91c4-82ec05f9f61a/500_neuroendocrinefeaturedimage.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/a143cfe0-0536-4681-91c4-82ec05f9f61a/500_neuroendocrinefeaturedimage.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/a143cfe0-0536-4681-91c4-82ec05f9f61a/neuroendocrinefeaturedimage.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Cropped Neuroendocrine featured image for front page tiles]]></pp:imageTitle><pp:imageDescription><![CDATA[A man at left and woman at right hike in the California foothills, with brown, hilly landscape and some green shrubs in the background. A buffalo grazes behind them in the distance.]]></pp:imageDescription></item><item>
                        <title>New AFib Treatment Helps Dad Regain His Heart Rhythm</title>
                        <link>https://www.cedars-sinai.org/newsroom/new-atrial-fibrillation-treatment-gets-dad-his-beat-back/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/new-atrial-fibrillation-treatment-gets-dad-his-beat-back/</guid><pp:caseid>635760</pp:caseid><pp:subtitle>Pulsed Field Ablation is a Newer Treatment Option for Some People With Atrial Fibrillation, Also Known as AFib. Procedure Uses Targeted Electrical Energy to Help Stop Abnormal Signals Causing Irregular Heartbeat</pp:subtitle><pp:summary><![CDATA[<p><span>This story originally published on June 11, 2024.</span></p>]]></pp:summary><description><![CDATA[<p><span>Everyone knows exhaustion is a rite of passage for new parents, which is why Henric Nieminen ignored the symptoms at first.</span></p><p style="margin-left:0in;"><span>The 52-year-old has always enjoyed a high-energy lifestyle, managing the intensity of producing films and television shows (</span><i><span>Ladder 49</span></i><span>, </span><i><span>Flight Plan</span></i><span>, </span><i><span>Top Gear</span></i><span>, </span><i><span>Wheeler Dealers</span></i><span>) by eating healthy, running and biking along the Los Angeles River. After his daughter was born in 2020, Nieminen assumed his constant exhaustion was the typical kind that comes with sleepless nights caring for a newborn. Still, he and his wife, Kaisa, found it odd that picking up his daughter left him depleted.</span></p><p><span><img class="image_resized image-style-align-right" style="aspect-ratio:400/auto;width:400px;" src="https://content.presspage.com/uploads/2110/e0264062-523b-42e2-b784-2e5bc737efc0/800_heart-model-cedars-sinai.jpg?x=1781030767765" alt="The yellow lines demonstrate the electrical system of the heart. The heart at right shows an irregular heartbeat and atrial fibrillation. Image by Getty." width="400" height="auto">“My battery was constantly drained,” Nieminen said. “Being physically active all my life, it was quite alarming. Deteriorating this quickly when I’m just over 50 seemed sort of dramatic.”</span></p><p><span>Nieminen also noticed his heart seemed to beat too fast at times and occasionally it would skip a beat, so in 2023 he made an appointment with Cedars-Sinai cardiologist </span><a href="https://www.cedars-sinai.org/provider/ronit-zadikany-3330842.html"><span style="padding:0in;">Ronit Zadikany, MD.</span></a><span style="padding:0in;"> </span><span>Zadikany diagnosed him with atrial fibrillation, an irregular heart rhythm that occurs when the upper and lower chambers of the heart beat out of sync. The condition tends to worsen with time and can cause the heart to beat too slowly, too quickly or irregularly, impeding blood flow. Common symptoms include fatigue, heart palpitations, dizziness and reduced stamina. Left untreated, atrial fibrillation can cause a slew of cardiovascular complications—including stroke.</span></p><p><span>Nieminen’s cardiologist referred him to Christine M. Albert, MD, MPH, an expert in atrial fibrillation and chair of the Department of Cardiology in the Smidt Heart Institute. Albert recommended</span><span style="background-color:white;"><span> cardioversion, a procedure commonly used to reset the heart to a normal rhythm. The results made </span></span><span>Nieminen</span><span style="background-color:white;"><span> feel like himself again, but only for a day. </span></span><span>A second cardioversion combined with a medication known to work for many people also had temporary effects.</span></p><p style="margin-left:0in;"><span style="background-color:white;">Albert was determined to find Nieminen a treatment that would have long-term results. She </span><span>suggested he might benefit from catheter ablation, a procedure that destroys cells and creates a small scar within the heart, breaking up or insulating the electrical signals causing the heart to beat out of sync. She connected him with </span><a href="https://www.cedars-sinai.org/provider/michael-shehata-128792.html"><span>Michael Shehata, MD</span></a><span>, a cardiac electrophysiologist in the&nbsp;</span><a href="https://www.cedars-sinai.org/programs/heart.html"><span>Smidt Heart Institute</span></a>.</p><p><span>Shehata was leading a clinical trial investigating a new catheter ablation called pulsed field ablation. Rather than create scars, pulsed field ablation targets heart cells involved in an abnormal heart rhythm.</span></p><p style="margin-left:0in;"><span>Nieminen underwent the procedure in January 2024.</span></p><p><span><img class="image_resized image-style-align-right" style="aspect-ratio:400/auto;width:400px;" src="https://content.presspage.com/uploads/2110/e4d83b29-73ef-4874-b8de-9a44109a7c1f/800_30780-hi--michaelshehata5.jpg?x=1718056256001" alt="Michael Shehata, MD" width="400" height="auto">“When other options fail, this procedure can be life-changing for patients,” Shehata said.</span></p><p style="margin-left:0in;"><span style="background-color:white;">Pulsed field ablation is done by threading a catheter through a vein in a patient’s leg until it reaches the top chambers of the heart. Once in place, a cardiologist sends a high-voltage electrical impulse through the catheter. The energy penetrates cell walls and destroys specific heart cells, preventing abnormal signals from causing an irregular heartbeat. The procedure takes 30 to 60 minutes.</span></p><p style="margin-left:0in;"><span>“The energy is delivered specifically to heart cells without injuring nerve cells, smooth muscle cells, or other, healthy cells,” said Shehata, who is also director of the Interventional Electrophysiology Laboratory at the Smidt Heart Institute.</span><span style="background-color:white;"> “For some patients with atrial fibrillation, this procedure may be safer than conventional ablation procedures that destroy small areas of heart tissue.”</span></p><p style="margin-left:0in;"><span>Following U.S. Food and Drug Administration </span><a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P230030" target="_blank"><span>approval</span></a><span> of several pulsed field ablation systems, the procedure is now available for use outside of a clinical trial.</span></p><p><span>Advances in treatment couldn’t come at a better time. Atrial fibrillation is the most common type of irregular heartbeat and d</span><span style="background-color:white;"><span>eaths related to the condition have been increasing for more than two decades, according to the </span></span><a href="https://www.cdc.gov/heart-disease/about/atrial-fibrillation.html" target="_blank"><span>U.S. Centers for Disease Control and Prevention</span></a><span style="background-color:white;"><span>.</span></span></p><p><span>Today, Nieminen is back to long runs and cycling through his neighborhood. He also works with local organizations to advocate for safe walking and biking paths in Los Angeles. Most importantly, he can now lift his daughter into the air like the high-energy dad he is.</span></p><p><span>A device that was implanted to record Nieminen’s heart rhythm shows proof of his progress: He has been free from atrial fibrillation since getting pulsed field ablation.</span></p><p><span>“Don’t hesitate to share with your doctors when something feels off because you feel like you’re being a hypochondriac or you think it’s too insignificant to bring up,” he said. “As you get older, it’s especially important to listen to your body, eat right and stay active, and that doesn’t necessarily mean doing a 10K. Everything your mom would tell you growing up: Stay active, eat healthy, get sleep and get checkups with your doctor. Mom knew what she was talking about.”</span></p><p><span style="color:#dc1e34;"><i><span><strong>Read more on Cedars-Sinai Stories and Insights: </strong></span></i></span><a href="https://www.cedars-sinai.org/blog/living-with-atrial-fibrillation.html"><span style="color:#dc1e34;"><i><span><strong>Back Into Rhythm | Adjusting to an AFib Diagnosis</strong></span></i></span></a></p>]]></description><category><![CDATA[Heart,News,michael-shehata-128792,ronit-zadikany-3330842,Stephanie Cajigal]]></category>
            <pubDate>Mon, 15 Jun 2026 06:00:00 -0700</pubDate>
            <pp:lastModified>Fri, 12 Jun 2026 19:05:36 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/fcd51847-8fe0-4584-88f9-05f83af7beae/500_nieminen1.jpeg?10000" length="0" type="image/jpeg" />
                <pp:image>https://content.presspage.com/uploads/2110/fcd51847-8fe0-4584-88f9-05f83af7beae/500_nieminen1.jpeg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/fcd51847-8fe0-4584-88f9-05f83af7beae/nieminen1.jpeg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Henric Nieminen rides a bicycle with his daughter after atrial fibrillation treatment at Cedars-Sinai. Photo courtesy of Henric Nieminen.]]></pp:imageTitle><pp:imageDescription><![CDATA[A man, Henric Nieminen, rides a bicycle beside his young daughter riding a scooter.]]></pp:imageDescription></item><item>
                        <title>How Pregnant Women Can Protect Their Hearts</title>
                        <link>https://www.cedars-sinai.org/newsroom/how-pregnant-women-can-protect-their-hearts/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/how-pregnant-women-can-protect-their-hearts/</guid><pp:caseid>748392</pp:caseid><pp:subtitle>Janet Wei, MD, Explains Key Findings From New Maternal Health Report</pp:subtitle><description><![CDATA[<p><span>Pregnancy is a window into a woman’s cardiovascular future, a new report shows.</span></p><p><span>Smidt Heart Institute cardiologist Janet Wei, MD, is one of the authors of a </span><a href="https://www.nationalacademies.org/news/opportunities-to-prevent-pregnancy-related-cardiovascular-disease-and-maternal-mortality-identified-in-new-report" target="_blank"><span>maternal health report</span></a><span> </span>from the National Academies of Sciences, Engineering, and Medicine<span>, a nonprofit organization that reviews published research and provides advice to the U.S. government. Wei, </span>associate professor of Cardiology and Biomedical Sciences<span>, sat down with the </span><i><span>Cedars-Sinai Newsroom</span></i><span> to explain how pregnancy affects women’s hearts. &nbsp;&nbsp;</span></p><h2><strong>How does pregnancy increase cardiovascular risk?</strong></h2><p>Pregnancy acts as a stress test for the heart and can uncover, or even worsen, problems like high blood pressure and diabetes. During pregnancy, the heart must work harder to support a growing fetus, and cardiac stress often continues after delivery.</p><p>Cardiovascular disease is the leading cause of pregnancy-related death in the U.S., yet most of these deaths are preventable. The National Academies of Sciences, Engineering, and Medicine report on maternal health highlights that although <span>57% of cardiovascular-related deaths occur between seven days and one year postpartum, preventive care is often focused on the prenatal and immediate postpartum period.</span></p><h2><strong>What are two takeaways from the report?</strong></h2><p><span>The committee reviewed published medical research and gathered input from a wide range of stakeholders, including clinicians, professional societies, advocacy organizations and patients.</span></p><p><span><img class="image_resized image-style-align-right" style="aspect-ratio:230/auto;width:230px;" src="https://content.presspage.com/uploads/2110/2c114377-1c0f-4376-aa1c-75cb712980d8/800_janet-wei-md-cedars-sinai-cropped.jpg?x=1779465195469" alt="Janet Wei, MD" width="230" height="auto">Several takeaways became clear. The report recommends, for example, that clinicians treat </span>pregnant women with chronic hypertension so that their blood pressure is reduced to less than <span>140/90 millimeters of mercury. &nbsp;</span>This is because consistently elevated blood pressure during pregnancy can cause pregnancy complications and increase a woman’s risk for developing cardiovascular disease.</p><p>The new guidelines also recommended that clinicians caring for patients <span>with postpartum hypertension or other hypertensive disorders</span> give their patients home blood pressure monitors and use a program that allows the patients to report their readings. <span>This way, clinicians can adjust treatment and set clear thresholds for action.&nbsp;</span></p><p><span>Cedars-Sinai is already doing this through a postpartum blood pressure </span><a href="https://www.cedars-sinai.org/newsroom/mothers-give-high-marks-for-post-childbirth-blood-pressure-care/"><span>monitoring program</span></a><span> that sends patients home with a blood pressure cuff and allows them to transmit readings to their care teams.&nbsp;(</span><a href="https://researchers.cedars-sinai.edu/Kimberly.Gregory?adobe_mc=MCMID%3D15143042538955239740718824350024281938%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1778796301&previousPageName=cs-org%253Acedars-sinai%253Aother"><span>Kimberly&nbsp;Gregory, MD, MPH</span></a><span>, director of the Division of Maternal-Fetal Medicine at Cedars-Sinai, served as an adviser to the National Academies committee that created the maternal health report.)</span></p><h2><strong>How often should women visit a doctor in the year after giving birth?</strong></h2><p><span>How frequently a woman should see her doctor during the postpartum period depends on her cardiovascular risk.&nbsp;</span></p><p>Not every woman can easily see a doctor or health specialist—especially in rural areas or when cost is a concern. Therefore,<span> the National Academies report recommends the Health Resources and Services Administration use its telehealth, rural health and maternal health programs to reduce geographic, financial and system barriers to preventive cardiovascular services.</span></p><h2><strong>What can pregnant women do to protect heart health?</strong></h2><p>The National Academies created a <a href="https://nap.nationalacademies.org/resource/29425/Maternal_Heart_Health_One_Pager_Women_Families.pdf" target="_blank">resource for women</a> that includes the following advice:</p><p><span><strong>Share your history.</strong> Tell your healthcare team your family history of heart disease, especially early heart attacks or strokes, and your pregnancy history, including any past complications.</span></p><p><strong>Keep postpartum follow-up appointments on your calendar. </strong>It’s important not to miss these appointments because risk for complications continues through the first year after delivery.</p><p><strong>Take warning signs seriously—trust your instincts</strong>. If something feels wrong during pregnancy or after birth, seek care right away and tell providers that you’re pregnant or that you gave birth recently.</p><p><span style="color:#dc1e34;"><i><strong>Read more from Cedars-Sinai Stories and Insights: </strong></i></span><a href="https://www.cedars-sinai.org/stories-and-insights/healthy-living/women-high-blood-pressure"><span style="color:#dc1e34;"><i><strong>High Blood Pressure—What Women Need to Know</strong></i></span></a></p>]]></description><category><![CDATA[News,janet-wei-1758637,Stephanie Cajigal,Heart,Heart Research,Women Heart,Womens Heart,Pregnancy and Maternity,Women Health,Womens Heart Research]]></category>
            <pubDate>Tue, 26 May 2026 07:00:00 -0700</pubDate>
            <pp:lastModified>Fri, 22 May 2026 23:01:53 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/c7665940-a9ab-4844-9b88-f9cb054cb8a1/500_pregnant-patient-on-couch-cedars-sinai.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/c7665940-a9ab-4844-9b88-f9cb054cb8a1/500_pregnant-patient-on-couch-cedars-sinai.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/c7665940-a9ab-4844-9b88-f9cb054cb8a1/pregnant-patient-on-couch-cedars-sinai.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[A new report authored by Smidt Heart Institute cardiologist, Janet Wei, MD, explains how pregnancy can affect a woman&amp;rsquo;s cardiovascular health. Photo by Getty.]]></pp:imageTitle><pp:imageDescription><![CDATA[Pregnant woman reclining on a sunlit sofa, gently holding her baby bump and smiling as she relaxes at home, anticipating motherhood and new life ahead]]></pp:imageDescription></item><item>
                        <title>Cedars-Sinai Expands Medical and Research Ties With Israel Healthcare Partners</title>
                        <link>https://www.cedars-sinai.org/newsroom/cedars-sinai-expands-medical-and-research-ties-with-israel-healthcare-partners/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/cedars-sinai-expands-medical-and-research-ties-with-israel-healthcare-partners/</guid><pp:caseid>745714</pp:caseid><pp:subtitle>Cedars-Sinai Recognizes Clinical, Science and Education Partnerships During Jewish-American Heritage Month</pp:subtitle><description><![CDATA[<p style="margin-left:0in;"><span>Reflecting its expanding international reach, Cedars-Sinai is building clinical, scientific and education partnerships with healthcare institutions in Israel. Now, during Jewish American Heritage Month, the organization is recognizing ongoing programs that foster innovation in patient care, physician training and scientific discovery.</span></p><p style="margin-left:0in;"><span>“Cedars-Sinai&nbsp;is&nbsp;proud&nbsp;of its rich Jewish heritage and its ongoing collaborations with medical centers in Israel,” said Cedars-Sinai President and CEO </span><a href="https://www.cedars-sinai.org/about/leadership/executive-management/peter-l-slavin.html"><span>Peter L. Slavin, MD</span></a><span>. “It is part of our overall commitment&nbsp;to the Jewish value of&nbsp;</span><i><span>Tikkun&nbsp;Olam,&nbsp;</span></i><span>healing the world through our actions.”</span></p><p><span><img class="image_resized image-style-align-right" style="aspect-ratio:450/auto;width:450px;" src="https://content.presspage.com/uploads/2110/618d9a45-9d86-4ee4-8d34-1154bb809cc9/800_cedars-sinai-delegation-israel.jpg?x=1779203805032" alt="Cedars-Sinai delegation with Israeli hosts in the northern city of Safed. Photo courtesy of Laurence Katznelson, MD." width="450" height="auto">One of Cedars-Sinai’s longest and most productive collaborations has been with </span><a href="https://www.shebaonline.org/medical-treatment-at-sheba-israel/" target="_blank"><span>Sheba Medical Center</span></a><span> outside Tel Aviv. The relationship began as a collaboration aimed at advancing cardiovascular medicine and the field of minimally invasive heart interventions.</span></p><p><span>Cedars-Sinai is now working with Sheba’s ARC Center for Digital Innovation to advance<strong> </strong>digital health technologies and AI-driven solutions for healthcare challenges. The two institutions also have established a program to enhance the perioperative care of patients with inflammatory bowel disease through tailored dietary, mental health and physical therapy interventions.</span></p><p style="margin-left:0in;"><span>Investigators from the two institutions are studying stem cells at the International Space Station to determine how microgravity affects the biology of cells or may enhance manufacturing of stem cells in space.</span></p><p><span>Cedars-Sinai staff members are engaged in other projects throughout Israel. Among other efforts, teams are:</span></p><ul><li data-list-item-id="e40538feef4a75c08cdcd1eb5c3048f49"><span>Implementing the Sheba inflammatory bowel disease program at Emek Medical Center in northern Israel and at Assuta Ashdod Medical Center in the southern part of the country.</span></li><li data-list-item-id="e5dd220cbc7e4303c639f71b446f02715"><span>Working on joint fellowship training programs in oncology, gynecology and endocrinology with Ichilov Hospital in Tel Aviv, where Cedars-Sinai also is engaged in joint data science and AI research programs as well as educational conferences for regenerative medicine, computational sciences and other specialties.</span></li><li data-list-item-id="e1b953600d255eae43bdd42c7a830c47c"><span>Collaborating on several joint projects with scientists at the Weizmann Institute of Science in central Israel, including one that employs CAR T cells to treat solid cancers.</span></li><li data-list-item-id="e7759ab1ac0dc97e1882bcf37f3f5a8db"><span>Teaching, mentoring and performing complex surgeries. Hand surgeon David Kulber, MD, partnered with colleagues at Sheba Medical Center earlier this year to perform surgery on injured soldiers, using biologic joint reconstruction techniques he pioneered at Cedars-Sinai.</span></li></ul><p><span>“We have a deep bench of projects with our partners in Israel,” said </span><a href="https://www.cedars-sinai.org/about/leadership/executive-management/shlomo-melmed-mbchb.html"><span>Shlomo Melmed, MB, ChB</span></a><span>,&nbsp;executive vice president of Academic Affairs and dean of the Medical Faculty at Cedars-Sinai.</span></p><p><span>A delegation of Cedars-Sinai physicians and leaders last year visited several peripheral Israeli hospitals in the cities of Ashkelon, Nahariya and Safed. The group discussed opportunities to pursue educational and training collaborations and knowledge exchanges. The visitors also learned about the hospitals’ triage systems for major incidents.</span></p><p><a href="https://www.cedars-sinai.org/provider/harry-sax-3191276.html"><span>Harry Sax, MD</span></a><span>, vice chair of the Jim and Eleanor Randall Department of Surgery and the associate&nbsp;dean of Cedars-Sinai’s International Academic Programs, said the “first-hand experience will help better prepare teams back in Los Angeles for responding to unexpected events."</span></p><p><span style="color:#dc1e34;"><i><span><strong>Read more from Cedars-Sinai Stories and Insights: </strong></span></i></span><a href="https://www.cedars-sinai.org/stories-and-insights/innovation-and-research/cedars-sinai-pioneers-a-new-era-for-ai-education"><span style="color:#dc1e34;"><i><span><strong>Cedars-Sinai Pioneers a New Era for AI Education</strong></span></i></span></a></p>]]></description><category><![CDATA[Exclude,Faculty News,Soshea Leibler,Innovation,Technology]]></category>
            <pubDate>Thu, 21 May 2026 07:00:00 -0700</pubDate>
            <pp:lastModified>Thu, 25 Jun 2026 23:02:11 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/d274e5c0-2e81-44f2-bff7-784de744aa82/500_cedars-sinai-plaza-level-exterior.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/d274e5c0-2e81-44f2-bff7-784de744aa82/500_cedars-sinai-plaza-level-exterior.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/d274e5c0-2e81-44f2-bff7-784de744aa82/cedars-sinai-plaza-level-exterior.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Cedars-Sinai is advancing clinical and research initiatives through enhanced collaboration with Sheba Medical Center outside Tel Aviv. Photo by Cedars-Sinai.]]></pp:imageTitle><pp:imageDescription><![CDATA[Two towers on the Cedars-Sinai Medical Center campus as seen from the healing gardens.]]></pp:imageDescription></item><item>
                        <title>Cedars-Sinai Enhances Clinical Decision-Making With OpenEvidence</title>
                        <link>https://www.cedars-sinai.org/newsroom/cedars-sinai-enhances-clinical-decision-making-with-openevidence/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/cedars-sinai-enhances-clinical-decision-making-with-openevidence/</guid><pp:caseid>744805</pp:caseid><pp:subtitle>New Clinical Reference Tool Links Individual Patient’s Electronic Health Records With the Latest Medical Evidence to Enhance Diagnoses and Treatments</pp:subtitle><description><![CDATA[<p><span>Cedars-Sinai clinicians now have enterprise access to an AI-enabled clinical reference tool designed to support diagnosis and treatment decisions by combining medical evidence with relevant information from a patient’s electronic health record.</span></p><p><span>The deployment of OpenEvidence reflects Cedars-Sinai’s broader strategy to use AI tools and technologies to safely improve care precision and produce better patient outcomes.</span></p><p><span><img class="image_resized image-style-align-right" style="width:200px;" src="https://content.presspage.com/uploads/2110/e80bfee0-e1e1-4d2a-8cd3-92944c24c1a7/500_shaun-miller-md-cedars-sinai.jpg?x=1778609044372" alt="Shaun Miller, MD, MBA" width="200">Through this partnership, Cedars-Sinai physicians, nurses, pharmacists and therapists can ask clinical questions and retrieve medical literature that is relevant to an individual patient’s health profile. The AI tool can help answer clinical questions by linking the latest scientific findings with a patient’s prior procedures, comorbidities, medications, allergies and other health data recorded over time.</span></p><p><span>Cedars-Sinai also plans to incorporate its own care pathways, protocols and best practices into the OpenEvidence enterprise platform. This will enable Cedars-Sinai clinicians to view current medical literature alongside Cedars-Sinai-specific guidance for delivering safe, high-quality care.</span></p><p><span>“Integrating OpenEvidence into our electronic health records allows clinicians to look at the latest medical evidence in the context of a patient’s medical history and individual health data, giving physicians and other healthcare professionals a more complete and actionable understanding at the moment of care,” said </span><a href="https://www.cedars-sinai.org/provider/shaun-miller-1756800.html"><span>Shaun Miller, MD, MBA</span></a><span>, chief health informatics officer at Cedars-Sinai.</span></p><p><span>Patient information from the electronic health record will be used only to support care decisions for individual patients and will not be stored by OpenEvidence or used for any other purpose.</span></p><p><span>“Medicine is not practiced in the abstract. It is practiced on individual patients with unique histories and complexities,” said Daniel Nadler, CEO and founder of OpenEvidence. “This partnership with Cedars-Sinai establishes a new standard: clinical AI that doesn’t just retrieve information but interprets the world’s medical knowledge in the context of the specific patient. We are building a tool that aligns cutting-edge evidence with real-world care to drive better outcomes.”</span></p><p><span>OpenEvidence is one example of Cedars-Sinai’s broader AI strategy, which aims to streamline and improve patient care, reduce administrative burden on clinicians and educate the workforce about the evolving uses of these technologies.</span></p><p><span><img class="image_resized image-style-align-right" style="width:200px;" src="https://content.presspage.com/uploads/2110/24af8ae1-a361-4cfc-a91f-d27923593895/500_odeh-mouneer-ma-cedars-sinai.jpg?x=1778609067445" alt="Mouneer Odeh, MA" width="200">For example, Cedars-Sinai is using AI to help nurses and other care team members </span><a href="https://www.cedars-sinai.org/newsroom/artificial-intelligence-lightens-burden-on-nurses/"><span>document patient care</span></a><span> in real time, analyze and produce </span><a href="https://www.cedars-sinai.org/newsroom/a-bigger-better-ai-tool-for-interpreting-common-heart-test/"><span>reports from echocardiograms</span></a><span>, and </span><a href="https://www.cedars-sinai.org/newsroom/new-ai-tool-predicts-best-pancreatic-cancer-treatment/"><span>predict</span></a><span> which of two available chemotherapy options for pancreatic cancer would be more effective for an individual patient.</span></p><p><span>Miller said it is critical to deploy fair, appropriate, effective and safe tools that provide tangible benefits to the roughly 1 million patients treated at Cedars-Sinai each year.</span></p><p><span>“We want to create a coherent, secure AI ecosystem rather than isolated pilots, and we approach all AI integration carefully,” Miller said. &nbsp;</span></p><p><span>Before any AI system goes live at Cedars-Sinai, it goes through a specially designated committee that reviews tools prior to deployment and audits their impact. The committee includes data scientists, clinical experts, administrative leaders and other specialists specific to the particular area under review.</span></p><p><span>This oversight process is designed to ensure new tools meet Cedars-Sinai’s guidelines for human oversight and verification of AI-generated output, data privacy, and protection of patient health information and intellectual property.</span></p><p><span>“We see artificial intelligence as an opportunity to rethink how we deliver care and run our operations,” said </span><a href="https://www.cedars-sinai.org/newsroom/cedars-sinai-announces-chief-data-and-artificial-intelligence-officer/"><span>Mouneer Odeh, MA</span></a><span>, chief data and artificial intelligence officer at Cedars-Sinai. “As technologies like OpenEvidence become part of how we work, our strategy centers on improving workflows while supporting the people who do the work.”</span></p><p><span>AI, Odeh said, is advancing at an incredible pace.</span></p><p><span>“We are constantly evaluating new technologies with cautious optimism, so we can safely deliver better experiences for our patients and care teams while providing exceptional care to the communities we serve,” he said. &nbsp;</span></p><p><span style="color:#dc1e34;"><i><span><strong>Cedars-Sinai Health Sciences University is advancing groundbreaking research and educating future leaders in medicine, biomedical sciences and allied health sciences. </strong></span></i></span><a href="https://www.cedars-sinai.edu/health-sciences-university.html?prevPageName=cs-org%3Acedars-sinai%3Anewsroom"><span style="color:#dc1e34;"><i><span><strong>Learn more</strong></span></i></span></a><span style="color:#dc1e34;"><i><span><strong> about the university.</strong></span></i></span></p>]]></description><category><![CDATA[Faculty News,Exclude,Artificial Intelligence,Artificial Intelligence Research,AI,shaun-miller-1756800,Cara Martinez]]></category>
            <pubDate>Wed, 20 May 2026 06:30:00 -0700</pubDate>
            <pp:lastModified>Mon, 18 May 2026 19:23:13 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/019aa9a8-e0bf-4e19-945a-7a91cfc07f6d/500_cedars-sinai-plaza-exterior.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/019aa9a8-e0bf-4e19-945a-7a91cfc07f6d/500_cedars-sinai-plaza-exterior.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/019aa9a8-e0bf-4e19-945a-7a91cfc07f6d/cedars-sinai-plaza-exterior.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[For the first time at enterprise scale, Cedars-Sinai clinicians can query medical literature in the full context of an individual patient&amp;rsquo;s record. Photo by Cedars-Sinai.]]></pp:imageTitle><pp:imageDescription><![CDATA[Exterior shot of Cedars-Sinai hospital, taken from plaza level. Green plants in foreground, large building in background.]]></pp:imageDescription></item><item>
                        <title>Emergency Care in Sport Conference Targets Athlete Safety, Preparation</title>
                        <link>https://www.cedars-sinai.org/newsroom/emergency-care-in-sport-conference-targets-athlete-safety-preparation/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/emergency-care-in-sport-conference-targets-athlete-safety-preparation/</guid><pp:caseid>744807</pp:caseid><pp:subtitle>Cedars-Sinai, Los Angeles Rams, and National Football League Convene National Experts as Orthopedic Surgeon Clarence Shields, MD, Receives Inaugural Honor</pp:subtitle><description><![CDATA[<p>When emergencies happen in sports, experts agree that the difference between life and death often comes down to seconds—and preparation.</p><p>Preparation was at the center of the 2026 Emergency Care in Sport (ECS) Conference in Woodland Hills, where nearly 200 sports medicine professionals, athletic trainers and healthcare leaders gathered for a two-day immersive training focused on emergency response.</p><p>Hosted by the <a href="https://www.cedars-sinai.org/about/sports-partnerships/la-rams.html">Los Angeles Rams</a>, <span>the National Football League (NFL), and </span>Cedars-Sinai, the conference combined expert-led instruction with hands-on, scenario-based training designed to prepare clinicians and athletic staff to respond to critical situations on the field.</p><p>“Sport is unpredictable, and when emergencies happen, there’s no time to hesitate,” said <a href="https://www.cedars-sinai.org/provider/casey-batten-678618.html">Casey Batten, MD</a>,&nbsp;co-director of Nonoperative Orthopaedics and Sports Medicine at Cedars-Sinai&nbsp;<a href="https://www.cedars-sinai.org/programs/ortho.html">Orthopaedics&nbsp;and Sports Medicine</a>, head team physician for the Rams, and chief medical officer&nbsp;for the LA28 Olympic and Paralympic Games. “This training is about building muscle memory so that when something goes wrong, teams can respond immediately, confidently and in a coordinated way.”</p><p>The conference featured a multidisciplinary lineup of national leaders in sports medicine and emergency care, including <a href="https://www.therams.com/team/front-office-roster/reggie-scott" target="_blank">Reggie Scott</a>, senior vice president of Sports Medicine and Performance for the Rams; Allen Sills, MD,&nbsp;<span> </span>chief medical officer for the National Football League; and Ron Courson, associate athletic director for Sports Medicine at the University of Georgia.</p><p><img class="image_resized image-style-align-right" style="aspect-ratio:374/auto;width:374px;" src="https://content.presspage.com/uploads/2110/800_clarenceshieldsmd.jpg?x=1778723447358" alt="Clarence Shields, MD " width="374" height="auto">Through panel discussions and interactive demonstrations, speakers and session leaders emphasized the importance of Emergency Action Plans, proper medical oversight, access to essential equipment, and involving trained sports medicine experts at all levels of sport—from youth leagues to professional teams.</p><p>A highlight of the conference was the presentation of the inaugural Dr. Greg Elkins Memorial High School Team Doctor of the Year Award, recognizing exceptional dedication to the care and safety of student-athletes.</p><p>The award honors the legacy of Greg Elkins, MD, a nationally prominent and widely respected sports medicine physician known for his decades of service to high school athletes and his leadership in shaping national sports medicine policy.</p><p>Elkins Award recipient <a href="https://www.cedars-sinai.org/provider/clarence-shields-2412658.html?_ga=2.52482730.347590584.1668445557-214391996.1666994773">Clarence Shields, MD</a>, a Cedars-Sinai orthopedic surgeon, was honored for his pioneering work in expanding access to care for underserved student-athletes in Los Angeles.</p><p><span>A Los Angeles native, Shields graduated from&nbsp;Creighton University School of Medicine, completed his orthopedic surgery residency at&nbsp;Los Angeles County-USC Medical Center, and fulfilled his fellowship training in sports medicine at the&nbsp;then–Kerlan-Jobe Orthopaedic Institute. He later served as president of the&nbsp;American Orthopaedic Society for Sports Medicine&nbsp;and as a longtime team physician for the&nbsp;Los Angeles Rams.</span></p><p>In 1994, Shields founded <a href="https://www.cedars-sinai.org/community/programs/team-heal.html">Team HEAL</a>—Helping Enrich Athletes’ Lives—a program that provides athletic training services and healthcare resources to high schools in underserved communities. Today, the program serves more than a dozen schools and 2,800 student-athletes annually and has helped more than 30,000 young athletes since its inception.</p><p>“Dr. Shields’ leadership reminds us that sports medicine is about more than treating injuries—it is about protecting futures,” Batten said. “By founding Team HEAL, Dr. Shields expanded access to care for underserved communities and connected local high schools with volunteer physicians who have made a lasting difference in the lives of student-athletes.”</p><p><span style="color:#dc1e34;">&nbsp;<i><span><strong>Read more from Stories and Insights: </strong></span></i></span><a href="https://www.cedars-sinai.org/stories-and-insights/expert-advice/how-to-prevent-sports-injuries-in-young-athletes"><span style="color:#dc1e34;"><i><span><strong>How to Prevent Sports Injuries in Young Athletes</strong></span></i></span></a><br><br>&nbsp;</p>]]></description><category><![CDATA[Rams,Faculty News,Orthopaedics,Sports Medicine,Melissa Vizcarra]]></category>
            <pubDate>Fri, 15 May 2026 07:00:00 -0700</pubDate>
            <pp:lastModified>Fri, 15 May 2026 03:07:09 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/89c534f6-8fc2-4dc5-9f7f-9a9f6cdc131d/500_187092556.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/89c534f6-8fc2-4dc5-9f7f-9a9f6cdc131d/500_187092556.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/89c534f6-8fc2-4dc5-9f7f-9a9f6cdc131d/187092556.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Nearly 200 sports medicine professionals, athletic trainers and healthcare leaders attended the 2026 Emergency Care in Sport Conference, hosted by Cedars-Sinai, the Los Angeles Rams, and the National Football League. Photo by Getty.]]></pp:imageTitle><pp:imageDescription><![CDATA[Injured football player laying on the field holding their leg while an athletic training is kneeling next to them.]]></pp:imageDescription></item><item>
                        <title>Cedars-Sinai Adds Stem Cell Skill to Key Parkinson’s Disease Study</title>
                        <link>https://www.cedars-sinai.org/newsroom/cedars-sinai-adds-stem-cell-skill-to-key-parkinsons-disease-study/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/cedars-sinai-adds-stem-cell-skill-to-key-parkinsons-disease-study/</guid><pp:caseid>743587</pp:caseid><pp:subtitle>Collaboration, Funded by $9 Million Grant, Will Use Advanced Technology to Investigate Link Between Pesticide Exposure and Parkinson’s Disease</pp:subtitle><description><![CDATA[<p><span>Cedars-Sinai Health Sciences University investigators are bringing their stem cell expertise to a collaboration with two other academic medical centers with the goal of clarifying the connection between pesticide exposure and Parkinson’s disease.&nbsp;</span></p><p><span>The project, which includes investigators from UCLA, the University of Southern California (USC), and the University of Münster in Germany, is funded by a three-year, $9 million grant from Aligning Science Across Parkinson’s, in partnership with The Michael J. Fox Foundation for Parkinson’s Research.</span></p><p><span>In the debilitating neurodegenerative condition, one of the major problems is that brain cells producing dopamine—the chemical in the brain that helps nerves coordinate muscle movement—die more rapidly than normal. As these cells die off, patients experience tremor, stiffness, and movement and balance issues.</span></p><p><span><img class="image_resized image-style-align-left" style="aspect-ratio:236/auto;width:236px;" src="https://content.presspage.com/uploads/2110/223ed21d-6c1c-4983-8512-e3d25d809af0/800_svendsen-clive.svendsenc.jpg?x=1777500394102" alt="Clive Svendsen, PhD" width="236" height="auto">“We think that Parkinson’s disease is caused by a combination of genetic traits in the patient and environmental exposures—especially to certain pesticides and air pollution,” said </span><a href="https://researchers.cedars-sinai.edu/Clive.Svendsen"><span>Clive Svendsen, PhD</span></a><span>, executive director of the Cedars- Sinai </span><a href="https://www.cedars-sinai.edu/health-sciences-university/research/departments-institutes/regenerative-medicine.html"><span>Board of Governors Regenerative Medicine Institute</span></a><span> and one of the principal investigators of the study. “It seems the genes load the gun while the environment pulls the trigger. With this grant, we will generate lines of stem cells from people living in a pesticide-treated area in the San Fernando Valley and attempt to figure out why some developed Parkinson’s and some did not.”</span></p><p><span>Svendsen said that only about 5%-10% of Parkinson’s disease cases are caused by a single genetic mutation, and evidence is building that mutations in many other areas of the genome may also contribute to disease.&nbsp;&nbsp;</span></p><p><span>“If you have mutations in an array of different genes, we know that increases your risk for developing Parkinson’s,” Svendsen said. “We are trying to determine which of those genetic vulnerabilities interact with pesticides—and how. If we can figure that out, we can begin to think about new approaches to treatment.”</span></p><p><span>The team will recruit groups of relatives—some who developed Parkinson’s disease and some who did not. Investigators will reprogram participants’ cells to create induced pluripotent stem cells, which they can then turn into dopamine-producing neurons that replicate the brain cells at risk in Parkinson’s patients. They will then expose those cells to the pesticides or air pollution present where the participants live.</span></p><p><span>“By investigating how the environment and a person’s unique genetics interact to drive Parkinson’s, this team is uncovering the diverse biological drivers of the disease,” said Sonya Dumanis, PhD, managing director of ASAP. “This is exactly the kind of bold, integrative science the Collaborative Research Network is designed to accelerate. With a better understanding of these disease mechanisms, we can lay the groundwork for new, personalized therapeutics and better outcomes for Parkinson's patients."</span></p><p><span>&nbsp;The investigators’ theory is that the dopamine neurons generated from people with Parkinson’s disease will die more quickly after pesticide exposure than the neurons from family members exposed to the same pesticides or air pollution who did not develop the disease.</span></p><p><span>“If that turns out to be the case, we can compare the genetic makeup of those individuals, and the proteins their genes express, and try to figure out what triggered the development of Parkinson’s disease in some of them but not others,” Svendsen said.</span></p><p><span style="color:#dc1e34;"><i><span><strong>Cedars-Sinai Health Sciences University is advancing groundbreaking research and educating future leaders in medicine, biomedical sciences and allied health sciences.&nbsp;</strong></span></i></span><a href="https://www.cedars-sinai.edu/health-sciences-university.html?adobe_mc=MCMID%3D79521921680015491943235909713257507329%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1733161540"><span style="color:#dc1e34;"><i><span><strong><u>Learn more</u></strong></span></i></span></a><span style="color:#dc1e34;"><i><span><strong>&nbsp;about the university.</strong></span></i></span></p>]]></description><category><![CDATA[Christina Elston,Exclude,Faculty News,RMI,clive-svendsen-4940080]]></category>
            <pubDate>Mon, 04 May 2026 06:00:00 -0700</pubDate>
            <pp:lastModified>Thu, 30 Apr 2026 23:31:30 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/28e9a114-8ada-4662-acae-bb16de48a8c4/500_cedars-sinaiinvestigatorswillcreateneuronsfromthestemcellsofpeoplewithparkinsonrsquosdiseasetostudytheconnectionbetweenthediseaseandpesticideexposure.imagebygetty..jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/28e9a114-8ada-4662-acae-bb16de48a8c4/500_cedars-sinaiinvestigatorswillcreateneuronsfromthestemcellsofpeoplewithparkinsonrsquosdiseasetostudytheconnectionbetweenthediseaseandpesticideexposure.imagebygetty..jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/28e9a114-8ada-4662-acae-bb16de48a8c4/cedars-sinaiinvestigatorswillcreateneuronsfromthestemcellsofpeoplewithparkinsonrsquosdiseasetostudytheconnectionbetweenthediseaseandpesticideexposure.imagebygetty..jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Cedars-Sinai investigators will create neurons from the stem cells of people with Parkinson&amp;rsquo;s disease to study the connection between the disease and pesticide exposure. Image by Getty.]]></pp:imageTitle><pp:imageDescription><![CDATA[Neuron cell close-up view - 3d rendered image of Neuron cell on black background with bright spots at the ends of axons to indicate the neurons are firing.]]></pp:imageDescription></item><item>
                        <title>Cedars-Sinai President Emeritus Elected to the American Academy of Arts and Sciences</title>
                        <link>https://www.cedars-sinai.org/newsroom/cedars-sinai-president-emeritus-elected-to-the-american-academy-of-arts-and-sciences/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/cedars-sinai-president-emeritus-elected-to-the-american-academy-of-arts-and-sciences/</guid><pp:caseid>743454</pp:caseid><pp:subtitle>Thomas M. Priselac Is Recognized for Excellence in Scientific, Cultural and Nonprofit Leadership</pp:subtitle><description><![CDATA[<p><span>Cedars-Sinai President and CEO Emeritus </span><a href="https://www.cedars-sinai.org/newsroom/cedars-sinai-president-and-ceo-thomas-m-priselac-to-retire/"><span>Thomas M. Priselac</span></a><span> has been elected to the </span><a href="https://www.amacad.org/" target="_blank"><span>American Academy of Arts and Sciences</span></a><span> for his extensive record of leadership with a nonprofit organization.</span></p><p><span>Priselac led Cedars-Sinai for more than 30 years as president and CEO and served in the same role for Cedars-Sinai Health System since its creation in 2017. During his tenure, Cedars-Sinai significantly expanded the scope and quality of its clinical, educational, research and community benefit programs.</span></p><p><span>Priselac retired in 2024 and transitioned to emeritus status in 2025. Shortly after, Cedars-Sinai </span><a href="https://www.cedars-sinai.org/newsroom/cedars-sinai-honors-ceo-emeritus-thomas-m-priselac/"><span>established</span></a><span> the Thomas M. Priselac Center for Innovation in Performance Improvement and the Thomas M. Priselac Administrative Fellowship to foster the next generation of healthcare leaders.</span></p><p><span>“I am honored to receive this recognition from the Academy,” Priselac said. “I share this achievement with the entire Cedars-Sinai community, including the Board of Directors, our clinical and management leaders, and the staff who made Cedars-Sinai the organization it has become.”</span></p><p><span>The Academy, chartered in 1780, was established to recognize accomplished leaders in academia, the arts, industry, journalism, philanthropy, policy, research and science, and to engage them in addressing significant challenges facing the nation.</span></p><p><span>Under Priselac’s leadership, Cedars-Sinai evolved from a respected regional hospital into one of the nation’s highest-regarded academic health systems, broadening its services to reach more patients locally and internationally.</span></p><p><span>Priselac also greatly expanded Cedars-Sinai’s focus on&nbsp;medical research&nbsp;and&nbsp;education, leading to the creation of </span><a href="https://www.cedars-sinai.edu/health-sciences-university.html?prevPageName=cs-org%3Acedars-sinai%3Anewsroom"><span>Cedars-Sinai Health Sciences University</span></a><span>.</span></p><p><span>Throughout his tenure as president and CEO, Priselac focused on improving the health of the region’s historically marginalized communities, establishing partnerships with local community organizations to strengthen them and those they serve.</span></p><p><span>“For more than three decades, Tom dedicated his talent, passion and excellence to Cedars-Sinai, building one of the most dynamic academic medical institutions in the country,” said </span><a href="https://www.cedars-sinai.org/about/leadership/executive-management/peter-l-slavin.html"><span>Peter L. Slavin, MD</span></a><span>, president and CEO of Cedars-Sinai Medical Center and Cedars-Sinai Health System. “This noteworthy recognition from the Academy emphasizes his remarkable tenure and fierce dedication to our patients, colleagues, the Los Angeles community and beyond.”</span></p><p><span>Throughout his career, Priselac has been a leader in healthcare on the local, state and national levels. He is a past chair of the of the Association of American Medical Colleges and served as chair of the American Hospital Association. He is also a past chair of the California Hospital Association and of the Hospital Association of Southern California.</span></p><p><span>Priselac’s health policy work includes serving on the advisory board of the USC Schaeffer Center for Health Policy and Economics, the RAND Social and Economic Policy advisory board, and the National Academies of Science, Engineering and Medicine Roundtable on Quality Care for People with Serious Illness.</span></p><p><span>Priselac’s civic engagements have included serving as a member of the Los Angeles Chamber of Commerce board, the Southern California Leadership Council and the Civic Alliance. He has received numerous awards for his leadership in healthcare and his commitment to improving the health of historically marginalized groups, including the American Hospital Association</span><span dir="RTL">’</span><span>s Distinguished Service Award, the Charles R. Drew University Board of Trustees Medal of Honor, the National Center for Healthcare Leadership Healthcare Leadership Award and B</span><span dir="RTL">’</span><span>nai B</span><span dir="RTL">’</span><span>rith International</span><span dir="RTL">’</span><span>s National Healthcare Leadership Award.</span></p><p><span>Priselac holds the Warschaw/Law Endowed Chair in Healthcare Leadership at Cedars-Sinai and is also an adjunct professor at the UCLA Fielding School of Public Health.</span></p><p><span style="color:#dc1e34;"><i><span style="text-align:left;"><strong>Cedars-Sinai Health Sciences University is advancing groundbreaking research and educating future leaders in medicine, biomedical sciences and allied health sciences.&nbsp;</strong></span></i></span><a href="https://www.cedars-sinai.edu/health-sciences-university.html"><span style="color:#dc1e34;"><i><span><strong>Learn more</strong></span></i></span></a><span style="color:#dc1e34;"><i><span style="text-align:left;"><strong>&nbsp;about the university.</strong></span></i></span></p>]]></description><category><![CDATA[Exclude,Faculty News]]></category>
            <pubDate>Wed, 29 Apr 2026 07:00:00 -0700</pubDate>
            <pp:lastModified>Thu, 25 Jun 2026 23:17:32 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/99c53bf4-7119-4d42-b847-faa105a4919b/500_tom-priselac-cedars-sinai.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/99c53bf4-7119-4d42-b847-faa105a4919b/500_tom-priselac-cedars-sinai.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/99c53bf4-7119-4d42-b847-faa105a4919b/tom-priselac-cedars-sinai.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Cedars-Sinai is honoring Thomas M. Priselac, who spent 30 years as president and CEO and served the organization for 45 years total, before retiring in 2024. Photo by Cedars-Sinai.]]></pp:imageTitle><pp:imageDescription><![CDATA[Thomas M. Priselac, wearing a button-down shirt and tie, smiles while sitting in his former office. He spent 30 years as president and CEO and served the Cedars-Sinai for 45 years total, before retiring in 2024.]]></pp:imageDescription></item><item>
                        <title>Cedars-Sinai Event Explores Ethics of Longevity Science</title>
                        <link>https://www.cedars-sinai.org/newsroom/cedars-sinai-event-explores-ethics-of-longevity-science/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/cedars-sinai-event-explores-ethics-of-longevity-science/</guid><pp:caseid>743085</pp:caseid><pp:subtitle>Free Public Event May 3, ‘Informing Innovation: Emerging Medicine and Jewish Ethics,’ Features Scientists, Religious Scholars Discussing Breakthroughs in Aging, Genomics</pp:subtitle><description><![CDATA[<p style="margin-left:0in;"><span>Cedars-Sinai experts and prominent scholars of religion, Jewish law and ethics are coming together on May 3 for a free public discussion focusing on the ethical, moral and theological questions that can result from medical breakthroughs.</span></p><p><span><img class="image_resized image-style-align-right" style="aspect-ratio:335/auto;width:335px;" src="https://content.presspage.com/uploads/2110/b64a0bb9-bf87-4633-8a10-a67bec670ef3/800_dr-rabbi-jason-weiner-cedars-sinai.jpg?x=1776975896392" alt="Rabbi Jason Weiner, PhD" width="335" height="auto">The May 3 panel discussion, “Informing Innovation: Emerging Medicine and Jewish Ethics,” begins at 9 a.m. and features experts focusing on the latest advancements in genetic and genomic testing, as well as gerotherapeutics—drugs that target the biological processes of aging.</span></p><p><span>“What was once considered science fiction is now real, and as scientific and medical innovation accelerate, the question is no longer just what’s possible—but what’s responsible,” said </span><a href="https://www.cedars-sinai.org/programs/support-services/services/spiritual-care/team/jason-weiner-bcc.html"><span>Rabbi Jason Weiner, PhD</span></a><span>, senior rabbi and director of the </span><a href="https://www.cedars-sinai.org/programs/support-services/services/spiritual-care.html"><span>Spiritual Care Department</span></a><span> at Cedars-Sinai. “As a faith-based institution, we believe it’s essential to explore the science </span><i><span>and</span></i><span> its ethical, moral and theological implications. This event creates space for those conversations so people can make more informed decisions about their health.”</span></p><h2 style="margin-left:0in;"><span>Topics Include:</span></h2><ul><li data-list-item-id="e77185dd6bd67affa9636f2bbd6a61aae"><p style="margin-left:0in;"><span>What research shows about emerging “anti-aging” therapies</span></p></li><li data-list-item-id="ea8d0128ecef8700b76c51601eee63737"><p style="margin-left:0in;"><span>Clinical trials targeting the root causes of aging—and the potential impact on cancer, dementia, heart disease and other conditions</span></p></li><li data-list-item-id="e67679b2ecb2ad8e6270fdcd31f3703e7"><p style="margin-left:0in;"><span>The difference between evidence-based medicine and widely marketed but unproven products</span></p></li><li data-list-item-id="e6496394c8c4783ae5bc4e0ba96d66389"><p style="margin-left:0in;"><span>What genetic testing can and cannot reveal</span></p></li></ul><p style="margin-left:0in;"><span><img class="image_resized image-style-align-right" style="aspect-ratio:195/auto;width:195px;" src="https://content.presspage.com/uploads/2110/ee856850-177a-46d5-8626-2c8a2c9c11c8/500_joyce-so.jpeg?x=1776976113265" alt="Joyce So, MD, PhD" width="195" height="auto">“Advancements in genomic technologies have bolstered the promise of solving medical mysteries, predicting future health risks, and advancing personalized medicine,” said </span><a href="https://researchers.cedars-sinai.edu/Joyce.So"><span>Joyce So, MD, PhD</span></a><span>, chief genomics officer at Cedars-Sinai and a speaker at the event. “But that promise also raises ethical and theological questions. Asking those questions now helps ensure we use these powerful tools wisely.”</span></p><p><span>So’s presentation will explore direct-to-consumer genetic testing, genetic discrimination, privacy and confidentiality concerns, predictive testing without clear treatment options, and disparities in access to—and understanding of—genetic information.</span></p><p><a href="https://researchers.cedars-sinai.edu/James.Kirkland"><span>James Kirkland, MD, PhD</span></a><span>, director of the Center for Advanced Gerotherapeutics at Cedars-Sinai, will address common misconceptions about longevity science, including the gap between promising research and proven therapies. He also will discuss lifestyle interventions being studied now and how emerging gerotherapeutic approaches could reshape clinical care in the next decade.</span></p><p><span><img class="image_resized image-style-align-right" style="aspect-ratio:195/auto;width:195px;" src="https://content.presspage.com/uploads/2110/8df89125-85cc-43b9-9299-92b1b284603a/500_james-kirkland-md-cedars-sinai3.jpg?x=1776976055636" alt="James Kirkland, MD, PhD" width="195" height="auto">“If scientists can safely slow the fundamental processes of aging, the impact could extend across many diseases at once,” Kirkland said. “Early clinical trials are already exploring how conditions linked to aging, such as Alzheimer’s disease and other forms of dementia, begin developing long before symptoms appear. If these approaches prove safe, the next step could be preventing disease in people at high risk.”</span></p><p style="margin-left:0in;"><span>Kirkland also will share his team’s research into removing damaged “aging” cells or preventing them from releasing harmful substances that contribute to disease and decline later in life.</span></p><p style="margin-left:0in;"><span>Other event speakers include </span><a href="https://www.puahfertility.org/staff" target="_blank"><span>Rabbi Elan Segelman</span></a><span>, U.S. rabbinic director of </span><a href="https://www.puahfertility.org/" target="_blank"><span>PUAH</span></a><span>; and internationally known Torah scholar </span><a href="https://minchasasher.com/about/" target="_blank"><span>Rav Asher Weiss Shlit”a</span></a><span>, who will give the keynote address.</span></p><p style="margin-left:0in;"><span>“Informing Innovation: Emerging Medicine and Jewish Ethics” will take place from 9 a.m. to 1 p.m. at Harvey Morse Auditorium, 8701 Gracie Allen Drive, Los Angeles, CA 90048.</span></p><p style="margin-left:0in;"><span>Attendees are encouraged to register at </span><a href="https://forms.cloud.microsoft/pages/responsepage.aspx?id=__JTm1PnCUO1fKCGwrBLmi2RZ7nVN2pAgt01b3oWZxdUM0tFSzVCODlVRk1CUUg1MFlCNU9MMTZEMi4u&route=shorturl" target="_blank"><span>csethicssymposium.com</span></a><span>.</span></p><h2 style="margin-left:0in;"><span><strong>Media</strong></span></h2><p style="margin-left:0in;"><span>To arrange an interview, contact Kristin Reynolds at 424-241-8108 or&nbsp;</span><a href="mailto:marykristin.reynolds@cshs.org"><span>marykristin.reynolds@cshs.org</span></a><span>.</span></p>]]></description><category><![CDATA[Exclude,Faculty News,Kristin Reynolds,Spiritual Care,Aging]]></category>
            <pubDate>Fri, 24 Apr 2026 07:30:00 -0700</pubDate>
            <pp:lastModified>Thu, 23 Apr 2026 23:46:50 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/faedf9e4-78e7-44b3-9dac-a279cdc8920e/500_gerotherapeutics-cedars-sinai.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/faedf9e4-78e7-44b3-9dac-a279cdc8920e/500_gerotherapeutics-cedars-sinai.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/faedf9e4-78e7-44b3-9dac-a279cdc8920e/gerotherapeutics-cedars-sinai.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[On May 3, Cedars-Sinai will bring together scientific experts, religious scholars and the public to discuss longevity science, genetic testing and the ethics shaping the future of medicine. Image by Getty.]]></pp:imageTitle><pp:imageDescription><![CDATA[A person in a lab coat holds a clock with DNA strands at its center, symbolizing the research on genetic clocks that influence life expectancy and human lifespan.]]></pp:imageDescription></item><item>
                        <title>Cedars-Sinai Animal Care and Use Program Recognized</title>
                        <link>https://www.cedars-sinai.org/newsroom/cedars-sinai-animal-care-and-use-program-recognized/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/cedars-sinai-animal-care-and-use-program-recognized/</guid><pp:caseid>741538</pp:caseid><pp:subtitle>International Organization Recognizes Strong Institutional Support, Staff Training and Facilities Maintenance</pp:subtitle><description><![CDATA[<p><span>The Cedars-Sinai animal care and use program has been reaccredited for the maximum of three years by AAALAC International, a private, nonprofit organization dedicated to improving animal welfare in science and education. Cedars-Sinai has consistently maintained this accreditation, which is awarded through a rigorous process, for decades.</span></p><p><span>In renewing the accreditation, AAALAC International commended Cedars-Sinai on strong institutional support of “an excellent program” and cited several of the program’s qualities:</span></p><ul><li data-list-item-id="ec9123bbf43a9148c3170c4a4d126c294"><span>A&nbsp;knowledgeable and engaged Institutional Animal Care and Use Committee (IACUC), which ensures that animal research complies with federal regulations</span></li><li data-list-item-id="e984654dfa3900f387c82fd931a796fda"><span>Thorough training of Comparative Medicine staff, who are responsible for the care of animals and facilities, and who provide technical support to investigators</span></li><li data-list-item-id="ee1f113e859fe60a4e256abaa2ea321ad"><span>Extremely clean and well-maintained animal facilities</span></li><li data-list-item-id="e92cd7dd51e78e60a4d15730723187e21"><span>A strong veterinary care program with an experienced attending veterinarian</span></li><li data-list-item-id="ea676747677b271f89b869068839a0b72"><span>A collegial team approach</span></li></ul><p><span>“We are honored that AAALAC International continues to recognize Cedars-Sinai’s commitment to maintaining the highest quality in its animal care and use program,” said </span><a href="https://researchers.cedars-sinai.edu/Jeffrey.Golden"><span>Jeffrey A. Golden, MD</span></a><span>, executive vice dean of Research and Education and director of the Burns and Allen Research Institute at Cedars-Sinai. “This important achievement is made possible by concerted efforts across our institution.”</span></p><p><span>Participation in accreditation is voluntary. The process included an internal review, followed by an on-site assessment of the animal care and use program by AAALAC evaluators, during which they visited multiple labs and spoke with many lab members about their critical role in animal care at Cedars-Sinai.</span></p><p><span>“Maintaining this important accreditation requires collaboration among many teams,” said Ajay Sagar, associate director of Animal Research Programs Compliance. “The effort is led by the Department of Comparative Medicine, and also includes the IACUC and the offices of Research Compliance and Integrity, Plant Operations and Research Administration, as well as the Cedars-Sinai research community at large.”</span></p><p><span>With reaccreditation secured, program leaders continue to plan updates and improvements.</span></p><p><span>“We are working on new training programs for investigators, a centralized repository for training records, and improvements in managing animal breeding colonies,” said Sandra Duarte Vogel, DVM, executive director and attending veterinarian in the </span><a href="https://www.cedars-sinai.edu/health-sciences-university/research/cores/comparative-medicine.html"><span>Department of Comparative Medicine</span></a><span> at Cedars-Sinai. “We will continue to support our institution’s research efforts by looking to the future.”</span></p><p><span style="color:#dc1e34;"><i><span><strong>Cedars-Sinai Health Sciences University is advancing groundbreaking research and educating future leaders in medicine, biomedical sciences and allied health sciences. </strong></span></i></span><a href="https://www.cedars-sinai.edu/health-sciences-university.html"><span style="color:#dc1e34;"><i><span><strong>Learn more</strong></span></i></span></a><span style="color:#dc1e34;"><i><span><strong> about the university.</strong></span></i></span></p>]]></description><category><![CDATA[Exclude,Faculty News,Newsroom Author]]></category>
            <pubDate>Tue, 14 Apr 2026 08:00:00 -0700</pubDate>
            <pp:lastModified>Mon, 13 Apr 2026 20:32:17 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/9f3f350a-2e36-4b3a-bf55-f11fbcd8f314/500_cedars-sinai-research-2.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/9f3f350a-2e36-4b3a-bf55-f11fbcd8f314/500_cedars-sinai-research-2.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/9f3f350a-2e36-4b3a-bf55-f11fbcd8f314/cedars-sinai-research-2.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Cedars-Sinai was again recognized for improving animal welfare in science and education. Photo by Cedars-Sinai.]]></pp:imageTitle><pp:imageDescription><![CDATA[Cedars-Sinai Medical Center&amp;#039;s campus shown with the research building in the background and in the foreground a futuristic black metal statue with blue glass.]]></pp:imageDescription></item><item>
                        <title>Study Based on National Registry Finds Strong Outcomes for Transcatheter Tricuspid Valve Replacement</title>
                        <link>https://www.cedars-sinai.org/newsroom/study-based-on-national-registry-finds-strong-outcomes-for-transcatheter-tricuspid-valve-replacement/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/study-based-on-national-registry-finds-strong-outcomes-for-transcatheter-tricuspid-valve-replacement/</guid><pp:caseid>741794</pp:caseid><pp:subtitle>Cedars-Sinai Investigators Say 30-Day Results Show Transcatheter Valve Replacement Improves Symptoms</pp:subtitle><description><![CDATA[<p><span>A national study led by investigators from Cedars-Sinai Health Sciences University found that transcatheter tricuspid valve replacement, or TTVR, delivered strong early results in real-world practice. Patients treated with TTVR experienced near elimination of tricuspid regurgitation, low rates of stroke, and meaningful improvements in symptoms and quality of life within 30 days.</span></p><p><span>The study, “Real-World Outcomes of Transcatheter Tricuspid Valve Replacement: Analysis From the STS/ACC TVT Registry,” published in the </span><a href="https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.3446?utm_campaign=articlePDF%26utm_medium=articlePDFlink%26utm_source=articlePDF%26utm_content=jama.2026.3446" target="_blank"><i><span>Journal of the American Medical Association</span></i></a><i><span>.</span></i></p><p><span><img class="image_resized image-style-align-right" style="aspect-ratio:350/auto;width:350px;" src="https://content.presspage.com/uploads/2110/3c0e8279-aa7c-41de-b7f1-dab0518be66b/800_raj-makkar-cedars-sinai.jpg?x=1775852363495" alt="Raj Makkar, MD" width="350" height="auto">“These findings show that transcatheter tricuspid valve replacement is translating well from the clinical trial setting into routine practice across the United States,” said </span><a href="https://researchers.cedars-sinai.edu/Raj.Makkar?prevPageName=cs-org%3Acedars-sinai%3Anewsroom%3Aminimally-invasive-procedure-for-aortic-valve-disease-has-similar-outcomes-as-surgery-study-reports"><span>Raj Makkar, MD</span></a><span>, vice president of Cardiovascular Innovation and Intervention at Cedars-Sinai, the Karsh Distinguished Chair in Interventional Cardiology in the Smidt Heart Institute, and corresponding author of the study. “In a large, older and medically complex patient population, we saw very high procedural success, near-complete elimination of tricuspid regurgitation, and rapid improvement in how patients feel and function.”</span></p><p><a href="https://www.cedars-sinai.org/newsroom/new-options-for-people-with-tricuspid-valve-disease/"><span>Tricuspid regurgitation</span></a><span> occurs when the tricuspid valve does not close properly, allowing blood to flow backward in the heart. The condition is common in older adults and can lead to worsening heart failure symptoms, repeated hospitalization and increased risk of death.</span></p><p><span>Historically, open-heart surgery was often the only treatment option for this condition, but many older patients were not candidates because of age or other medical problems. Today, transcatheter tricuspid valve replacement offers a less invasive alternative in which doctors replace the damaged valve using a catheter, or tube, threaded through a blood vessel.</span></p><p><span>Researchers analyzed 1,034 attempted TTVR procedures performed between February 2024 and March 2025 at 82 medical centers across the U.S. The average patient age was 77.</span></p><p style="margin-left:0in;"><span>The analysis found that more than 98% of patients had the valves successfully implanted. At 30 days post-procedure, more than 97% of patients had their condition improve to mild or minimal tricuspid regurgitation, and patients reported substantial improvement in symptoms, physical and social function, and quality of life.</span></p><p><span>Study authors note that early real-world outcomes were </span><a href="https://www.cedars-sinai.org/newsroom/smidt-heart-institute-physicians-advance-transcatheter-tricuspid-valve-replacement/"><span>consistent with results</span></a><span> from the TRISCEND II randomized trial of TTVR. Patients in this new study, however, experienced lower incidence of bleeding and heart block requiring electronic pacemaker implantation than patients participating in TRISCEND II. The current study also found that outcomes were generally consistent in patients with and without preexisting cardiac implantable electronic devices such as pacemakers, an important finding because these devices are common in patients with severe tricuspid valve disease.</span></p><p><span><img class="image_resized image-style-align-right" style="aspect-ratio:349/auto;width:349px;" src="https://content.presspage.com/uploads/2110/800_aakriti-gupta-md-cedars-sinai.jpeg?x=1775852405360" alt="Aakriti Gupta, MD" width="349" height="auto">“For patients with severe tricuspid regurgitation, treatment options have historically been limited, especially when surgery carries high risk,” said </span><a href="https://researchers.cedars-sinai.edu/Aakriti.Gupta?prevPageName=cs-org%3Acedars-sinai%3Anewsroom%3Acedars-sinai-heart-experts-available-for-interviews-at-aha25&adobe_mc=MCMID%3D15143042538955239740718824350024281938%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1774047971&previousPageName=cs-org%253Acedars-sinai%253Aother"><span>Aakriti Gupta, MD</span></a><span>, assistant professor of Cardiology and study author. “What is especially encouraging here is that in real-world care, not just in a randomized trial, patients experienced meaningful improvement in symptoms and quality of life within only 30 days.”</span></p><p><span>Investigators said the results support the growing role of TTVR as a treatment option for patients with severe tricuspid regurgitation and highlight the importance of continued follow-up to understand longer-term outcomes.</span></p><p><a href="https://researchers.cedars-sinai.edu/Moody.Makar?adobe_mc=MCMID%3D15143042538955239740718824350024281938%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1774048903&previousPageName=cs-org%253Acedars-sinai%253Aother"><span>Moody Makar, MD</span></a><span>, associate professor of Anesthesiology at Cedars-Sinai, is also an author of the study.</span></p><p><i><span>Additional authors include&nbsp;Brian P. O’Neill, MD; Christina Lalani, MD; Rahul Sharma, MBBS; Pradeep Yadev, MD; Tiberio M. Frisoli, MD; Vinod Thourani, MD; Mackram F. Eleid, MD; James Lee, MD; Vasilis C. Babaliaros, MD; Christiane Haeffele, MD, MPH; Tanvir J. Bajwa, MD; Peter Flueckiger, MD; Robert J. Cubeddu, MD; Laura J. Davidson, MD; Ratnasari Padang, MBBS, PhD; Pedro Villablanca Spinetto, MD; Suhail Allaqaband, MD; Akhil Narang, MD; Mathew Williams, MD; Patrick Gleason, MD; Gilbert H.L. Tang, MD; Sahil Khera, MD; John P. Vavalle, MD; Isida Byku, MD; Jeremiah P. Depta, MD; Santiago Garcia, MD; Samir Kapadia, MD; Alan Zajarias, MD; Jake M. Chanin, MD; Susheel K. Kodali, MD; Howard C. Herrmann, MD; M. Andrew Morse, MD; George Petrossian, MD; Joseph A. Sivak, MD; Rebecca T. Hahn, MD; Yang Song, PhD; Martin B. Leon, MD; Robert W. Yeh, MD, MSc; Charles J. Davidson, MD.</span></i></p><p><i><span>The study was funded by Edwards Lifesciences.</span></i></p><p><span style="color:#dc1e34;"><i><span style="text-align:left;"><strong>Cedars-Sinai Health Sciences University is advancing groundbreaking research and educating future leaders in medicine, biomedical sciences and allied health sciences.&nbsp;</strong></span></i></span><a href="https://www.cedars-sinai.edu/health-sciences-university.html?prevPageName=cs-org%3Acedars-sinai%3Anewsroom%3Astudy-shows-people-use-same-neurons-to-see-and-imagine-objects"><span style="color:#dc1e34;"><i><span><strong>Learn more</strong></span></i></span></a><span style="color:#dc1e34;"><i><span style="text-align:left;"><strong>&nbsp;about the university.</strong></span></i></span></p>]]></description><category><![CDATA[Stephanie Cajigal,Exclude,Research,Heart,Heart Research,Heart Valve Disease Research,rajendra-makkar-885543,aakriti-gupta-3174704]]></category>
            <pubDate>Mon, 13 Apr 2026 08:00:00 -0700</pubDate>
            <pp:lastModified>Sat, 11 Apr 2026 01:41:15 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/0849bd97-1fc8-468a-8017-bea114fc4330/500_cath-lab-cedars-sinai.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/0849bd97-1fc8-468a-8017-bea114fc4330/500_cath-lab-cedars-sinai.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/0849bd97-1fc8-468a-8017-bea114fc4330/cath-lab-cedars-sinai.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[In 2024, Cedars-Sinai physicians performed the first transcatheter tricuspid valve replacement after approval by the U.S. Food and Drug Administration. Photo by Cedars-Sinai.]]></pp:imageTitle><pp:imageDescription><![CDATA[Doctor in the cath lab at Cedars-Sinai]]></pp:imageDescription></item><item>
                        <title>Physician-Scientist Ravi Thadhani, MD, MPH, Named AAAS Fellow</title>
                        <link>https://www.cedars-sinai.org/newsroom/physician-scientist-ravi-thadhani-md-mph-named-aaas-fellow/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/physician-scientist-ravi-thadhani-md-mph-named-aaas-fellow/</guid><pp:caseid>740197</pp:caseid><pp:subtitle>Cedars-Sinai’s Chief Medical Officer Recognized With the Distinguished Lifetime Honor</pp:subtitle><description><![CDATA[<p><a href="https://www.cedars-sinai.org/about/leadership/executive-management/ravi-thadhani-md-mph.html"><span>Ravi Thadhani, MD, MPH</span></a><span>, executive vice president of Clinical Affairs and chief medical officer for Cedars-Sinai Medical Center and Cedars-Sinai Health System,&nbsp;has been elected a Fellow of the American Association for the Advancement of Science (AAAS).</span></p><p><span>The organization, one of the world’s largest general scientific societies and publisher of the&nbsp;</span><i><span>Science</span></i><span>&nbsp;family of journals, has awarded fellowships since 1874.</span></p><p><span>The distinguished lifetime honor recognizes Thadhani’s pioneering work in the field of nephrology and in the study of preeclampsia, a leading cause of maternal and perinatal morbidity and mortality. He played a leading role in developing the first Food and Drug Administration-approved test to predict preeclampsia.</span></p><p><span>“Dr. Thadhani is an internationally respected leader in clinical and translational research,” said </span><a href="https://www.cedars-sinai.org/about/leadership/executive-management/peter-l-slavin.html"><span>Peter L. Slavin, MD</span></a><span>, president and CEO of Cedars-Sinai Medical Center and Cedars-Sinai Health System. “His visionary work strengthens Cedars-Sinai and extends beyond our healthcare system to the broader medical and research community.”</span></p><p><span>Thadhani is among nearly 500 scientists, engineers and innovators who have been elected a 2025 Fellow for their scientifically and socially distinguished achievements throughout their careers.</span></p><p><span>Thadhani joins the ranks of several Cedars-Sinai faculty who have been honored, with the most recent being </span><a href="https://www.cedars-sinai.org/about/leadership/executive-management/shlomo-melmed-mbchb.html"><span>Shlomo Melmed, MB, ChB</span></a><span>, executive vice president of Medicine and Health Sciences and dean of the Medical Faculty at Cedars-Sinai, who was </span><a href="https://www.cedars-sinai.org/newsroom/cedars-sinais-shlomo-melmed-mb-chb-elected-aaas-fellow/"><span>elected in 2025.</span></a></p><p><span>“I feel immensely grateful to have a career dedicated to serving patients and science,” Thadhani said. “My work and life have been enriched by the countless mentors, colleagues, trainees and mentees who have collaborated alongside me—people and experiences for which I am deeply thankful.”</span></p><p><span>Thadhani began his career at Massachusetts General Hospital and Harvard Medical School. He served as vice dean for Research and Education at Cedars-Sinai Medical Center from 2017 to 2019, then returned to Harvard as professor of Medicine and chief academic officer, and dean for Faculty Affairs at Mass General Brigham.</span></p><p><span>In 2022, Thadhani was named executive vice president for Health Affairs at Emory University, vice chair of the Emory Healthcare Board of Directors and executive director of Emory’s Woodruff Health Sciences Center, which includes Emory’s schools of medicine, public health and nursing.</span></p><p><span>He returned to Cedars-Sinai in October 2025, rejoining the team involved in this research: Anders Berg, MD, PhD, vice chair of Clinical Pathology; S. Ananth Karumanchi, MD, professor of Medicine and director of&nbsp;the Renovascular Research Center;&nbsp;and&nbsp;Sarah J. Kilpatrick, MD, PhD, chair of the&nbsp;Department of Obstetrics and Gynecology.</span></p><p><span>Shortly after his return to Cedars-Sinai, Thadhani </span><a href="https://www.cedars-sinai.org/newsroom/cedars-sinais-ravi-thadhani-md-mph-elected-to-national-academy-of-medicine/"><span>was elected</span></a><span> to the National Academy of Medicine, one of the highest honors in the fields of health and medicine.</span></p><p><span>He has been inducted into several additional honor societies, including the American Society for Clinical Investigation, the Association of American Physicians, the American Epidemiological Society, and the American Clinical and Climatological Association.</span></p><p><span>Thadhani<strong>&nbsp;</strong>is the author or co-author of more than 300 scientific manuscripts that have been published in </span><i><span>The New England Journal of Medicine</span></i><span>,&nbsp;</span><i><span>The Lancet,</span></i><span> the&nbsp;</span><i><span>Journal of the American Medical Association </span></i><span>and other top-tier academic journals.</span></p><p><span style="color:#dc1e34;"><i><span><strong>Cedars-Sinai Health Sciences University is advancing groundbreaking research and educating future leaders in medicine, biomedical sciences and allied health sciences.&nbsp;</strong></span></i></span><a href="https://www.cedars-sinai.edu/health-sciences-university.html?adobe_mc=MCMID%3D79521921680015491943235909713257507329%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1733161540"><span style="color:#dc1e34;"><i><span><strong>Learn more</strong></span></i></span></a><span style="color:#dc1e34;"><i><span><strong>&nbsp;about the university.</strong></span></i></span></p>]]></description><category><![CDATA[Exclude,Faculty News,Cara Martinez]]></category>
            <pubDate>Thu, 26 Mar 2026 08:30:00 -0700</pubDate>
            <pp:lastModified>Wed, 25 Mar 2026 21:38:52 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/690e5778-58df-41e7-bebc-aa3bdd99771c/500_thadhani_md_cedars-sinai.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/690e5778-58df-41e7-bebc-aa3bdd99771c/500_thadhani_md_cedars-sinai.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/690e5778-58df-41e7-bebc-aa3bdd99771c/thadhani_md_cedars-sinai.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Ravi Thadhani, MD, MPH, has been recognized for his pioneering work in nephrology, preeclampsia and kidney disease.  Photo by Cedars-Sinai.]]></pp:imageTitle><pp:imageDescription><![CDATA[A man in a suit and tie, Ravi Thadhani, MD, MPH, stands outside on the plaza level of Cedars-Sinai Medical Center.]]></pp:imageDescription></item><item>
                        <title>New MRI System Could Aid Early Detection of Heart Failure</title>
                        <link>https://www.cedars-sinai.org/newsroom/new-mri-system-could-aid-early-detection-of-heart-failure/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/new-mri-system-could-aid-early-detection-of-heart-failure/</guid><pp:caseid>740093</pp:caseid><pp:subtitle>Cedars-Sinai Study Shows Tool’s Potential for Measuring Cardiac Oxygen Consumption, a Key Indicator of Heart Health</pp:subtitle><description><![CDATA[<p><span>The heart’s ability to use oxygen efficiently is a critical indicator of its health, but tests to measure this function have drawbacks that can limit their use. A new Cedars-Sinai Health Sciences University study found that a new MRI system developed at Cedars-Sinai might overcome this challenge.</span></p><p><span>The findings, published in </span><a href="https://www.science.org/doi/10.1126/scitranslmed.ady6269" target="_blank"><i><span>Science Translational Medicine</span></i></a><span>, could one day improve management of heart failure, in which the heart fails to pump enough blood to meet the body’s need for blood and oxygen. Poor use of oxygen by the heart is an early indicator of heart failure, which affects nearly 7 million people in the U.S.</span></p><p><span><img class="image_resized image-style-align-left" style="aspect-ratio:200/auto;width:200px;" src="https://content.presspage.com/uploads/2110/016ce650-8df3-4966-a139-4d8efc555c8f/500_hsin-jungyangphd.jpg?x=1774303328315" alt="Hsin-Jung Yang, PhD" width="200" height="auto">“Our study shows how MRI could be used to quickly and noninvasively determine heart oxygen use in the clinic,” said </span><a href="https://researchers.cedars-sinai.edu/Hsin-Jung.Yang"><span>Hsin-Jung Yang, PhD</span></a><span>, director of Cardiac Imaging Research in the Biomedical Research Imaging Institute and corresponding author of the study. “With further research and development, this advance could unlock new frontiers in early diagnosis, personalized therapy and next-generation treatments for heart failure.”</span></p><p><span>The current gold standard for measuring heart oxygen use, coronary sinus catheterization, requires threading a thin, flexible tube called a catheter from a patient’s neck or groin into the heart's main vein. The procedure, which takes 30 to 60 minutes and involves injection of a contrast dye to guide the catheter, is too invasive for routine heart oxygen monitoring.</span></p><p><span>MRI uses radio waves, a strong magnet and a computer to create detailed images of areas inside the body. Standard MRI can only produce clear images of the heart, which moves with every beat and every breath, if patients hold their breath at points during the exam. And in order to use these images to measure oxygen, doctors have to take multiple MRI scans—a process that takes several minutes—and draw blood at the same time.</span></p><p><span>“The system we designed addresses the motion of the heart,” Yang said. “Patients do not need to hold their breath, and it can give precise numbers within three minutes.”</span></p><p><span><img class="image_resized image-style-align-left" style="aspect-ratio:200/auto;width:200px;" src="https://content.presspage.com/uploads/2110/ee02691d-7e06-4bfd-9217-7af94cb560ef/500_david-underhill-md-cedars-sinai.jpg?x=1774303353879" alt="David Underhill, PhD" width="200" height="auto">The team proved the accuracy of its MRI method by using it to measure heart oxygen use in patients with and without heart failure, and comparing its readings to readings obtained by heart catheterization.</span></p><p><span>“Noninvasive testing that detects issues in the heart’s use of oxygen can provide an early warning that heart failure is developing,” Yang said. “Now that we have promising cardiometabolic therapies lined up, earlier detection may allow us to take steps to prevent and treat the condition.”</span></p><p><a href="https://researchers.cedars-sinai.edu/David.Underhill"><span>David Underhill, PhD,</span></a><span> chair of the </span><a href="https://www.cedars-sinai.edu/health-sciences-university/research/departments-institutes/biomedical-sciences.html"><span>Department of Biomedical Sciences</span></a><span>, said the study makes a major contribution toward improving healthcare for heart disease, the No. 1 cause of death.</span></p><p><span>“Along with its potential for saving lives through early intervention for heart failure, this accessible tool could offer new avenues for cardiac research,” Underhill said. “It could allow us to study patients who have risk for, but no symptoms of, heart failure without exposing them to catheterization, contrast or radiation.”</span></p><p><i><span>Additional Cedars-Sinai authors include Li-Ting Huang, Chia-Chi Yang, Archana Malagi, Xinqi Li, Ghazal Yoosefian, Xinheng Zhang, Ziyang Long, Xiaoming Bi, Janet Wei, Alan C. Kwan, C. Noel Bairey Merz and Debiao Li.</span></i></p><p><i><span>Other authors include Guan Wang, Henghui Zhang, Ranran Zhang, Hao Ho, Yuheng Huang, Michael D. Nelson, Anthony Christodoulou and Rohan Dharmakumar.</span></i></p><p><i><span>Funding<strong>:</strong> This work was supported by grants from National Institutes of Health (R01HL165211 to H.-J.Y. R01HL181091 to H.-J.Y., R01HL156818 to H.-J.Y., R01HL148788 to R.D., R01HL146158 to C.N.B.M., R01HL124649 to C.N.B.M., R01HL153500 to J.W., K23HL125941 to C.N.B.M., U54AG065141 to C.N.B.M., and U54AG094168-01 to C.N.B.M.), The Barbra Streisand Women’s Cardiovascular Research and Education Program to C.N.B.M., The Linda Joy Pollin Women’s Heart Health Program to C.N.B.M.,The Erika Glazer Women’s Heart Health Project to C.N.B.M., The Adelson Family Foundation to C.N.B.M., and US Department of Defense (HT94252510956 to H.-J.Y.).</span></i></p><p><i><span>Competing interests<strong>:</strong> C.N.B.M. serves as a director and holds stock in iRhythm. D. Li, A. G. Christodoulou, J. L. Shaw, Y. Xie, and C. Nguyen are inventors on US patent no. 10,436,871 (“Low-rank tensor imaging for multidimensional cardiovascular MRI”). H. J. Yang and C. C. Yang are inventors on a provisional US patent, US Prov 63/721,228 (PCT/US2025/055499, “Systems and methods for determining oxygen consumption using magnetic resonance imaging”). The other authors declare that they have no competing interests.</span></i></p><p><span style="color:#dc1e34;"><i><span><strong>Cedars-Sinai Health Sciences University is advancing groundbreaking research and educating future leaders in medicine, biomedical sciences and allied health sciences. </strong></span></i></span><a href="https://www.cedars-sinai.edu/health-sciences-university.html"><span style="color:#dc1e34;"><i><span><strong><u>Learn more</u></strong></span></i></span></a><span style="color:#dc1e34;"><i><span><strong> about the university.</strong></span></i></span></p>]]></description><category><![CDATA[Exclude,Research,Heart Research,Heart,Heart Failure Research,Imaging Research]]></category>
            <pubDate>Wed, 25 Mar 2026 11:00:00 -0700</pubDate>
            <pp:lastModified>Tue, 07 Apr 2026 22:34:22 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/bcef5fcb-c0ed-4e6f-8bf4-07a92a4fa6e8/500_cedars-sinaiinvestigatorsleddevelopmentofanewmrisystemthatcanmeasuretheheartrsquosabilitytouseoxygen.photobygettyimages..jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/bcef5fcb-c0ed-4e6f-8bf4-07a92a4fa6e8/500_cedars-sinaiinvestigatorsleddevelopmentofanewmrisystemthatcanmeasuretheheartrsquosabilitytouseoxygen.photobygettyimages..jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/bcef5fcb-c0ed-4e6f-8bf4-07a92a4fa6e8/cedars-sinaiinvestigatorsleddevelopmentofanewmrisystemthatcanmeasuretheheartrsquosabilitytouseoxygen.photobygettyimages..jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Cedars-Sinai investigators led development of a new MRI system that can measure the heart&amp;rsquo;s ability to use oxygen. Photo by Getty Images.]]></pp:imageTitle><pp:imageDescription><![CDATA[Mature man going through MRI scanner in examination room at hospital.]]></pp:imageDescription></item><item>
                        <title>Susan Cheng, MD, MMSc, MPH, to Lead Department of Cardiology at Cedars-Sinai</title>
                        <link>https://www.cedars-sinai.org/newsroom/susan-cheng-md-mmsc-mph-to-lead-department-of-cardiology-at-cedars-sinai/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/susan-cheng-md-mmsc-mph-to-lead-department-of-cardiology-at-cedars-sinai/</guid><pp:caseid>738235</pp:caseid><pp:subtitle>Established Academic Scientist to Expand Clinical, Research and Educational Programs at Smidt Heart Institute</pp:subtitle><description><![CDATA[<p><a href="https://researchers.cedars-sinai.edu/Susan.Cheng?adobe_mc=MCMID%3D75360244188131661941566734971363994374%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1754577108&prevPageName=cs-org%3Acedars-sinai%3Anewsroom%3Acedars-sinai-reports-heart-attacks-general-illness-spiked-after-la-fires"><span>Susan Cheng, MD, MMSc, MPH</span></a><span>,&nbsp;a clinician-scientist who has made seminal contributions to cardiovascular research and clinical care, has been appointed chair of the Department of Cardiology in the </span><a href="https://www.cedars-sinai.org/programs/heart.html?utm_source=google&utm_medium=cpc&utm_campaign=&utm_content=&utm_term=cardiac%20surgery%20hospital&utm_match=p&acct=3628634129&device=c&cid=20938227040&agid=156336143014&kwid=kwd-305606346612&adid=687367022395&ext=&gad_source=1&gad_campaignid=20938227040&gbraid=0AAAAAD_aIjGHmakRgYJbu587HWf9-qn_I&gclid=CjwKCAiAzZ_NBhAEEiwAMtqKy9H6ylMkfVjLrrzdjefIkaCyfH3xKWhfTT637fwft6kvH531HdQbvhoCnXEQAvD_BwE"><span>Smidt Heart Institute at Cedars-Sinai</span></a><span>.</span></p><p><span>Throughout her career, Cheng has maintained National Institutes of Health funding for research aimed at uncovering the drivers of cardiovascular aging. She has authored more than 450 scientific studies, many appearing in high-impact journals, including </span><i><span>JAMA</span></i><span>, </span><i><span>Circulation</span></i><span> and </span><i><span>The New England Journal of Medicine</span></i><span>.</span></p><p><span>Cheng identified differences in how males and females develop elevated blood pressure and demonstrated how people vary in their responses to COVID-19 vaccines over time. Her research has garnered multiple awards and contributed to Cedars-Sinai’s reputation as an international leader in biomedical sciences.</span></p><p><span>“Dr. Cheng is the perfect leader to build and enrich our already flourishing Department of Cardiology,” said </span><a href="https://www.cedars-sinai.org/about/leadership/executive-management/shlomo-melmed-mbchb.html"><span>Shlomo Melmed, MB, ChB,</span></a><span>&nbsp;dean of the Medical Faculty and executive vice president of Medicine and Health Sciences. “We welcome her to this academic leadership role and look forward to the contributions she will make in strengthening the Smidt Heart Institute.”</span></p><p><span>Cheng, who succeeds Christine M. Albert, MD, MPH, has served on the editorial boards of major professional journals and on leadership committees for the American Society for Clinical Investigation, the American Heart Association and the American College of Cardiology.</span></p><p><span>She founded the largest COVID-19 clinical research program on the West Coast at the outset of the pandemic in 2020. More recently, she has led research to investigate the </span><a href="https://www.cedars-sinai.org/newsroom/cedars-sinai-reports-heart-attacks-general-illness-spiked-after-la-fires/"><span>public health effects of the 2025 Los Angeles wildfires</span></a><span>.</span></p><p><span>Cheng has mentored dozens of junior faculty members in cardiology, anesthesiology, neurology, obstetrics and oncology, taking special pride in advising early-career investigators as well as high school and college students.</span></p><p><span>“I look forward to supporting the Smidt Heart&nbsp;Institute’s&nbsp;talented clinicians and researchers as they work to improve the lives of those affected by cardiovascular disease,”&nbsp;Cheng said.&nbsp;&nbsp;</span></p><p><span>Cheng received her bachelor’s degree from Harvard College and her medical degree from McMaster University in Canada, as well as a master of medical science degree from the Massachusetts Institute of Technology and a master of public health degree from Harvard University. She completed her internal medicine training at Johns Hopkins University and cardiology training at Brigham and Women’s Hospital, where she served as associate director of the Cardiovascular Imaging Core Laboratory.</span></p><p><span>In her new role, Cheng will lead strategic clinical, research and educational growth for the Department of Cardiology. As the new department chair, she will hold the Stephen R. Corday, MD, Distinguished Chair in Cardiology.</span></p><p><span>“Dr. Cheng has strengthened our institution and made many meaningful contributions through her research laboratory since joining Cedars-Sinai seven years ago,” said </span><a href="https://researchers.cedars-sinai.edu/Eduardo.Marban?prevPageName=cs-org%3Acedars-sinai%3Anewsroom%3Acirm-awards-cedars-sinai-more-than-20-million"><span>Eduardo Marbán, MD, PhD</span></a><span>, executive director of the&nbsp;</span><a href="https://www.cedars-sinai.edu/health-sciences-university/research/departments-institutes/smidt-heart-institute.html?prevPageName=cs-org%3Acedars-sinai%3Anewsroom%3Acirm-awards-cedars-sinai-more-than-20-million"><span>Smidt Heart Institute</span></a><span>&nbsp;and the Mark Siegel Family Foundation Distinguished Chair. “We are excited for her to continue developing our world-class cardiology department.”</span></p><p><span style="color:#dc1e34;"><i><span><strong>Read more from the Cedars-Sinai Newsroom: </strong></span></i></span><a href="https://www.cedars-sinai.org/newsroom/cedars-sinai-reports-heart-attacks-general-illness-spiked-after-la-fires/"><span style="color:#dc1e34;"><i><span><strong>Cedars-Sinai Reports Heart Attacks, General Illness Spiked After LA Fires</strong></span></i></span></a></p>]]></description><category><![CDATA[Exclude,Faculty News,susan-cheng-763325,Stephanie Cajigal,Heart,Heart Research]]></category>
            <pubDate>Fri, 06 Mar 2026 10:59:00 -0800</pubDate>
            <pp:lastModified>Fri, 06 Mar 2026 21:57:57 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/c6c1b7e5-e464-4f11-ae5b-ea25540a6c7f/500_susan-cheng-cedars-sinai.jpg?66413" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/c6c1b7e5-e464-4f11-ae5b-ea25540a6c7f/500_susan-cheng-cedars-sinai.jpg?66413</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/c6c1b7e5-e464-4f11-ae5b-ea25540a6c7f/susan-cheng-cedars-sinai.jpg?66413</pp:imageOriginal><pp:imageTitle><![CDATA[Susan Cheng, MD, MMSc, MPH, of the Smidt Heart Institute at Cedars-Sinai, is a leading expert in cardiovascular aging. Photo by Cedars-Sinai.]]></pp:imageTitle><pp:imageDescription><![CDATA[A female physician Susan Cheng, MD, MMSc, MPH, sits in a club chair in her office.]]></pp:imageDescription></item><item>
                        <title>David Kruse, MD, to Serve in Medical Role Supporting Team USA at the Milano Cortina 2026 Paralympic Winter Games</title>
                        <link>https://www.cedars-sinai.org/newsroom/david-kruse-md-to-serve-in-medical-role-supporting-team-usa-at-the-milano-cortina-2026-paralympic-winter-games/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/david-kruse-md-to-serve-in-medical-role-supporting-team-usa-at-the-milano-cortina-2026-paralympic-winter-games/</guid><pp:caseid>736597</pp:caseid><pp:subtitle>Cedars-Sinai Sports Medicine Specialist Will Lead Team USA Village Clinic in Milan and Support Medical Planning for LA28 Olympic &amp; Paralympic Games</pp:subtitle><description><![CDATA[<p><a href="https://researchers.cedars-sinai.edu/David.Kruse"><span>David Kruse, MD</span></a><span>, a sports medicine specialist in the </span><a href="https://www.cedars-sinai.org/programs/ortho.html"><span>Department of Orthopaedics at Cedars-Sinai</span></a><span>, will serve as Head Team Physician for the Team USA Milan Village Sports Medicine Clinic at the </span><a href="https://www.olympics.com/en/milano-cortina-2026/paralympic-games" target="_blank"><span>Milano Cortina 2026 Paralympic Winter Games</span></a><span>.</span></p><p><span>In this role, Kruse will lead the medical infrastructure supporting Paralympic athletes in Milan—whose medical needs are often complex due to underlying health conditions—along with their coaches and staff.</span></p><p><span>The Milano Cortina 2026 Paralympic Winter Games will take place from March 6 to March 15, 2026.&nbsp;</span></p><p><span><img class="image_resized image-style-align-right" style="aspect-ratio:266/auto;width:266px;" src="https://content.presspage.com/uploads/2110/dcc11b15-1d43-4131-9be3-1342cedc1588/800_david.kruse.jpg?x=1771373854907" alt="David Kruse, MD" width="266" height="auto">“Dr. Kruse’s deep understanding of elite sport and athlete-centered care makes him uniquely qualified to lead medical operations for Team USA’s Milan Village Sports Medicine Clinic at the Paralympic Games,” said Jonathan Finnoff, chief medical officer of the U.S. Olympic & Paralympic Committee. “His experience supporting athletes with complex medical needs, combined with his leadership across multiple Olympic and Paralympic Games, will be invaluable in delivering world-class care.”</span></p><p><span>Kruse’s appointment reflects his two decades of experience caring for elite athletes and his deep roots in the Olympic and Paralympic Movement. A former competitive gymnast, Kruse competed on the U.S. Senior National Team for four years. He served as a team physician for USA Gymnastics from 2008 to 2024. He served as part of the Olympic Games medical staff in Rio 2016 and Tokyo 2020. In 2020, he became USA Gymnastics’ medical director, overseeing athlete care through the Olympic and Paralympic Games Tokyo 2020 and Paris 2024.</span></p><p><span>At Cedars-Sinai, Kruse practices primary care sports medicine and non-operative orthopaedics, with clinical expertise in musculoskeletal injuries, sports concussion, ultrasound-guided procedures and the medical needs of athletes. He also brings specialized insight into treating gymnasts and dancers—experience informed by his collegiate athletic career as a six-time All-American, NCAA Team Champion and captain of the gymnastics team at the University of California, Berkeley.</span></p><p><span>Much of Kruse’s current work also focuses on preparations for the LA28 Olympic and Paralympic Games. Alongside Casey Batten, MD, </span><a href="https://www.cedars-sinai.org/newsroom/casey-g-batten-md-named-chief-medical-officer-for-la28-olympic-and-paralympic-games/"><span>chief medical officer for LA28</span></a><span>, Kruse serves as Senior Medical Advisor, helping the LA28 Organizing Committee plan medical services for athletes, staff, officials and spectators.</span></p><p><span>“Dr. Kruse brings an exceptional combination of clinical skill, firsthand athletic experience and medical leadership within the Olympic and Paralympic Movement,” Batten said. “His expertise will be essential in supporting Team USA at Milano Cortina 2026 and as we continue to build a world-class medical system for the LA28 Games.”</span></p><p><span>Kruse also is a member of the U.S. Olympic & Paralympic Medical Network, through which Cedars-Sinai provides care for Team USA athletes as they prepare for national and international competitions leading to the LA28 Games.</span></p><p><span><strong>Kruse is available to speak to media about:</strong></span></p><ul><li data-list-item-id="e91b31c7d456e6ba7ebf0dab99dfe73b5"><span>Medical planning and operations for Team USA at the Milano Cortina 2026 Paralympic Winter Games</span></li><li data-list-item-id="e76e901065a6d008120849f7584db57fe"><span>Olympic & Paralympic athlete health, safety and performance</span></li><li data-list-item-id="e36b07b701316d30812de5a74dd43a190"><span>Common injuries and medical challenges in Paralympic and adaptive sports</span></li><li data-list-item-id="eaecd6be7b42a9f342e979d1dde51f234"><span>Differences in care for Paralympic versus Olympic athletes</span></li><li data-list-item-id="e8407383a04b8d9ef61cf1e16d57a1a74"><span>Paralympic and adaptive sports medicine and emerging care models</span></li></ul><p style="margin-left:0in;"><span>To arrange interviews, contact Melissa Vizcarra at 719-502-5001 or </span><a href="mailto:melissa.vizcarra@cshs.org" target="_blank"><span>melissa.vizcarra@cshs.org</span></a><span>.</span></p>]]></description><category><![CDATA[Faculty News,Olympics,Orthopaedics,Sports Medicine]]></category>
            <pubDate>Wed, 25 Feb 2026 06:00:00 -0800</pubDate>
            <pp:lastModified>Wed, 25 Feb 2026 01:55:52 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/6db25c76-ac23-4cef-ac73-abf949b149eb/500_gettyimages-2257789252.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/6db25c76-ac23-4cef-ac73-abf949b149eb/500_gettyimages-2257789252.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/6db25c76-ac23-4cef-ac73-abf949b149eb/gettyimages-2257789252.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Cedars-Sinai orthopedic specialist David Kruse, MD, will serve as Head Team Physician for Team USA&amp;#039;s Milan Village Sports Medicine Clinic at the 2026 Paralympic Winter Games. Image by Getty.]]></pp:imageTitle><pp:imageDescription><![CDATA[Photo of the multicolored Olympic rings set against a snow-capped mountain in Italy to mark the 2026 Winter Olympic and Paralympic games.]]></pp:imageDescription></item><item>
                        <title>What Every Woman Needs to Know About Heart Disease</title>
                        <link>https://www.cedars-sinai.org/newsroom/what-every-woman-needs-to-know-about-heart-disease/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/what-every-woman-needs-to-know-about-heart-disease/</guid><pp:caseid>737065</pp:caseid><pp:subtitle>Barbra Streisand Women’s Heart Center Director Discusses Myths, Warning Signs, Steps Women Can Take to Protect Their Hearts, and the Growing Heart Attack Risk for Younger Women</pp:subtitle><description><![CDATA[<p><a href="https://researchers.cedars-sinai.edu/Noel.BaireyMerz"><span>C. Noel Bairey Merz, MD</span></a><span>, has a pretty good idea why many women with heart disease don’t get the healthcare they need.</span></p><p><span>“Too often, when a young woman has heart disease symptoms, a physician will ignore those symptoms and tell her that she needs to lose weight,” said Bairey Merz, director of the </span><a href="https://www.cedars-sinai.org/programs/heart/specialties/womens.html"><span>Barbra Streisand Women’s Heart Center</span></a><span> in the </span><a href="https://www.cedars-sinai.org/programs/heart.html"><span>Smidt Heart Institute</span></a><span> at Cedars-Sinai. “That’s because heart disease symptoms in women can be very different from what men experience. So it’s crucial that women know what to look for.”</span></p><p><span><img class="image_resized image-style-align-right" style="aspect-ratio:383/auto;width:383px;" src="https://content.presspage.com/uploads/2110/614448ed-ab1d-45a8-8efb-071c25092d45/800_noel-bairey-merz-cedars-sinai.jpeg?x=1771891537356" alt="C. Noel Bairey Merz, MD" width="383" height="auto">Although heart disease is the leading cause of death among women in the U.S., according to the </span><a href="https://www.cdc.gov/heart-disease/about/women-and-heart-disease.html" target="_blank"><span>Centers for Disease Control and Prevention</span></a><span>, most heart disease research has been conducted on men. And even though rates of heart disease and heart attacks are increasing among women 35 to 54 years old, they are less likely to receive evidence-based treatments such as statins and more likely to be told they are “too young” to have heart disease, Bairey Merz said.</span></p><p><span>“These delays and dismissals have had serious consequences,” she said. “The Women’s Ischemia Syndrome Evaluation [WISE] study that I led for the National Heart, Lung, and Blood Institute helped us better understand that heart disease doesn’t always look the same in women. That insight ultimately pushed the field to rethink and improve how we diagnose and treat it.”</span></p><p><span>Despite these advances, women with heart disease are still more likely to be misdiagnosed, underdiagnosed or undertreated—sometimes delaying care that could save their lives.</span></p><p><span>“The good news is that heart disease is largely preventable,” Bairey Merz said. “And for women in particular—who may not experience obvious symptoms or whose symptoms are subtle—knowledge is a powerful prevention tool.”</span></p><p><span>To explain what women should watch for, the </span><i><span>Cedars-Sinai Newsroom</span></i><span> spoke with Bairey Merz about what women can do to protect their hearts and advocate for the healthcare they need.</span></p><h2><span><strong>What are some of the biggest myths about heart disease?</strong></span></h2><p><span>Many people believe that heart disease primarily affects men, that heart attacks always involve crushing chest pain, or that cancer is the top cause of death. In reality, heart disease kills more women than all cancers combined, yet fewer than half of women recognize it as their greatest health threat.</span></p><p><span>While men tend to develop cardiovascular disease earlier, women are more likely to experience poorer outcomes.</span></p><h2><span><strong>Why are heart attack rates increasing among younger women?</strong></span></h2><p><span>For decades, heart attack death rates declined sharply, thanks to improved research, standardized treatment guidelines, and widespread use of effective medications and procedures. While heart attack deaths are still much lower than they once were, the increase in heart problems among younger adults is concerning.</span></p><p><span>Researchers are looking into exact causes for the increase, but we know that contributing factors include low levels of physical activity and prolonged sedentary behavior, rising rates of diabetes and obesity, chronic stress, and environmental exposures such as air pollution.</span></p><h2><span><strong>What does a heart attack feel like for women?</strong></span></h2><p><span>The so-called “Hollywood heart attack”—tingling in the left arm that leads to sudden, crushing chest pain—is common in men and can occur in women as well. But many women experience subtler symptoms, including shortness of breath, nausea, unusual fatigue, back or jaw pain, or chest discomfort that doesn’t feel severe or dramatic.</span></p><p><span>Because these symptoms don’t match common expectations of a heart attack, they may be overlooked or dismissed. Anyone experiencing them should seek medical care immediately.</span></p><h2><span><strong>What causes heart attacks in women?</strong></span></h2><p><span>An increasing number of heart attacks are occurring in people without significant blockages in the major coronary arteries, a pattern seen more often in women. While men’s heart disease more commonly involves blockage in large arteries, women are more likely to experience dysfunction of the heart’s smaller blood vessels. This condition—called ischemia with no obstructive coronary artery disease [INOCA]—can cause reduced blood flow to the heart even when major arteries appear clear.</span></p><p><span>Even women who are physically fit can develop INOCA. In the past, if a woman had heart attack symptoms but a “normal” angiogram showing clear major arteries, her condition might not have been recognized. Continued awareness and ongoing education around INOCA are helping clinicians better diagnose and treat these patients.</span></p><h2><span><strong>What is a normal heart rate for women?</strong></span></h2><p><span>A normal resting heart rate for most adults is between 60 and 100 beats per minute, according to the </span><a href="https://www.heart.org/en/healthy-living/fitness/fitness-basics/target-heart-rates" target="_blank"><span>American Heart Association</span></a><span>. Because women’s hearts are typically smaller, their resting heart rate may run slightly higher than men’s. Women should consult their doctor if their resting heart rate is below 60 or above 100 beats per minute when not exercising.</span></p><h2><span><strong>How can women protect heart health and prevent heart disease?</strong></span></h2><p><span>Heart disease develops silently over decades. While heart disease can be managed with highly effective treatments, prevention is the most powerful strategy.</span></p><p><span>An estimated 80% of heart disease cases are preventable with lifestyle modifications. These include staying current with annual screenings and knowing cholesterol, blood pressure and blood sugar levels; exercising at least 30 minutes daily; breaking up prolonged sitting because a sedentary lifestyle is considered as strong a risk factor as smoking; managing stress; getting seven to nine hours of sleep; avoiding smoking; and following a nutritious diet.</span></p><p><span>A Mediterranean-style, largely plant-based diet rich in fruits, vegetables, nuts, beans, whole grains, olive oil and lean proteins is recommended. Parents are encouraged to help ensure their children make healthy food choices, too.</span></p><p><span>Heart health isn’t about deprivation. It’s about building lifelong habits that prevent disease before it starts.</span></p><p><span style="color:#dc1e34;"><i><span><strong>Read more on the Cedars-Sinai Blog:</strong></span></i><span><strong> </strong></span></span><a href="https://www.cedars-sinai.org/stories-and-insights/healthy-living/women-high-blood-pressure" target="_blank"><span style="color:#dc1e34;"><i><span><strong>High Blood Pressure—What Women Need to Know</strong></span></i></span></a></p>]]></description><category><![CDATA[Stephanie Cajigal,Kristin Reynolds,Heart,Women Heart,Womens Heart,Womens Heart Research,cnoel-baireymerz-2285393,News,Homepage]]></category>
            <pubDate>Tue, 24 Feb 2026 07:00:00 -0800</pubDate>
            <pp:lastModified>Thu, 25 Jun 2026 22:49:48 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/d4263e9d-d7cf-447c-b6e7-309cd7167217/500_womens-heart-health-cedars-sinai2.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/d4263e9d-d7cf-447c-b6e7-309cd7167217/500_womens-heart-health-cedars-sinai2.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/d4263e9d-d7cf-447c-b6e7-309cd7167217/womens-heart-health-cedars-sinai2.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Heart disease&amp;mdash;the leading cause of death among U.S. women&amp;mdash;often causes symptoms so subtle that heart disease remains underdiagnosed in younger women. Cedars-Sinai heart experts underscore the need for greater awareness and prevention. Photo by Getty.]]></pp:imageTitle><pp:imageDescription><![CDATA[A female physician in a white lab coat anbd purple scrubs sits on a black stool,  while her patient sits on an exam table. The physician is  pressing a stethoscope to the young woman&amp;#039;s chest to listen to her heart.]]></pp:imageDescription></item><item>
                        <title>Cedars-Sinai Executive Bryan Croft Joins AHA Regional Policy Board</title>
                        <link>https://www.cedars-sinai.org/newsroom/cedars-sinai-executive-bryan-croft-joins-aha-regional-policy-board/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/cedars-sinai-executive-bryan-croft-joins-aha-regional-policy-board/</guid><pp:caseid>735301</pp:caseid><pp:subtitle>Board Members Advise on, Advocate for Hospital Policies That Help Patients and Communities</pp:subtitle><description><![CDATA[<p><a href="https://www.cedars-sinai.org/about/leadership/executive-management/bryan-croft.html"><span>Bryan Croft</span></a><span>, Cedars-Sinai’s executive vice president and chief operating officer, Hospital Operations, Cedars-Sinai Medical Center and CEO of Cedars-Sinai Marina del Rey Hospital, has been selected to join the </span><a href="https://www.aha.org/" target="_blank" rel="noreferrer noopener"><span>American Hospital Association</span></a><span> (AHA) Regional Policy Board 9, where he will advise on and advocate for healthcare policies vital to hospitals and their patients.</span></p><p style="margin-left:0in;"><span>“I am honored to join Regional Policy Board 9 during such an important era for healthcare,” Croft said. “As technology and AI continue to evolve and transform healthcare, I hope to work with my Regional Policy Board colleagues to utilize these tools to further strengthen hospitals, while remaining focused on our highest priority—exceptional patient care.”</span></p><p style="margin-left:0in;"><span>The AHA is a national nonprofit organization that represents and supports hospitals, health systems and their patients. Its regional policy boards facilitate dialogue among the AHA, its members and state hospital associations, helping to shape key advocacy efforts and policy recommendations. </span></p><p style="margin-left:0in;"><span>Regional Policy Board 9 consists of healthcare leaders from AHA member hospitals and health systems across California, Alaska, Hawaii, Nevada, Oregon and Washington. The board meets three times annually and collaborates throughout the year to address pressing healthcare challenges. Croft’s appointment, which began on Jan. 1, is effective through Dec. 31, 2028.</span></p><p style="margin-left:0in;"><span>“Bryan Croft will make a great addition to AHA’s Regional Policy Board 9 in its work to support innovative and effective policy solutions for the many challenges hospitals face today,” said Carmela Coyle, president & CEO of the California Hospital Association. “Bryan brings years of hospital experience and a willingness to ask the tough questions that drive conversations forward.”</span></p><p style="margin-left:0in;"><span>Said Sean Barry, AHA regional executive for Region 9, “Bryan brings deep experience navigating California’s complex healthcare policy environment through his leadership at Cedars-Sinai. He offers keen insights and asks questions others don’t always think to ask. His perspective will be an important asset as we advocate for hospitals and health systems across the region.”</span></p><p style="margin-left:0in;"><span>As executive vice president and chief operating officer of Hospital Operations, Croft leads the day-to-day operations of Cedars-Sinai Medical Center, overseeing service line and clinical support services with the goal of ensuring the delivery of high-quality, effective and efficient patient care. He also serves as CEO of Cedars-Sinai Marina del Rey Hospital.</span></p><p style="margin-left:0in;"><span>“Croft’s drive for healthcare innovation will be very helpful to the deliberations of the board,” said </span><a href="https://www.cedars-sinai.org/about/leadership/executive-management/peter-l-slavin.html"><span>Peter L. Slavin</span></a><span>, Cedars-Sinai’s president and CEO. </span></p><p style="margin-left:0in;"><span>“Croft’s participation on the Regional Policy Board reflects both his expertise and Cedars-Sinai’s leadership as the Regional Emerging Special Pathogen Treatment Center for Region 9,” Slavin said. “Bryan’s experience leading continuous improvement initiatives ensures our region is represented by an individual with the expertise and commitment needed to advance healthcare preparedness.”</span></p><p style="margin-left:0in;"><span>Croft joined Cedars-Sinai in 2010 as vice president of Operations and was promoted to senior vice president of Operations in 2017. He has been instrumental in advancing Cedars-Sinai’s operations and developing clinical programs and services, working collaboratively with department chairs, senior management and medical staff.</span></p><p style="margin-left:0in;"><span>His leadership accomplishments include operational and strategic oversight of the Smidt Heart Institute at Cedars-Sinai and the Cedars-Sinai Marina del Rey Hospital replacement facility, and expansion and establishment of new clinical programs.</span></p><p style="margin-left:0in;"><span>Croft earned a bachelor’s degree in business administration from Texas Tech University and a master’s degree in healthcare administration from Trinity University.</span></p><p style="margin-left:0in;"><span style="color:#dc1e34;"><i><span><strong>Read more on Cedars-Sinai Stories & Insights: </strong></span></i></span><a href="https://www.cedars-sinai.org/stories-and-insights/advancing-our-mission/investments-in-emergency-care"><span style="color:#dc1e34;"><i><span><strong>Investments in Emergency Care</strong></span></i></span></a></p>]]></description><category><![CDATA[Exclude,Faculty News,Sally Stewart]]></category>
            <pubDate>Thu, 12 Feb 2026 07:00:00 -0800</pubDate>
            <pp:lastModified>Sat, 14 Nov 2026 05:06:43 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/9ad517ef-2e32-4c72-8174-06fe231feb07/500_bryan-croft-cedars-sinai.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/9ad517ef-2e32-4c72-8174-06fe231feb07/500_bryan-croft-cedars-sinai.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/9ad517ef-2e32-4c72-8174-06fe231feb07/bryan-croft-cedars-sinai.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Cedars-Sinai executive vice president and chief operating officer, Bryan Croft, will advise on vital healthcare policies as the newest member of the American Hospital Association&amp;rsquo;s Regional Policy Board 9. Photo by Cedars-Sinai.]]></pp:imageTitle><pp:imageDescription><![CDATA[Male executive vice president and chief operating officer, Bryan Croft, smiling in a suite and stripped tie.]]></pp:imageDescription></item><item>
                        <title>Good Morning America: Christopher ‘Kid’ Reid Reveals He Underwent Heart Transplant</title>
                        <link>https://www.cedars-sinai.org/newsroom/good-morning-america-christopher-kid-reid-reveals-he-underwent-heart-transplant/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/good-morning-america-christopher-kid-reid-reveals-he-underwent-heart-transplant/</guid><pp:caseid>735500</pp:caseid><description><![CDATA[<p><i><span>Good Morning America</span></i><span> recently<strong> </strong>interviewed Cedars-Sinai cardiologist </span><a href="https://www.cedars-sinai.org/provider/erika-jones-1568295.html"><span>Erika Jones, MD</span></a><span>, and </span><a href="https://www.cedars-sinai.org/provider/laura-dichiacchio-3563922.html"><span>Laura DiChiacchio, MD, PhD</span></a><span>, a cardiothoracic surgeon in the </span><a href="https://www.cedars-sinai.org/programs/heart.html"><span>Smidt Heart Institute</span></a><span>, to discuss the heart transplant received by Christopher “Kid” Reid of the iconic rap duo Kid ’n Play at Cedars-Sinai in August 2025.</span></p><p><span>Reid had been diagnosed with heart failure at Cedars-Sinai after experiencing fatigue and shortness of breath. The condition occurs when the heart is too weak to pump enough blood throughout the body, causing fluid to build up.</span></p><p><span>Reid told </span><i><span>Good Morning America </span></i><span>co-anchor Michael Strahan he initially dismissed his symptoms. He urged others—especially people of color—to seek medical care when something feels wrong.</span></p><p><span>“A lot of times, we don’t go because we don’t want the bad news, or we’re too busy just hustling, trying to make it from day to day,” Reid said. “And we … feel like we don’t got time, or we’ll get over it. Well, you might not.”</span></p><p><span>Jones told </span><i><span>Good Morning America </span></i><span>that during a follow-up visit, it was clear medications were no longer controlling Reid’s condition.</span></p><p><span>“He came in very swollen again,” she said, “and that is a little unusual in somebody who’s been started on treatment.”</span></p><p><span>DiChiacchio told </span><i><span>Good Morning America </span></i><span>that bloodwork revealed the condition was worsening and Reid needed an immediate heart transplant.</span></p><p><span>“So when we think about status for a heart transplant,” DiChiacchio said, “he was very high on that list because of how ill he was and really dealing with a kind of life or death situation.”</span></p><p><span>Days later a donor heart became available, and DiChiacchio and team successfully completed the transplant.</span></p><p><span>&nbsp;Reid told Strahan he is grateful for a second chance at life.</span></p><p><span>“This thing is … a beautiful life,” he said. “And, you know, I wanna be around for it.”</span></p><p><span>According to the </span><a href="https://www.cdc.gov/nchs/products/databriefs/db108.htm" target="_blank"><span>Centers for Disease Control and Prevention</span></a>,<span> 6.7 million U.S. adults have heart failure. Risk factors include high blood pressure, diabetes and coronary artery disease, though regular exercise, adequate sleep and proper nutrition can lower risk.</span></p><p><span>Click </span><a href="https://www.goodmorningamerica.com/culture/story/christopher-kid-reid-reveals-underwent-heart-transplant-129853168" target="_blank"><span>here</span></a><span> to watch the entire segment of </span><i><span>Good Morning America</span></i><span>.</span></p>]]></description><category><![CDATA[News,Cardiac Surgery,Heart Transplant,erika-jones-1568295,laura-dichiacchio-3563922,Kristin Reynolds,Heart]]></category>
            <pubDate>Fri, 06 Feb 2026 06:30:00 -0800</pubDate>
            <pp:lastModified>Fri, 06 Feb 2026 01:29:57 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/7f0fb053-6e8e-40bf-ae33-4d6e9b372957/500_chris-kid-reid-cedars-sinai.jpeg?10000" length="0" type="image/jpeg" />
                <pp:image>https://content.presspage.com/uploads/2110/7f0fb053-6e8e-40bf-ae33-4d6e9b372957/500_chris-kid-reid-cedars-sinai.jpeg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/7f0fb053-6e8e-40bf-ae33-4d6e9b372957/chris-kid-reid-cedars-sinai.jpeg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Christopher &amp;ldquo;Kid&amp;rdquo; Reid (right) received a lifesaving heart transplant at Cedars-Sinai. Photo courtesy of Christopher Reid.]]></pp:imageTitle><pp:imageDescription><![CDATA[Smiling nurse in scrubs with smiling patient in white shirt and blue hat in a hospital room before the patient is released to go home.]]></pp:imageDescription></item><item>
                        <title>Cedars-Sinai Dean of Medical Faculty to Transition to Dean Emeritus</title>
                        <link>https://www.cedars-sinai.org/newsroom/cedars-sinai-dean-of-medical-faculty-to-transition-to-dean-emeritus/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/cedars-sinai-dean-of-medical-faculty-to-transition-to-dean-emeritus/</guid><pp:caseid>735049</pp:caseid><pp:subtitle>Shlomo Melmed, MB, ChB, Executive Vice President of Medicine and Health Sciences, Will Serve as an Executive Adviser to the President and CEO and a Distinguished Professor of Medicine</pp:subtitle><description><![CDATA[<p>For 46 years, <a href="https://www.cedars-sinai.org/about/leadership/executive-management/shlomo-melmed-mbchb.html">Shlomo Melmed, MB, ChB,</a> has helped guide Cedars-Sinai’s rise from a respected community hospital to a global leader in academic medicine. That evolution dramatically accelerated during Dr. Melmed’s 28 years as dean of the Medical Faculty and executive vice president of Medicine and Health Sciences.</p><p>Melmed has decided to transition to the role of dean emeritus of the Medical Faculty and executive adviser to the president and CEO at the end of 2026, or after a new dean is recruited. He will continue to serve as a distinguished professor of Medicine, conduct research and maintain his clinical practice as co-director of the Cedars-Sinai Pituitary Center. He also will continue to hold the Helene and Philip Hixon Distinguished Chair in Investigative Medicine.</p><p><span>“Cedars-Sinai has emerged as an international leader in medical innovation and translational scientific discovery under Dr. Melmed’s leadership,” said </span><a href="https://www.cedars-sinai.org/about/leadership/executive-management/peter-l-slavin.html"><span>Peter L. Slavin, MD</span></a><span>, president and CEO of Cedars-Sinai Medical Center and Cedars-Sinai Health System. “His trailblazing contributions have helped turn Cedars-Sinai into a major force in academic medicine.”</span></p><p>Since being named dean in 1998, Melmed has steadily grown the size of Cedars-Sinai’s faculty—expanding it from about 100 to more than 900 currently. During this nearly three-decade period, he raised annual research expenditures from about $30 million to $580 million. Cedars-Sinai now ranks among the top 10 non-university hospitals nationwide receiving research funding from the National Institutes of Health. At the same time, research space at Cedars-Sinai has grown from 90,000 square feet to 670,000 square feet. A new research building under construction on the Cedars-Sinai campus will add to this extraordinary growth.</p><p>Melmed has fostered major advances in interdisciplinary research, expanded clinical programs by creating new departments and institutes and strengthened graduate medical and research education. He established Cedars-Sinai Graduate School of Biomedical Sciences and more recently, Cedars-Sinai Health Sciences University.</p><p><span>“We are a stronger and more focused organization because of Dr. Melmed’s influence,” Slavin said.</span></p><p><span>Melmed is an internationally recognized physician-scientist whose research has transformed the understanding of pituitary biology and endocrine disease. His laboratory has been consistently funded by NIH since 1980. He has published and lectured on pituitary disease internationally and led the top professional societies in his field while mentoring dozens of trainees now holding prominent positions of their own.</span></p><p><span>He is a Fellow of the American Association for Advancement of Science, Master of the American College of Physicians and recipient of prestigious national and international endocrinology awards. He edits the major endocrinology textbooks and was editor-in-chief of the widely respected </span><i><span>Endocrinology </span></i><span>and </span><i><span>Pituitary</span></i><span> journals.</span></p><p><span>Melmed also is an elected member of the Association of American Physicians and American Society for Clinical Investigation. He served on the Endocrine Society Council, as president of the International Society of Endocrinology and as president and a founding member of the Pituitary Society. Additionally, he is a member of the California Institute for Regenerative Medicine’s Independent Citizens’ Oversight Committee.</span></p><p><span>He said he looks forward to transitioning into his new role assisting Slavin and Cedars-Sinai leadership.</span></p><p><span>“Serving Cedars-Sinai and our community have been the highlight of my career in academic medicine,” he said. “I am truly honored and excited to open the next chapter.”</span></p><p><span style="color:#dc1e34;"><i><span><strong>Read More From Cedars-Sinai Newsroom:</strong> </span></i></span><a href="https://www.cedars-sinai.org/newsroom/cedars-sinais-shlomo-melmed-mb-chb-elected-aaas-fellow/"><span style="color:#dc1e34;"><i><span><strong>Cedars-Sinai’s Shlomo Melmed, MB, ChB, Elected AAAS Fellow</strong></span></i></span></a></p>]]></description><category><![CDATA[News,Faculty News,HSU]]></category>
            <pubDate>Tue, 03 Feb 2026 06:00:00 -0800</pubDate>
            <pp:lastModified>Mon, 05 Oct 2026 17:19:40 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/9a2f2f9a-d12f-43dd-af1d-1ea0f6159016/500_shlomomelmedmbchbexecutivevicepresidentofacademicaffairsanddeanofthemedicalfaculty.2.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/9a2f2f9a-d12f-43dd-af1d-1ea0f6159016/500_shlomomelmedmbchbexecutivevicepresidentofacademicaffairsanddeanofthemedicalfaculty.2.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/9a2f2f9a-d12f-43dd-af1d-1ea0f6159016/shlomomelmedmbchbexecutivevicepresidentofacademicaffairsanddeanofthemedicalfaculty.2.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Under the leadership of Shlomo Melmed, MB, ChB, Cedars-Sinai dramatically accelerated from a respected community hospital to a global leader in academic medicine. Photo by Cedars-Sinai.]]></pp:imageTitle><pp:imageDescription><![CDATA[Shlomo Melmed, MB, ChB, wearing a navy blue suit standing in a hallway with windows behind him at Cedars-Sinai Medical Center]]></pp:imageDescription></item><item>
                        <title>Cedars-Sinai Again Earns Top Stem Cell Transplant Ranking</title>
                        <link>https://www.cedars-sinai.org/newsroom/cedars-sinai-again-earns-top-stem-cell-transplant-ranking/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/cedars-sinai-again-earns-top-stem-cell-transplant-ranking/</guid><pp:caseid>733751</pp:caseid><pp:subtitle>Patients Receiving Transplants to Treat Blood Cancers at Cedars-Sinai Have Higher Survival Rates</pp:subtitle><description><![CDATA[<p><span>For the sixth consecutive year, Cedars-Sinai patients who receive donor stem cell transplants for blood cancers like leukemia have significantly better survival outcomes than patients treated at most other institutions.</span></p><p><img class="image_resized image-style-align-left" style="width:200px;" src="https://content.presspage.com/uploads/2110/ababe748-9934-444c-bb50-5e3208e2e399/500_john-chute-md-cedars-sinai.jpg?x=1768852248690" alt="John Chute, MD" width="200"><span>These outcomes place the medical center at the top of rankings recently released by the Center for International Bone and Marrow Transplant Research (CIBMTR).</span> <span>Cedars-Sinai is one of just seven adult transplant centers out of 176 in the U.S. where patient survival after transplant is significantly better than predicted.</span></p><p>“We have a carefully chosen approach to pretransplant conditioning and graft-versus-host disease prevention for our patients, which plays a vital role in our strong survival outcomes,” said <a href="https://researchers.cedars-sinai.edu/John.Chute">John Chute, MD</a>, director of the Division of Hematology and Cellular Therapy at <a href="https://www.cedars-sinai.edu/health-sciences-university/research/departments-institutes/cancer.html">Cedars-Sinai Cancer</a>. “We also have a dedicated system for keeping patients in touch with their care team, which helps identify problems before they become serious.”&nbsp;<span>&nbsp;</span></p><p><span>The greatest risk to stem cell transplant patients is during the first 100 days after transplant, said </span><a href="https://researchers.cedars-sinai.edu/Ronald.Paquette">Ronald Paquette, MD</a><span>, clinical director of the Stem Cell and Bone Marrow Transplant Program at Cedars-Sinai Cancer. &nbsp;</span></p><p><span>“We have modified our pretransplant regimens and post-transplant care to minimize toxicity to the patients and give them the best chance for a successful recovery,” Paquette said. “We also are careful to select stem cell donors who can provide the best-quality stem cell and immune cell recovery.”</span></p><p><img class="image-style-align-left" style="width:200px;" src="https://content.presspage.com/uploads/2110/3ca6c0ab-b99a-4811-b2c7-93dd29845e63/500_paquetteronald.paquetter-cedars-sinai.jpg?x=1782420292486" width="200" alt="Ronald Paquette, MD">An allogeneic transplant uses stem cells from a donor, rather than the patient’s own cells, and Paquette said the approaches to these transplants are specific to each institution.</p><p>Along with a uniform approach to pretransplant therapy, <span>Chute and Paquette attributed Cedars-Sinai’s top ranking to the frequent use of younger half-matched donors—often a child or grandchild of the patient—to get patients to transplant more quickly.</span></p><p>“In addition to that, there is no replacement for the people who take care of the patients, from the transplant coordinators to the physicians, nurses and advanced practice providers,” Chute said. “The dedication of our team provides that crucial element that yields the best possible results for our patients.”</p><p>Chute and Paquette are currently exploring stem cell transplant for patients who would once have been thought “too old” for the procedure.</p><p>“Age 75 used to be the upper limit, but that was arbitrary,” Paquette said. “We have transplanted several patients over age 75 and all are doing well so far. We are hoping to learn more about the biology of transplant via these patients, to learn about the pluses and minuses of doing transplants in patients this age. We want to learn not only how to extend their survival but also how to maximize their quality of life.”</p><p><span style="color:#dc1e34;"><i><span><strong>Cedars-Sinai Health Sciences University is advancing groundbreaking research and educating future leaders in medicine, biomedical sciences and allied health sciences.&nbsp;</strong></span></i></span><a href="https://www.cedars-sinai.edu/health-sciences-university.html?adobe_mc=MCMID%3D79521921680015491943235909713257507329%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1733161540"><span style="color:#dc1e34;"><i><span><strong><u>Learn more</u></strong></span></i></span></a><span style="color:#dc1e34;"><i><span><strong>&nbsp;about the university.</strong></span></i></span></p>]]></description><category><![CDATA[Christina Elston,Cancer,john-chute-965963,ronald-paquette-1204253,Exclude,Faculty News,BMT Research]]></category>
            <pubDate>Tue, 20 Jan 2026 08:00:00 -0800</pubDate>
            <pp:lastModified>Thu, 25 Jun 2026 22:45:00 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/9f8b3315-a477-4e1f-a417-fee38c00a73d/500_bone-marrow-stem-cell-transplant-cedars-sinai.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/9f8b3315-a477-4e1f-a417-fee38c00a73d/500_bone-marrow-stem-cell-transplant-cedars-sinai.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/9f8b3315-a477-4e1f-a417-fee38c00a73d/bone-marrow-stem-cell-transplant-cedars-sinai.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[Cedars-Sinai has earned a top ranking for stem cell transplants from the Center for International Bone and Marrow Transplant Research for the sixth year in a row. Photo by Getty Images.]]></pp:imageTitle><pp:imageDescription><![CDATA[Close up of young nurse give saline through a catheter to senior patient. Attractive mature woman lying down on bed, receive treatment from doctor get saline solution in recovery room at hospital ward]]></pp:imageDescription></item><item>
                        <title>Huntington Health Names John M. Corman, MD, as President Following National Search</title>
                        <link>https://www.cedars-sinai.org/newsroom/huntington-health-names-john-m-corman-md-as-president-following-national-search/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/huntington-health-names-john-m-corman-md-as-president-following-national-search/</guid><pp:caseid>732898</pp:caseid><description><![CDATA[<p><a href="https://www.huntingtonhealth.org/" target="_blank">Huntington Health</a>, a <a href="https://www.cedars-sinai.org/home.html">Cedars-Sinai</a> affiliate,&nbsp;is proud to announce <a href="https://www.huntingtonhealth.org/physicians/john-m-corman-md/" target="_blank">John M. Corman, MD</a>, as its new&nbsp;president, effective&nbsp;immediately. This appointment follows an extensive national search that attracted highly accomplished healthcare leaders from across the country. <img class="image_resized image-style-align-left" style="aspect-ratio:300/auto;width:300px;" src="https://content.presspage.com/uploads/2110/11ccb88e-d9df-418c-9309-73714079d878/800_john-corman-md-huntington-health-cedars-sinai.jpg?x=1767921338596" alt="John M. Corman, MD. Photo by Huntington Health." width="300" height="auto"></p><p>“Dr. Corman exemplifies the values and vision of&nbsp;Huntington Health and&nbsp;Cedars-Sinai Health System,” said <a href="https://www.cedars-sinai.org/about/leadership/executive-management/peter-l-slavin.html">Peter&nbsp;L.&nbsp;Slavin, MD</a>,&nbsp;president and CEO of Cedars-Sinai Medical Center and Cedars-Sinai Health System. “His commitment to clinical excellence, innovation and patient-centered care will strengthen Huntington’s role as a trusted partner in advancing&nbsp;the&nbsp;health&nbsp;of&nbsp;the communities we serve.”&nbsp;</p><p>Dr. Corman brings exceptional leadership experience and a deep dedication to healthcare quality,&nbsp;innovation&nbsp;and patient-centered care. Since joining Huntington in May 2023 as&nbsp;chief&nbsp;clinical&nbsp;officer, and serving as interim president for several months, he has connected with physicians, clinical&nbsp;teams&nbsp;and stakeholders to align practices that promote quality outcomes and patient experiences.&nbsp;</p><p>“Dr. Corman has earned the trust and respect of our medical staff through his thoughtful, collaborative approach and consistent focus on patient care,” said <a href="https://www.huntingtonhealth.org/physicians/wufaa-alrashid-md/" target="_blank">Wafaa Alrashid, MD</a>,&nbsp;chief of&nbsp;staff&nbsp;at&nbsp;Huntington Hospital. “His leadership reflects a deep understanding of both clinical practice and the patient experience, and we are confident in his ability to guide Huntington forward.”&nbsp;</p><p>With more than two decades of clinical and executive leadership—including roles as&nbsp;chief&nbsp;clinical&nbsp;officer and&nbsp;medical&nbsp;director at Virginia Mason Franciscan Health—Dr. Corman is recognized for his strategic insight, collaborative leadership&nbsp;style&nbsp;and unwavering commitment to excellence. A board-certified urologist, he has performed&nbsp;more than&nbsp;2,000 minimally invasive surgeries, published in leading journals such as the New England Journal of Medicine and served as a clinical professor for more than 20 years.&nbsp;</p><p>“Dr. Corman’s proven track record in clinical excellence and strategic leadership makes him the ideal choice to lead Huntington Health,” said Paul Johnson,&nbsp;chair&nbsp;of the Huntington Health&nbsp;board&nbsp;of&nbsp;directors.&nbsp;“On behalf of our entire board of directors, we are thrilled to welcome him to this post.”&nbsp;</p><p>As&nbsp;president, Dr. Corman will focus on quality care, patient experience and strengthening Huntington’s role as a trusted local institution within Cedars-Sinai Health System. His leadership will guide Huntington into its next chapter of innovation and community partnership.&nbsp;</p><p><span style="color:#dc1e34;"><i><span style="text-align:start;"><strong>Read more on the Cedars-Sinai Newsroom:&nbsp;</strong></span></i></span><a href="https://www.cedars-sinai.org/newsroom/after-the-wildfires-huntington-health-expands-lung-care/"><span style="color:#dc1e34;"><i><span style="text-align:start;"><strong><u>After the Wildfires—Huntington Health Expands Lung Care</u></strong></span></i></span></a></p>]]></description><category><![CDATA[Exclude,Faculty News,Huntington Hospital,Newsroom Author]]></category>
            <pubDate>Fri, 09 Jan 2026 16:45:00 -0800</pubDate>
            <pp:lastModified>Sat, 10 Jan 2026 01:36:09 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/5e87d616-9ecd-43b9-a58c-b1ea12fafd87/500_huntington-health-cedars-sinai.jpg?62578" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/5e87d616-9ecd-43b9-a58c-b1ea12fafd87/500_huntington-health-cedars-sinai.jpg?62578</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/5e87d616-9ecd-43b9-a58c-b1ea12fafd87/huntington-health-cedars-sinai.jpg?62578</pp:imageOriginal><pp:imageTitle><![CDATA[As president of Huntington Health, a Cedars-Sinai affiliate, John M. Corman, MD, will focus on quality care, patient experience and strengthening Huntington&amp;rsquo;s role as a trusted local institution within Cedars-Sinai Health System.  Photo by Huntington Health.]]></pp:imageTitle><pp:imageDescription><![CDATA[A photo of the Huntington Health hospital and campus.]]></pp:imageDescription></item><item>
                        <title>Cedars-Sinai and University Health Network Advance AI in Healthcare</title>
                        <link>https://www.cedars-sinai.org/newsroom/cedars-sinai-and-university-health-network-advance-ai-in-healthcare/</link>
                        <guid>https://www.cedars-sinai.org/newsroom/cedars-sinai-and-university-health-network-advance-ai-in-healthcare/</guid><pp:caseid>731979</pp:caseid><pp:subtitle>International Health AI Experts in Applied AI, Medicine and Surgery Convened for Second Annual Artificial Intelligence in Medicine Symposium</pp:subtitle><description><![CDATA[<p><span>Cedars-Sinai and Canada’s largest research hospital, University Health Network (UHN), brought together more than 200 international leaders in applied artificial intelligence, medicine and surgery for the second annual Artificial Intelligence in Medicine Symposium.</span></p><p><span>A follow-up to a successful inaugural event in 2024, the symposium sought to advance the practical deployment of artificial intelligence in healthcare. Attendees from more than 40 institutions explored how to implement AI within clinical settings during the Dec. 12-13 event while addressing critical regulatory and ethical considerations.</span></p><p><span>“The event was designed to offer a road map to help health systems innovate, implement and integrate AI technologies to improve patient outcomes,” said </span><a href="https://researchers.cedars-sinai.edu/Sumeet.Chugh?adobe_mc=MCMID%3D25626552416573380630225081718067442095%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1730847770&prevPageName=cs-org%3Acedars-sinai%3Anewsroom%3Acedars-sinai-heart-experts-available-for-interviews-at-aha25&adobe_mc=MCMID%3D69600867641298967930721811880595177365%7CMCORGID%3DF47CD0AC591352EC0A495E82%2540AdobeOrg%7CTS%3D1764806137&previousPageName=cs-org%253Acedars-sinai%253Aother"><span>Sumeet Chugh, MD</span></a><span>, vice dean and chief artificial intelligence health research officer at Cedars-Sinai and co-chair of the symposium. “By convening experts from around the world, we created opportunities to exchange ideas, tackle challenges and accelerate the safe and effective use of AI in healthcare.”</span></p><p><span>The partnership between co-hosts Cedars-Sinai and UHN emphasizes the importance of global collaboration in a rapidly changing technological landscape.</span></p><p><span>“UHN is proud to partner with Cedars-Sinai and co-host this collaborative international symposium dedicated to advancing artificial intelligence in medicine,” said Barry Rubin, PhD, program medical director of UHN’s Peter Munk Cardiac Centre and symposium co-chair. “Our goal at UHN is to integrate AI and digital tools to improve patient outcomes and enhance the precision, speed and personalization of treatment.”</span></p><p><span>During a fireside chat, </span><a href="https://www.cedars-sinai.org/about/leadership/executive-management/peter-l-slavin.html"><span>Peter L. Slavin, MD</span></a><span>, president and CEO of Cedars-Sinai Health System, and Kevin Smith, PhD, president and CEO of UHN, discussed the need to maintain strong organizational culture while leveraging AI to enhance care delivery.</span></p><p><span>“In a time when forces are pulling countries and people apart, partnerships like these are essential,” Slavin said.  “AI should not only improve efficiencies but also ensure equity in care and democratize access to information for patients.”</span></p><p><span>Smith also emphasized his hope for AI to transform care delivery without jeopardizing culture.</span></p><p><span>“Culture is our bedrock,” Smith said. “We strive to integrate AI into our workflows to improve lives, outcomes and efficiencies—without changing the culture of our unique medical center.”</span></p><p><span>The event featured panel discussions and debates on pressing topics that included data privacy, the need to train future clinicians on AI documentation tools, and the challenges of data usage and commercialization.</span></p><p><span>“Provocative topics and debates were purposeful,” Chugh said. “To answer tough questions, we first have to stimulate the conversations that will address these challenges.”</span></p><p><span>Cedars-Sinai and UHN have committed to reconvening for the third annual symposium in December 2026, continuing their shared mission to lead the global conversation on responsible AI integration in medicine.</span></p><p><span style="color:#dc1e34;"><i><span><strong>Read More From the Cedars-Sinai Newsroom: </strong></span></i></span><a href="https://www.cedars-sinai.org/newsroom/cedars-sinai-strengthens-ai-foundation-accelerates-momentum/preview/feb4d5e6fdc1a0292cd88d4117ca0891be76506c"><span style="color:#dc1e34;"><i><span><strong>Cedars-Sinai Strengthens AI Foundation, Accelerates Momentum</strong></span></i></span></a></p>]]></description><category><![CDATA[Exclude,Faculty News,AI,Cara Martinez,Artificial Intelligence Research,CME]]></category>
            <pubDate>Fri, 19 Dec 2025 07:00:00 -0800</pubDate>
            <pp:lastModified>Thu, 02 Jul 2026 17:51:08 +0000</pp:lastModified>
            <enclosure url="https://content.presspage.com/uploads/2110/a3d909e3-bf1b-4693-9664-7d87e9939657/500_ai-medicine-cedars-sinai.jpg?10000" length="0" type="image/jpg" />
                <pp:image>https://content.presspage.com/uploads/2110/a3d909e3-bf1b-4693-9664-7d87e9939657/500_ai-medicine-cedars-sinai.jpg?10000</pp:image>
                <pp:imageOriginal>https://content.presspage.com/uploads/2110/a3d909e3-bf1b-4693-9664-7d87e9939657/ai-medicine-cedars-sinai.jpg?10000</pp:imageOriginal><pp:imageTitle><![CDATA[More than 200 international attendees gathered at Cedars-Sinai to explore how to implement AI within clinical settings. Photographed left to right: Barry Rubin, MD, PhD; Barry Stein, MD, MBA; Shlomo Melmed, MB, ChB; and Sumeet Chugh, MD. Photo by Thomas Neerken. Photo by Cedars-Sinai.]]></pp:imageTitle><pp:imageDescription><![CDATA[Four healthcare executives stand together outside an auditorium at Cedars-Sinai.]]></pp:imageDescription></item></channel>
                    </rss>